



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

Clinical Investigations

► Endometrial CD56+ natural killer cells

Endometrial CD56+ natürel killer hücreleri

Gulchin Babayeva, Yunus Emre Purut, Burak Giray, Pembe Oltulu, Rabia Alakuş, Mehmet Cengiz Çolakoğlu; Konya, İstanbul, Turkey

► Comparison of intramuscular and subcutaneous progesterone

İntramüsküler ve subküutanöz progesteron karşılaştırılması

Emre Niyazi Turgut, Fazilet Kübra Boynukalın, Meral Gültomruk, Zalihе Yarkiner, Mustafa Bahçeci; İstanbul, Kyrenia, Turkey, Cyprus

► Letrozole priming in vitro maturation

Letrozol ile öncülenmiş in vitro maturasyon

Şafak Hatırnaz, Ebru Saynur Hatırnaz, Alper Başbuğ, Mine Kanat Pektaş, Onur Erol, Michael Dahan, Seang Tan; Samsun, Quebec, Düzce, Afyonkarahisar, Antalya, Quebec, Turkey, Canada

► Electro-acupuncture in hysterosalpingography

Histerosalpingografide elektro-akupunktur

Zeyneb Bakacak, Adnan Demirel, Murat Bakacak, Aykut Urfalioğlu, Aslı Yaylalı, Ömer Faruk Boran, Mustafa Kaplanoğlu, Hakan Kiran, Mehtap Gızır; Kahramanmaraş, Bolu, Turkey

► Pentoxifylline against preterm fetal injury

Preterm fetal hasara karşı pentoksifilin

Mekin Sezik, Afsin Köker, Özlem Özmen, Mehmet Haligür, Duygu Kaşikci, Ahmet Aydoğan, Orhan Özatik; Isparta, Burdur, Adana, Turkey

► Results of prenatally diagnosed pes equinovarus

Prenatal tanı konulan pes ekinovarus sonuçları

Mete Sucu, Süleyman Cansun Demir; Adana, Turkey

► Prediction model vaginal birth after cesarean

Sezaryen sonrası vajinal doğum tahmin modeli

Pinkey Lakra, Bhagyashri Patil, Sunita Siwach, Manisha Upadhyay, Shivanı Shivani, Vijayata Sangwan, Rajiv Mahendru; Haryana, India

► Prenatal diagnosis of congenital heart diseases

Konjenital kalp hastalıklarının prenatal tanısı

Pelin Koşger, Melih Velipaşaoglu, Tuğçem Keskin, Hikmet Kıztanır, Birsen Uçar; Eskişehir, Turkey

► Pulmonary morbidity related to diaphragm surgery

Diafragma ilişkili pulmoner morbiditenin tanımlanması

Mykhailo V Medvediev, Antonio Malvasi, Sarah Gustapane, Andrea Tinelli; Dnipropetrovsk, Bari, Lecce, Lecce, Ukraine, Italy

► Hemorrhagic corpus luteum: Clinical management update

Hemorajik korpus luteum: Klinik yönetimin güncellemesi

Yasin Durmuş, Alper Karalok, Sinem Ayşe Duru Çöteли, Nurettin Boran, Mehmet Ünsal, Gökhan Boyraz, Taner Turan; Ankara, Turkey

► Adenoid cystic carcinoma of Bartholin's gland

Akciğer lobektomi sonrası rastlanan Bartholin kanseri

Seda Şahin Aker, Cevriye Cansız Ersöz, Fırat Ortaç; Ankara, Turkey



Neverit TUBOCVM 4ÜMFZNBOJZF .BUFSOJUZ 5SBJOJ





TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

Emre Selî

"CEÇMLBEJS 5VSHVU
:BMF 6OJWFSTJUZ OCTUFUSJDT (ZOFDPMPHTZU BOE VQMF QISIEO'DUJW 6 OADWF OTDFUTZ 'BDVMUZ PG . F
\$POOFDUJDVU 64"

Silber Sherman

*MHŠO 5ÇSL ¶ÇPÙMV
*OGFSUJMJuZ \$FOUFS PG 4U -PVJT BU 4U QØLOFÜT6 ØRJTAQFSUTBJW Z1'BOOMMDJZFRBGM UFF EAJFDSMØFD P% FQBS
"MBTLB 64"

"LŠO 4JWBTMŠPÙMV

"OLBSB "UBUÙSL 5SBJOJOH BOE 3FTFBSDI (B[JBOUFBM 6MJJWFS TRGZ CBTDFM 8ZDPTGB.FEJDJOF %
(ZOFDPMPHZ "OLBSB 5VSLFZ (ZOFDPMPHZ (B[JBOUFQ 5VSLFZ

'BUJI ÜFOEBÙ

.FUF (ÇSPM 6ÙVS
"DCBEFN 6OJWFSTJUZ 'BDVMUZ PG .FEJDJOFOO% #QBSBNFOTUIPZG 80PONTFLOTU \$JBDM UBOCTUFUSJDT
(ZOFDPMPHZ TUBOCVM 5VSLFZ .BUF SOBM 'FUBM .FEJDJOF 1FOOTZMWBOJB 64"

"MQFS 5BOSŠWFSEJ

"EOBO .FOEFSFT 6OJWFSTJUZ 'BDVMUZ PG ;FLEBJD 5ØFJ S%#FQSBBLU8NFNFO PTG) 6B MWF LSSJBDOJOH BOE
BOE (ZOFDPMPHZ "ZE•O 5VSLFZ \$MJOJD PG OCTUFUSJDT BOE (ZOFDPMPHZ "OLBSB

"NFS -ÇUô 5BQŠTŠ[

Yusuf Üstün
&UMJL ;ÜCFZEF)BO•N 8PNFO T)FBMUI 5SBJFØEJDBB QØE E QØE \$QØE UØPØMØUØBØS)PTQJUBM \$M
\$MJOJD PG OCTUFUSJDT BOE (ZOFDPMPHZ (ZØLFDSBM PSHZL "FØZLBSB 5VSLFZ

&CSV 5BSSN

(B[J :ŠMEŠSŠN
#BLFOU 6OJWFSTJUZ "EBOB "QQMJDBUJPO :FEOEU 5ØF FØSØBW FØFØUØZS 'BDVMUZ PG .FEJDJOF %F
%FQBSUNFOU PG OCTUFUSJDT BOE (ZOFDPMPHZ PØHØFØD PØBØB 5NUØLØCØV M 5VSLFZ

Contact

-FUJO &NFÉ #VMWBS•)ÜSSJZFU \$BEEFTJ)BSCJZF .BIBMMFTJ ,WFÉ
1IPOF 'BY & NBJM FEJUPS!UKPE PSH

All rights are reserved. Rights to the use and reproduction, including in the electronic media, of all communications, papers, photographs and illustrations appearing in this journal belong to the Turkish Journal of Obstetrics and Gynecology. Reproduction without prior written permission of part or all of any material is forbidden. The journal complies with the Professional Principles of the Press.

Reviewing the articles' conformity to the publishing standards of the Journal, typesetting, reviewing and editing the manuscripts and abstracts in English and publishing process are realized by Galenos.

Owner and Publisher	%VZHV :ME-S-N	Address: .PMMB (ÜSBOJ .BI ,BÉBNBL 4L /P TUBOCVM 5VSLFZ
%FSZB .PS	(BN[F "LTPZ	
&SLBO .PS)BUJDF 4FWFS	Phone:
1VCMJDBUJPO \$PPSEJOBUP\$.PMJLF &SFO	Fax:
#VSBL 4FWFS	1•OBS "LQ•OBS	E-mail: JOGP!HBMFOPT DPN US ZBZJO!HBMFOPT D
Web Coordinators	(ÜMBZ "L•O	Web: XXX HBMFOPT DPN US
'VBU)PDBMBS	,MFN →FMJL	1VCMJTIIFS \$FSUJØDBUF /VNCF
5VSHBZ "LQ•OBS	3BCJB 1BMB[P MV	00MJOF 1VCM 9ØPBUJNPØF %BUF
(SBQIJDT %FQBSUNFOU	3FTFBDevelopment	ISSN: E-ISSN:
"ZEB "MBDB	.FSU \$BO ,ÖTF	*OUFSOBUJPOBM TDJFOUJÀD KPVSOBM QVCMJTIIFE RV
→J EFN #JSJODJ	.FWMÜEF ,[MFN "LHÜOFZ	
(ÜM BI ,[HÜM		
'JOBODF \$PPSEJOBUP\$		
4FWJOÉ →BLNBL		





TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

AIMS AND SCOPE

5VSLJTI +PVSOBM PG OCTUFUSJDT BOE S ZOEFONMPHJTD BOPZS NQFSOMZJ DIFNE MN BE UFSISIB M T
+JOFLPMPPKJ WF OCTUFUSJL %FSOF J %BBSBWTUP OJTPG I F PPVGSDDFJ BQMS RQW B SJDFHWB RAXFES
KPVSOBM PG UIF 5VSLJTI 4PDJFUZ PGKPOVTQFBMS JDDBNQFE ZFQISD PMIPMIVZNFO BQTE QBH
QVCMJTIFE RVBSUFSMZ PO .BSDI +VODPQEZQJFINCEFSB B QPEG %FIP FBNSCUJSD MF
*U JT BO JOEFQFOEFOU QFFS SFWJFXFEO BODFES BPUJQDQBTMF K PPGS Q BM KQWGSMBTM FES F
JO &OHMJTI MBOHVBHF TJODF 4FCQWFSNCSFT BPOEV T DGPQDPM PABF
SFWJFXFE JO BDDPSEBODF XJUI iEPVCMF CMJOE QFFS SFWJFXu QSPDFTT GPS
CPUI SFGFSFFT BOE BVUIPST

5IF UBSHFU BVEJFODF PG 5VSLJTI +PVSOBM PG OCTUFUSJDT BOE (ZOFPDMPHZ
JODMVEFT HZOFDPMPHJTUT PCTUFUSJDTBOT VSPHZNDFPDMPHJUTS PEGSPEVDI
NFEJDJOF TQFDJBMJTUT HZOFDPMPHJDPBM PODPMPMHJQUT BQEBQTS QSJNB5Z DBMSFUT
QIZTJDJBOT JOUFSFTUFE JO HZOFDPMPHJDPBM PODPMPMHJQUT BQEBQTS QSJNB5Z DBMSFUT
XPSL PO BMM BTQFDUT PG PCTUFUSJDT BSBQEBMHTOPDPMPTHE5TFBDN PG BVSFLGSIFF U
+PVSOBM PG OCTUFUSJDT BOE (ZOFPDMPHZFT iWPUQVCXJXJUKPHEIE RSHMTJUZSHu 7
PSJHJOBM SFTFBSDI BSUJDMFT *O B QBJHJTP & PUSP ESFJBMBSTD P GSUJDFDMNT ESHJFJDXPTQ
FEJUPSJBMT MUUUFST UP UIF FEJUP S OBOTED SDJQUTUFT QDGFOT FROQNBZ JCIOTTT BGSNJBMFIE F
QVCMJTIFE

5IF (FOFSBM (VJEFMJOFT GPS NBOVTD SJQU QSFQBSBUJPO TQFDJÀFE CFMPX
BSF CBTFE PO i3FDPNNOEBUJPOT GPS UIF \$POEVDU 3FQPSUJJOH
&EJUJJOH 1VCMJDBUJPO PG 4DIPMBSMZ 8PSL JO .FEJDBM +PVSOBMT *\$.+&
3FDPPNNFOEBUJPOT u CZ UIF *OUFSOBUJPOBM \$PNNJUUFF PG .FEJDBM
+PVSOBM &EJUPST BSDIJWFE BU IUUQ XXX JDNKF PSH

5VSLJTI +PVSOBM PG OCTUFUSJDT BOTV 0QFO BDDFTT UP JUT DPOUFOU PO
\$FOUSBM 1.\$ 8FC PG 4DJFODF &NFSHJOH 4PVSDFT \$JUBUJPO *OEFY
&4\$* \$0 %0"+ *OEFY \$PQFSOJDVT 4DPQVT \$*/"- (PPHM
4DIPMBSMZ 5CJUBL 6MBLCJN 5VSLJTI .FEJDBM %BUBCBTF 5VSL .FEMJOF

and Turkiye Citation Index.

Open Access Policy

5IJT KPVSOBM QSPWJEFT JNNFEJBUF PQFO BDDFTT UP JUT DPOUFOU PO
UIF QSJODJQMF UIBU NBLJOH SFTFBSDI GSFFMZ BWBJMBCMF UP UIF QVCMJD
TVQQPSUJJOH B HSFBUFS HMPCBM FYDIBOHF PG LOPXMFEHF
0QFO "DDFTT 1PMJDZ JT CBTFE PO SVMFT PG #VEBQFTU 0QFO "DDFTT
*OJUJBUJWF #0" * IUUQ XXX CVEBQFTUPQFOBDDFTTJOJUJBUJWF PSH
#Z iPQFO BDDFTTu UP <QFFS SFWJFXFE SFTFBSDI MJUFSBUVSF> XF NFBO
JUT GSFF BWBJMBCJMJUZ PO UIF QVCMJD JOUFSOFU QFSNJJUJJOH BOZ VTFST UP
SFBE EPXOMPBE DPQZ EJTUSJCVUF QSJOU TFBSDI PS MJOL UP UIF GVMM
UFYUT PG UIFTF BSUJDMFT DSBXM UIFN GPS JOEYJOH QBTT UIFN BT EBUB
UP TPGUXBSF PS VTF UIFN GPS BOZ PUIFS MBXGVM QVSQPTF XJUIPVU
àOBODJBM MFHBM PS UFDIOJDBM CBSSJFST PUIFS UIBO UIPTF JOTFQBSBCMF
GSPN HBOJOJOH BDDFTT UP UIF JOUFSOFU JUTFMG 5IF POMZ DPOTUSBJOU PO
SFQSPEVDUJPO BOE EJTUSJCVUJPO BOE UIF POMZ SPMF GPS DPQZSJHIU JO
UIJT EPNBJO JT HJWFO UP BVUIPST UP SFUBJO DPOUSPM PWFS UIF JOUFHSJUZ
PG UIFJS XPSL BOE UIF SJHIU UP CF QSPQFSMZ BDLOPXMFEHFE BOE DJUFE

5IJT KPVSOBM JT MJDFOTFE VOEFS B \$SFBUJWF \$PNNPOT *OUFSOBUJPOBM
-JDFOTF

Permission

1FSNJTTJPO SFRVJSFE GPS VTF BOZ QVCMJTIFE VOEFS \$\$ #: /\$ MJDFOTF
XJUI DPNNFSDJBM QVSQPTFT TFMMJJOH FUD UP QSPUFDU DPQZSJHIU PXOFS
BOE BVUIPS SJHIUT 3FQVCMJDBUJPO BOE SFQSPEVDUJPO PG JNBHFT



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

INSTRUCTIONS FOR AUTHORS

Phone number:
E-mail: F E J U P S ! U K P E P S H



. BOV TDS JQUT TVCN JUUFE GPS QVCMJD B UJPC



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

INSTRUCTIONS FOR AUTHORS

5JUMF 1BHF

" TFQBSBUF UJUMF QBHF TIPVME MJTU 5VSLJTI BCTUSBDUT TIPVME IBWF LFZXPSET i
5IF NBOVTDSJQU UJUMF XIJDI TIPVME SPOUNXOBUFSH [UFBODBNPUBEM SP 5USLJZF #J
DIBSBDUFST DPVOUJOH MFUUFST BOE T4QFBADFFSTB MB QIZ CTFRVME DPOWJD M FETDDBBJSBT JTWFCNJ
EP OPU VTF BCCSFWJBUPOT PS DPNNFS DPOJBSN BONB NPFG JOTUJFUSJUMLBOE (ZOFDPMPHZ O

" TIPSU UJUMF PG OP NPSF UIBO DIBTSBUDFNSBUDJ SFWFZT DPOBDFOUGBRNNTFOUBSJF
BT B SVOOJOH GPPU BOE MFUUFST 4UBUFE XPSE DPVOUT BOE QBH

" MM BVUIPS OBNF T JOTUJUVUJPOBM DPSQPSBUF PS DPNNS FSDJBM BGaMJBWJSOT
BOE VQ UP UXP NBKPS EFHSFF T UP UTF QBHF MJNJUT

\$PSSFTQPOEJOH BVUIPS T OBNF BEESFTTBovHBMQQIPOF
UIF NPCJMF QIPOF OVNCFS GBY OVN "SUJDMF UZQFUSBDBOVTDJSQ MaxCount
DPSSFTQPOEJOH BVUIPS XJMM CF SFTC -FOHUI Count" Number of
PUIFS NBUFFST SFMBUJOSH UP UIF NBOV Authors Number of
F BOE

1SFDJT

5IF QSFDJT JT B POF TFOUFODF TZOPQTS \$PTP @F@PSUNPSSETUIBOSSET XPSET UIBU
EFTDSJCFT UIF CBTJD àOEJOHT PG UIF BSIIIDMF 1SFDJT PRNOMF DRO CF TFFO
CFMPX 4ZTUFNUBJD XPSET XPSET
SFWJFX QBHFT

A6TJOH B QPJOU RVFTUJPOOBJSF XF IBWF BWMVBUFE UFSFUE PG 3PCPUJD
TVSHFSZ USBJOJOH JO UIF HZOFDPMPMHJ DPNMSHUFSSZ GFMMMPXHJ QSPHSBNT BDSPTT
UIF OBUJPO

"CTUSBDU

" MM NBOVTDSJQUT TIPVME CF BDDPNQB .BOVTDSJQU MFOHUI JODMVEFT BMM QBHFT JO B NBOV
JO UIF BCTUSBDU TIPVME CF DPOTJTUF CPYFT àHFHOFTHICLUEUFQJEFVDUJPO TIPVME OPU FYDFFE
UBCMFT PS àHVSFT "WPJE VTF PG DF BQQSPYJNBUMCF /" OPU BQQMJDBCMFT

0SJHJOBM SFTFBSDI SFQPSUT TIPVME IBWF B TUSVDUFSFE BCTUSBDU PG OP NPSF
UIBO XPSET VTJOH UIF GPMMXPJOH BSBENJQH SFTFBSDIFT TIPVME IBWF UIF GPMMI

p0CKFDUJWF .BJO RVFTUJPO PCKFDUJWF PS IZQPUIFTJT TJOHMF QISBTF
TUBSUJOH XJUI GPS FYBNQMF i5P FWBMVBUFE UPS I5P FTUJNUBU <OFWFS TUBSU
XJUI i5P EFUFSNJOF u> 4UBUF DPODJTFMUIF QVSQPTF BOE SBUJPOB

p.BUFSJBMT BOE .FUIPET 4UVEZ EFTUJPOBQSUJQFOU SFGFSFOPFT BT CBDLHSF
NFBTVSFT BOE JO UIF DBTF PG B OFHBUJWPTUAZEZTUBUFTUJPO

p3FTVMUT .FBTVSFNFOUT FYQSFTTFE Materials and Methods OVNCFST BOE
QFSDFOUBHFT BOE XIFO BQQSPQSJBUF %QFBDBUF SFMBUJWF SFTFBSDIFT TUBU
XJUI DPOàEFODF JOUFSWBMT BOE MFWFM PG TUBUJTDDBM THOJAPBODUFIPET BOZ
SFTVMUT DPOUBJOFE JO UIF BCTUSBDU TUBUJTDDBM RFOUFE TFOUFE MPZPE JOPZAGàD
PG UIF NBOVTDSJQU UBCMFT PS àHVSFT EVQMJDUF UIF XPSL *EFOUJGZ NFUIPET PG

p\$PODMVTJPO %JSFDUMZ TVQQPSUFE BQQSPQBBUBM POUJWIF DMJTD BMD MVEJOH
JNQMJDJBUPOT GPS UIFJS TFMFDUJPO \$JUF BOZ TUBUJTDDBM
"VUIPST GSPN 5VSLFZ PS 5VSLJTI TQFBULFJYH BPFQSEFTWBFVFTQFPDOPENBPF UIBO UX
TCNCJU B 5VSLJTI BCTUSBDU JODMVEJOTUJFZCIFBOEPJOFST UTVDEF BFDUNBEBPFDBM EJGC
WF :ÖOUEFNMS #VMHVMBS 4POVÉu 5IF EBESTFUTSBID #RGTWPHSFTBOKIABEUSQJFOUT JOG
MBOHVBHF JT OPU 5VSLJTI XJMM CF QSPHWDPRFQMFSTF BSNP1P8HJFJUSBPTMFBMPEOCF QS
TFSWJDFT JOUP 5VSLJTI MBOHVBHF 4UBUF UIF HFOFSJD OBNFT PG UIF ESVHT XJU

" TUSVDUFSFE BCTUSBDU JT OPU SFRVUJF BXQWGSDFUWJSFXT BSUJDMFT BOE DBTF
SFQPSUT

Results

1SFTFOU UIF EFUBJMFE àOEJOHT TVQQPSUFE X
#FMPX UIF BCTUSBDU QSPWJEF UP LBZEXP SIBTCMFCCTC SFRWJBEJPVQJQTMIPIWMOUOPOU E VQM
CF VTFE BT LFZXPSET ,FZXPSET TIPVMEG CEFB QBI DJOF IF JGI\$PSN ROF PFSE JDBMPUIFS XJMM T

Keywords



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

CONTENTS

Clinical Investigations

- 236 Endometrial CD56+ natural killer cells in women with recurrent implantation failure: An immunohistochemical study
5FLSB SMBZBO JNQMB OUBTZPO CB BS'T' [M'L MBS'OEB FOEPNFUSJBM \$% OBUàSFM
(VMDIJO #BCBZFWB :VOVT &NSF 1VSU #VSBL (JSBZ 1FNCF 0MUVMV 3BCJB "MBLV .FI
- 240 Comparison of intramuscular versus subcutaneous aqueous progesterone for luteal phase support in artificially prepared frozen embryo transfer cycles
)PSNB ĐQMB JTMB DS M BĐPNO E VS F M Q S U ZIB OTJG MS/ T M C S SOBNBQTSLPàHMFISW IF SCBQTMV CL àUBO Ú[
QSPHFTUFSPVO MVUFBM GB[EFTUF J BÎ'T'OEBO LBS 'MB U'S'MNBT'
&NSF /JZB[J 5VSHVU 'B[JMFU ,àCSB #PZOVLBM'O .FSBM (àMUPNSVL ;BMJIF :BSL'OF S .V
- 247 *In vitro* maturation with letrozole priming: Can it be a solution for patients with cancerophobia? A pilot study
- F USP [PM JMFJ Ó ODNABISMFSOBTZPO ,BOTFS GPCJL IBTUMBSEB CJS ïÚ[àN PMBCJMJS N
BG BELU'S & BZQBS 'S OIB QFB C VJOFB O B BLUOB VSS P JNDIB % BIBOF B OSB Q BNT ïÚ[FC P ðà [DF
"GZPOLBSBIJTBS "OUBMZB 2VFCFD 5VSLFZ \$BOBEB
- 253 A randomized pilot study of electro-acupuncture treatment for hysterosalpingography pain relief and related anxiety
)JTUF SPTBMQJOHPHSBå JMJ LJMJ B S' WF BOLTJZFUF EF FMFLUSP BLVQVOLUVS UF
;FZ OFBCL B D'ELO B OF N JS/SMIB L B D'EIL & G B M"PMZM B MFSS ¥ P S B OTUB E B M B O)B LMBOS B.ØIUBQ
(J[JS ,BISBNBONBSB #PMV 5VSLFZ
- 259 Antenatal pentoxifylline therapy to prevent endotoxin-induced fetal injury in the preterm goat model
1SFUFSN HFCF LFÎJ NPEFMJOEF FOEPULPTJO JMF JOE àLMFOFO GFUBM IBTBS' O ÚO
.FLJO 4F[JL "G JO ,ÙLFS ½[MFN ½[NFO .FINFU)BM'HàS %VZH V ,B 'LD' "INFU "ZEP BO
- 270 The relationship between isolated pes equinovarus and aneuploidies and perinatal outcomes: Results of a tertiary center
[PMF QFT FLJOPWBSVT JMF BOÚQMPJEJMFS BS BT' OEB JMJ LJ WF QFSJOBUBM TPO
.FUF 4VDV 4àMFZNBO \$BOTVO %FNJS "EBOB 5VSLFZ
- 276 A prospective study of a new prediction model of vaginal birth after cesarean section at a tertiary care centre
Ã àOD à CBTBNBL CJS NFSLF[EF TF[BSZFO TPOSBT' WBKJOBM EP VN JÎJO ZFOJ CJS
1JOLFZ -BLSB #IBHZBTISJ 1BUJM 4VOJUB 4JXBDI .BOJTIB 6QBEIZBZ 4IJWBOJ 4IJWBOJ
- 283 Impact of the expanded examination of fetal heart to the prenatal diagnosis of congenital heart diseases
(FOJ MFUJM NJ GFUBM LBSEJZBL EF FSMFOEJSNFOJO LPOKFOJUBM LBMQ IBTUBM'L
1FMJO ,P HFS .FMJI 7FMJQB BP MV 5V ïFN ,FTLJO)JLN FU ,[UBO'S #JSTFO 6ÎBS &TLJ
- 290 Pulmonary morbidity related to diaphragm surgery performed for gynecological cancers
+ JOFLR ĐB BSBT U B M BZB Q EBB O P S F E F S S BGBNQTSB N 'HOESB F L M FEU Z BGSBOS B IJ Q F S JNQPOOF S
NPSCJEJUF JMF JM J LJ TJ
:BTJO %VSNV "MQFS ,BSBMPL 4JOFN "Z F %VSV ±ÚUFMJ /VSFUUJO #PSBO .FINFU ÄOT



OBSTETRICS AND GYNECOLOGY

CONTENTS

Hemorajik korpus luteum: Klinik yönetimin güncellemesi

Mykhailo V Medvediev, Antonio Malvasi, Sarah Gustapane, Andrea Tinelli; Dniproprovsk, Bari, Lecce, Lecce, Ukraine, Italy

- 308 Adenoid cystic carcinoma of Bartholin's gland diagnosed after lung lobectomy: Review of the literature and a case presentation

4 F H N F O U B M B L D J F S M P C F L U P N J T P O S B T ' S B T U M B O B O B E F O P J E L J T U J L C B S U I P M J
4 F E B B I J O "L F S \$ F W S J Z F \$ B O T ' [& S T Ú ['' S B U 0 S U B Í " O L B S B 5 V S L F Z

Case Report

- 312 Severe ovarian hyperstimulation syndrome and gonadotropin-releasing hormone agonist trigger in patients with hypogonadotropic hypogonadism: A report of two cases

) J Q P H P O B E I R J Q S P H Q P J L B B J J N B M B D S J ' B E P V B B S I J B Q F S T U J N T A M O B E S Z W M B P O B E P U S S F R M Q J B D P S O N H P O
B H P O J T U J Z M F U S J H H F S L J P M H V T V O V N V
" M J 4 B N J (à S C à [' V O E B (Ú E F ' B U N B , ' M ' Í ; F Z O F Q 6 N B Z (à S C à [3 à Z B % F W F F S , P O Z B T

Letter to the Editor

- 316 Rectus abdominis muscle with different abdominal pathologies: A cite to myofascial trigger point

' B S L M ' B C E P N J O B M Q B U P M P K J M F S M F S F L U V T B C E P N J O J T L B T ' . J Z P G B T Z B M U F U J L
' B U J I # B D ' F S T U B O C V M 5 V S L F Z

Index

- 331 2020 Referee Index

- 332 2020 Author Index

- 334 2020 Subject Index

Hemorrhagic corpus

Endometrial CD56+ natural killer cells in women with recurrent implantation failure: An immunohistochemical study

7 H N U D U O D \ D Q L P S O D Q W D V \ R Q E D ü D U
 & ' Q D W • U H O N L O O H U K • F U H O H U L p l

- * X O F K L Q % D E D M Q X D (P U F H D 3 % X U X D M P D L B H D R E H 2 D W 5 X D E X D \$ O D N X ü
- 0 H K P H W & H Q J L] d R O D N R y O X

¹Necmettin Erbakan University Meram Faculty of Medicine, Department of Obstetrics and Gynecology, Konya, Turkey

²= H \ Q H S . D P L O : R P H Q D Q G & K L O G U H Q ' L V H D V H V 7 U D L Q L Q J D Q G 5 H V H D U F K + R V S L W D

³Necmettin Erbakan University Meram Faculty of Medicine, Department of Pathology, Konya, Turkey

\$ E V W U D F W

2 E M H F W L Y H , P S O D Q W D W L R Q I D L O X U H L V D P X O W L I D F W R U L D O S U R E O H P R I U H S U R G X F W L
 7 K H U H L V L Q F U H D V L Q J H Y L G H Q F H W K D W W K H V H F D V H V R I U H F X U U H Q W L P S O D Q W D W L R Q
 provide immune-modulation at the interface between maternal decidua and the trophoblast. The aim of this study to evaluate whether there was a significant difference in the number of endometrial CD56+ NK between women with a history of recurrent implantation failure and women who had a live birth.
 0 D W H U L D O V D Q G 0 H W K R G V Patients with a history of recurrent implantation failure were included in the study. Twenty-five women with implantation failure were assigned to the case group, and 25 women who had one or more live births were assigned to the control group. Endometrial biopsies were obtained during the luteal phase on the 21st day of the menstrual cycle.

Results: 7 K H U H Z D V D V W D W L V W L F D O O \ V L J Q L I L F D Q W G L I I H U H Q F H E H W Z H H Q W K H J U R X S V
 The mean number of uNK was 10.5±10.5 cells/mm² in the case group and 19.2±11.2 cells/mm² in the control group. There was a statistically significant G L I I H U H Q F H E H W Z H H Q W K H W Z R J U R X S V S

& R Q F O X V L R Q Implantation failure is a multifactorial problem of reproductive medicine. The results of our study suggest that uterine NK play a progress of normal pregnancy and reduced uterine NK cell numbers were associated with implantation failure.

. H \ Z R U G V CD56, immunohistochemistry, in vitro I H U W L O L] D W L R Q U H F X U U H Q W L P S O D Q W D W L R Q I D L O X U H

Öz

\$ P D o p P S O D Q W D V \ R Q E D ü D U x V x] O x N O D U x U H S U R G • N W L I W x E E x Q P X O W L I D N W | U L \ H O E L
 \ x O O D U G D P H N D Q L] P D V x Q G D L P P • Q R O R M L N I D N W | U O H U L Q H W N L O L R O G X y X Q D G D L U N D Q
 D U D V x Q G D L P P • Q P R G • O D V \ R Q X V D y O D U d D O x ü P D P x] x Q D P D F x W H N U D U O D \ D Q L P S O D Q W D
 X 1. K • F U H O H U L D o x V x Q G D Q I D U N R O X S R O P D G x y x Q x Q D U D ü W x U x O P D V x G x U
 * H U H o Y H < | Q W H P O H U d D O x ü P D \ D W H N U D U O D \ D Q L P S O D Q W D V \ R Q E D ü D U x V x] O x y x R O D Q
 J U X E X Q X F D Q O x G R y X P | \ N • V • R O D Q N D G x Q L V H N R Q W U R O J U X E X Q X R O X ü W X U G X (Q
 O X W H D O I D] G D D O x Q G x + H U L N L J U X S X 1. D o x V x Q G D Q N D U ü x O D ü W x U x O G x
 % X O J X O D U + H U L N L J U X S D U D V x Q G D F D Q O x G R y X P S Y H G • ü • N V D \ x V x S D
 10,5±10,5 cells/mm². Kontrol grubunda ise 19,2±11,2 cells/mm² G L 2 O J X J U X E X Q G D X 1. V D \ x V x D Q O D P O x R O D U D N
 6 R Q X o p P S O D Q W D V \ R Q E D ü D U x V x] O x N O D U x U H S U R G • N W L I W x E E x Q P X O W L I D N W | U L \ H O E L
 U R O R \ Q D G x y x Y H V D \ x O D U x Q x Q D] D O P D V x Q x Q W H N U D U O D \ D Q L P S O D Q W D V \ R Q E D ü D U x V x
 \$ Q D K W D U . H O L P H O H U & L P P • Q R K L V W R N L P \ D in vitro I H U W L O L] D V \ R Q W H N U D U O D \ D Q L P S

PRECIS:We evaluated whether there was an effect of the number of endometrial CD56+ NK on women with a history of recurrent implantation failure.

\$ G G U H V V I R U & R U U H V S R Q G H Q F H < D] x ü P D \$ G U H V L * X O F K L Q % D E D \ H Y D 0 '

Necmettin Erbakan University Meram Faculty of Medicine, Department of Obstetrics and Gynecology, Konya, Turkey

Phone: +090 332 223 60 00 (P D L O d r g u n u v a r @ g m a i l . c o m 2 5 & , ' , ' o r c i d . o r g / 0 0 0 0 - 0 0 0 3 - 1 5 1 9 - 2 2 5 5

5 H F H L Y H G * H O L ü 7 D U L K L 24.09.2019 \$ F F H S W H G . D E X O 7 D U L K L 18.10.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

, QWURGXFWLRQ

Q R
writing.

7KH SDWLHQWV ZHUH LQ

Accomplished implantation of an eight-cell embryo into the endometrium is mandatory for reproduction. The rate of successful implantation of an embryo is approximately 30%.

Implantation failure is a multifactorial problem of reproductive Endometrial biopsies were obtained during the luteal phase as a failure of pregnancy after at least three previous assisted reproductive technique cycles, or implantation failure with paraffin-embedded tissue samples were incubated for 20 hours at 37°C. The menstrual cycle is divided into follicular and luteal phases. The follicular phase begins with the onset of menstruation and ends with ovulation. The luteal phase begins with ovulation and ends with the onset of menstruation. The duration of the follicular phase is approximately 14 days, and the duration of the luteal phase is approximately 10 days. The total duration of the menstrual cycle is approximately 28 days. The follicular phase is characterized by the growth of the ovarian follicles and the production of estrogen. The luteal phase is characterized by the regression of the ovarian follicles and the production of progesterone. The menstrual cycle is regulated by the hypothalamus, pituitary gland, and ovaries. The hypothalamus releases gonadotropin-releasing hormone (GnRH), which stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates the ovaries to release eggs, and FSH stimulates the ovaries to produce estrogen. Estrogen feedback inhibits the release of GnRH, which prevents the release of LH and FSH. This results in the regression of the ovarian follicles and the production of progesterone. Progesterone maintains the endometrium and prepares it for implantation. If implantation fails, the endometrium undergoes regression and sheds, resulting in menstruation. The menstrual cycle is a complex process involving many factors, and its regulation is not fully understood.

There is increasing evidence that these cases of RIF might have an immunologic background. The endometrium plays a role in implantation physiology via immune cells, cytokines, and hematoxylin. The same pathologist evaluated all samples using an Olympus BX53 microscope at 400x magnification. CD56+ involved in supporting immune tolerance during implantation cell counts were determined as cells/mm³. L J X U H and successful ongoing pregnancy. Uterine natural killer

X1. FHOOV H[SUHVV WKHLU VSHFLILF FHOOV VXUIDFH PDUNHU & DQG
 differ from blood NK cells. These uNK cells are the dominant OH XNRF\WH SRSXODWLRQ RI XWULOH O\PSKRFW\HV I\RU \LQGRZV
 decidua at the time of implantation and early placentation +LVWRJUDP QRUPDOLW\ SORWV DQG
 Although the function of uNK cells is uncertain, the regulation WHVW ZHUH XVHG WR DQDO\]H GDWD G
 of uNK cells at the time of eight-cell embryo implantation is PHDQ VWDQGDUG GHYLDWLRQ PHGL
 thought to feature in implantation. In a normal pregnancy, XVHG LQ WKH DQDO\VLV RI TXDQW\HW\W
 uNK cells provide immune-modulation at the interface between RU)LVKHU.V ([DFW WHVW ZDV XVHG W
 decidual tissue and trophoblast. We aimed to evaluate whether Mann-Whitney U test was used in the analysis of quantitative
 there was a significant difference in the count of endometrial GDWD 6WDWLWLFDO VLJQLILFDQFH Z
 CD56+ NK between women with RIF and women who had a Results

a Results

Materials and Methods

3DUWIEISDOWV DOG 6WXG\ 'HVLJO

more live births between January 2012 and December 2017 were statistically significant differences between the groups in were included in the study. RIF was defined as the failure of

good quality embryos to implant after at least 3 cycles of IVF.

anticardiolipin IgM and IgG, anti-DNA, antiphospholipid IgM

D Q G , J * D Q W L W R [R S O D V P D , J 0 D

excluded from the study. Women with abnormal thyroid function tests results, anti-thrombin III deficiency, protein C

R U 6 G H I L F L H Q F \ I D F W R U 9 / H L G H Q
mutation mutation of MT-HEPD6277T mouse IgM mutation

mutation, mutation of MTHFR C677T gene, and/or mutation of MTHFR A1298C gene, can also be deduced from the study.

of MTHFR A1298C gene were also excluded from the study.

+ \VWHURVDOSEQJRJUDSK\ ZDV SHU before the procedure and there were no abnormal findings.

before the procedure and there were no abnormal findings. Twenty-five women who had one or more live births were

Twenty-five women who had one or more live births were assigned to the control group. None of the 25 women in the

assigned to the control group. None of the 25 women in the control group received assisted reproduction treatment at any

WIPH 7KH QBEDQ HWKIEV FRPPIWW

This immunohistochemical (IHC) image shows a tissue section with various cellular components. A prominent feature is the presence of red-stained cells, which are labeled as "CD56 (+) endometrial stromal cells" and "metaplastic". These red-stained cells are scattered throughout the field. Some of these red-stained cells are also located within the lumen of an "Endometrial gland", indicated by a red arrow. The background consists of blue-stained nuclei, representing hematoxylin counterstain. The image is annotated with labels and arrows to identify specific cell types and their locations.

W H U P V R I W K H Q X P E H U R I G H O L Y H U uNK cells undergo apoptosis and live therefore thought to play a role in the initiation of menstrual bleeding. UNK cells also secrete several growth factors involved in angiogenesis, such as EGF, placental growth factor, and angiopoietin-2. Gianni et al. found that the number of endometrial CD56+ cells/mm² in the case group and 19.2±11.2 cells/mm² in the control group. There was a statistically significant difference (EGF, placental growth factor, and angiopoietin-2). H Q 7 D E O H 7 K H U H Z D V D V L J Q L I L F D Q M S & R U b i l o C M f d R e a l . F a s h d e s c r i b e d a c c e s s o r e p r e s s i o n of the number of UNK cells and the number of miscarriages/pregnancy loss. By contrast, Quenby et al. demonstrated that the number of UNK cells and the number of miscarriages/pregnancy loss were significantly reduced in women with endometriosis. H Q 7 D E O H 7 K H U H Z D V D O V R the mean count of UNK cells was significantly higher in women with recurrent pregnancy loss than women with had a live birth. O L Y H E L U W K U S & R U b i l o C M f d R e a l . F a s h d e s c r i b e d a c c e s s o r e p r e s s i o n of parity, live birth, miscarriages, and UNK of the patient group. UNK in 29 women with recurrent pregnancy loss are shown in Table 2.

Discussion

The endometrial leukocyte population consists of T-cells, number of live births and the number of endometrial CD56+ macrophages, and natural killer cells. T-cells constitute 45% of cells. Different etiologies except for reduced UNK, such as leukocytes in the proliferative phase. Although their numbers chromosomal abnormalities, could be a reason for miscarriage. remain constant throughout the cycle, their rate in proliferative phase is higher compared with other types of leukocytes. Dramatically from about 5% of stromal cells in the follicular phase is higher compared with other types of leukocytes. The most important leukocyte population in the endometrium and early luteal phases of the menstrual cycle to 30-40% comprises UNK cells. These lymphocytes contain the NK cell surface antigen CD56. During the implantation, large granulai implantation occurred. Gaynor and Colucci indicated that lymphocytes constitute 70-80% of the leukocyte population, UNK numbers increased further to as much as 70% of stromal and if conception occurs, their number increases more. UNK cells if implantation occurred. The current study demonstrated cells are particularly abundant in the uterus at the time of implantation and there was a positive correlation between the number of implantation and are in close contact with placental trophoblastic cells and the number of endometrial CD56+ cells, and F H O O V 81. F H O O V K D Y H D P D M R U U There was also a significantly reduced density of CD56+ cells G H Y H O R S P H Q W R I W K H S O D F H Q W D in women with recurrent implantation failure. In contrast, W H trophoblast invasion to decidua. In the absence of implantation, Tuckerman et al. found that the high density of CD56+ cells in the endometrium of women with RIF was directly involved in the development of RIF. L Q L P S O D Q W D W L R Q G X U D W L R Counting G G L W a higher density of endometrial CD56+ cells in women with RIF than in controls. They suggested that testing for endometrial NK cells might be helpful in women with idiopathic RIF during the luteal phase.

7 D E O H Patient demographics and comparison of the number of endometrial CD56+ NK between groups

	P S O D Q W I D L O X U H	D C o n t r o l s Q Q Q	p
Age (years)	33.5±5.6	34.4±5.3	0.224
No. of deliveries	0		
1 R R I P L V F D U U L D J H V			
uNK	10.5±10.5	19.2±11.2	

uNK: Uterine natural killer

7 D E O H Correlation coefficients of parity, live births, miscarriages, and UNK of the patient group

	3 D U L W \		/ L Y H E L U W K		O L V F D U U L D J H		uNK	
	r	p	r	p	r	p	r	p
3 D U L W \	1		0.870		0.963		0.476	
/ L Y H E L U W K	0.870		1.000		0.827		0.463	0.001
O L V F D U U L D J H V	0.963		0.827		1		0.430	0.002
uNK	0.476		0.463	0.001	0.430	0.002	1	

uNK: Uterine natural killer

Conclusion

Implantation failure is a multifactorial problem of reproductive fully understood. The results of our study suggest that uNKs play a role in the progress of normal pregnancy and reduced uNK cell numbers were associated with implantation failure. We believe that further studies will explain the role of these cells in the etiology.

(WKL FV

(WKL FV & R PPL W WTH loc S Stud Y Committee

DSSURYHG WKH VWXG\ DSSURYDO QR

, QIRUPHG & RePatiens Were informed orally and in writing.

3HHU UHYLHZ Externally and internally peer-reviewed.

\$XWKRUVKLS & RQWULEXWL RQV

& RQFH SW % * 3 2 0 & d 'HVLJQ <

Collection or Processing: P.O., R.A., Analysis or Interpretation:

3 2 5 \$ /LWHUDWXUH 6HDUFK 3 2

R.A., G.B.

& RQIOLFWRRI , QWHUHVW The authors report no conflict of interest.

)LQDQFLDO 'LVFORVXUH Authors have no financial interests & ROXFFL) 8WHULQH 1DWXUD

about the research.

References

& RXJKODQ & /HGJHU : :DQJ 4 /LX) 'HP LNURO \$ XUDQYHW D

Recurrent implantation failure: definition and management. Reprod Biomed Online 2014;28:14-38.

9DQ 0RXULN 06 0DFNORQ 16 + HLMQHQ & -6DQMLQQLQF ,LPBDQWDWQQQ - 9HUG ~ 9 cytokines, adhesion molecules, and immune cells in establishing an LPSODQWDWL RQ HQYLURQPHQW - /HXNR

%ORLV 6 7RPHWWHQ 0 .DQGLO - +DJHQ (,QWHUFHOXODU DGKHVLRQ PROHFXOH mediator capable of disrupting immune integration and tolerance mechanism at the feto-maternal interface in murine pregnancies. Immunol 2005;174:1820-9.

.RRSPDQ /\$.RSFRZ +' 5\EDORY % %R\W 6FKDW]) HW DO +XP DQ GHFLGXDO QDW NK cell subset with immunomodulatory potential. J Exp Med 2003;198:1201-12.

1DJOHU \$ /DQLHU / & ZLUOD 6 3KLOOLS human FcRIII-positive and negative natural killer cells. J Immunol 1989;143:3183-91.

*LXOLDQL (3DUNLQ ./ /HV VH\ %\$ <RX & KDUDFWHUL]DWLRQ RI XWHULQH 1. FHOC recurrent pregnancy loss and associated endometriosis. Am J

Reprod Immunol 2014;72:262-9.

4XHQE\ 6 9LQFH *)DUTXKDUVRQ 5 \$SOLC D GHIHF W LQ QDWXUH .V TXDOLW\ FRQWUR

& QLIIRFS . 0)CDQDJDDW\\$D 5HJDQ / (QGRPH cells in women with recurrent miscarriage: a histomorphometric

\$WSXG\ : UFLXW L5Q\\$URG(3 % *

6DFNV *)LQNHOVWHLQ (1DWXUDO NLOOH

Front Immunol 2020:e13291.

7XFNHUPDQ (0DULHH 1 3UDNDVK \$ /L

natural killer cells in perimplantation endometrium from women with repeated implantation failure after IVF. J Reprod Immunol 2010;87:60-6.

'LVWLQFWLRQV DQG ,QIOXHQFH RQ 3UHJC

Front Immunol 2017;8:467.

Where and when should natural killer cells be tested in women with

Where and when should natural killer cells be tested in women with repeated implantation failure? J Reprod Immunol 2015;108:142-8.

Comparison of intramuscular versus subcutaneous aqueous progesterone for luteal phase support in artificially prepared frozen embryo transfer cycles

+ R U P R Q U H S O D V P D Q x L O H K D] x U O D Q P x
 VL N O X V O D U x Q G D L Q W U D P X V N • O H U S U R J H V W H U R Q X Q O X W H D O I D] G H V W H y L

① (P U H 1 L \ D] L ② X D J I X O H W . • E U D ③ R H Q X D N O D O x Q D R P D O X L N K H ④ D U N x Q H U
 ⑤ O X V W D I D 1 % D K o H F L

1% D K o H F L + H D O W K * U R X S) X O \ D , 9) & H Q W H U p V W D Q E X O 7 X U N H \

2Cyprus Science University, Faculty of Medicine, Department of Statistics, Kyrenia, Cyprus

\$EVWUDFW

2 E M H F W L Y H Cryopreservation of embryos for future transfer attempts has noticeably increased in the last decade, especially due to the developments in in vitro I H U W O L] D W L R Q , 9) O D E R U D W R U L H V , Q S D U D O O H O G L I I H U H Q W S U R J H V V H P E U \ R W U D Q V I H U \$ &)(7 D W W H P S W V H V S H F L D O O \ Z L W K U H V S H F W W R W K H U R X W H R I S U R Y L G H P R U H L Q I R U P D W L R Q D E R X W W K H H I I L F D F \ S U R I L O H R I Q R Y H O V X E F X W D Q H R X V D 0 D W H U L D O V D Q G 0 H W K R G V This retrospective, single-centre cohort study included a total of 507 AC-FET cycles performed between

7 K U H H K X Q G U H G I R U W \ Q L Q H S D W L H Q W V U H F H L Y H G P J R I L Q W U D P X V F X O D U D V W Z L F H G D L O \ 2 Q O \ W K H I L U V W D Q G V L Q J O H E O D V W R F \ V W W U D Q V I H U V I U R P W K H V D \ H D U V E R G \ P D V V D Q Q G H \ * N V S D H B P F R Q F H Q \ W / U D B W H R L Q P S Q D Q W D W L R Q J H Q H W L F W H V W L Q J F R X W F R P H Z D V W K H O L Y H E L U W K U D W H / % 5

Results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cycles.

. H \ Z R U G V 6 X E F X W D Q H R X V D T X H R X V S U R J H V W H U R Q H L Q W U D P X V F X O D U S U R J H V W H U R Q H

Öz

\$ P D o 6 R Q R Q \ x i o \ g r d I H U W O D Q N \ O D W \ R Q , 9) O D E R U D W X Y D U x Q G D P H \ G D Q D J H O H Q W H N Q R C E X H P E U L \ R O D U x Q J H O H F H N W H N L W U D Q V I H U L Ü O H P V D \ x O D U x I D U N H G L O L U E L U ü H N L O G o \] • O P \ ü H P E U L \ R W U D Q V I H U L + 5 ' d (7 | Q F H V L X \ J X O D Q D Q S U R J H V W H U R Q 3 \ H U L Q H N R o R N W D U W x ü x O P D \ D E D Ü O D Q P x ü W x U % X o D O x ü P D G D \ H Q L E L U I R U P \ O D V \ R Q R O D Q V X E D G D K D I D] O D E L O J L H G L Q P H \ L D P D o O D G x N

PRECIS: 6 X E F X W D Q H R X V D T X H R X V S U R J H V W H U R Q H L V D Q H I I H F W L Y H D O W H U Q D W L Y H transfer cycles.

\$ G G U H V V I R U & R U U H V S R Q G P H Q H H L A D] k ü P D U S & W H O V L % D K o H F L + H D O W K * U R X S) X O \ D , 9) & H Q W H U p V W D Q E X O 7 X U N H \ Phone: +90 533 641 20 10 (P D L O dremreturgut@gmail.com 2 5 & , ' , ' orcid.org/0000-0002-5986-3121 5 H F H L Y H G * H O L Ü 7 D U L K L 17.06.2020 \$ F F H S W H G . D E X O 7 D U L K L 18.10.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

*HUHO YH <|QWHPOHU 5HWURVSHNWLI WHN PHUNH]OL NRKRUW oDOxüPDVx RODUDN GL] WDQH +5 'd(7 VLNOXVXQX L oHUPHNWHGLU +DVWDODUxQ .XQGD PJ LQWUDP 63 J•QGH LNL GHID NXOODQxOGx \$|Qx WHGDYL VLNOXVXQGD HOGH HGLOHQ YH GRQGXU KDVWDQxQ WHNUDUOD\DQ WHGDYL VLNOXVODUx oDOxüPD\D GDKLO HGLYOP H GNSPDKL O HG NRQVDQWUD^VRQ QROD\UDN NDEXO HGLOGL 3UHLP SODQWDV\RQ JHQHWLN WDQx X\JXODQDC RUDQODUx /%5 HOH DOxQGx %XOJXODU gQFHNL ,9) GHQHPH VD\xVx LQIHWLLOLWH WSL JLUYH VHUXP HVWUDGLRO IDUNOxOxN J\|VWHUGL 3RJLWLI JHEHOLN S NOLQLN JHEHOLN S YH /%5 S EHQ]HUGL bNLOL ORMLVWLW UHJUHV\RQ DQDOL]LQGH WRSODQDQ RRVLW VD\xVx >D\DU HQGRPHWUL\DO NDOxQOxN \$25 &, S YH NUL\RSUH]HUYDV\RQ J•Q RODUDN DQODPOx EXOXQGX)DNDW NXOODQxODQ 3 WSL /%5 VRQXoODUxQGD DQODPOx 6RQXo 63 HQMHNVL\RQODUx JHEHOLN VRQXoODUx •]HULQGH NDUüxODüWxUxODELOLU ELU \$QDKWDU .HOLPHOHU 6XEN•WDQ|| SURJHVWHURQ LQWUDP•VN•OHU SURJHVWHURQ GRQ

Introduction

Almost 37 years ago, the first human pregnancy was reported following the developments in the in vitro cryopreservation of embryos and subsequent FET strategy has doubled in the last decade. Artificial endometrial preparation is one of the methods used for FET cycles and has been found as successful as the other approaches. These cycles, minimal

monitoring is required, and the timing of embryo transfer and Materials and Methods

LQLWLDWL RQ RI SURJHVWH ThBrode, 3 LV PRUH IOH[LEOH it allows both the physicians and embryology staff to easily HVLJQ

R U J D Q L] H G D L O \ E X V L Q H V V S O D Q Q L D . In this retrospective, single-center cohort study, we reviewed Exogenous P replacement is preceded by estrogen the pregnancy outcomes of 507 AC-FET cycles, performed supplementation and its use is mandatory to prepare the between June 2018 and April 2020 in Bahceci Fulya IVF centre. endometrium for successful implantation and the survival The reason for choosing the time interval in this way was the of the pregnancy. Exogenous P can be administered by different routes: intramuscular, vaginal, oral, rectal, and subcutaneous. Oral micronised P formulations are Ethics approval was obtained from the institutional review recently, subcutaneous. Oral micronised P formulations are exposed to the first-pass effect within the liver, hence they have experience and reports in the literature, we switched to the a low effect profile. Vaginal formulations such as capsules, gels or suppositories showed a similar efficacy profile when compared with each other or by the intramuscular route transfer . Only the first single blastocyst transfers from the +R Z H Y H U G H E D W H V U H J D U G L Q J W K same embryo were included in the study. The eligibility criteria W L P L Q J I R U O X W H D O S K D V H V X S S R U W U / W K H D F Q G S Q H V H Z H U U H D R V J R Q Q R Z V 2 L O E D V H G L Q W U D P X V F X O D U S U R J H V W H U R Q H O , 3 3 D Q N G U I P s 2 N o n r e p r o d u c t i o n concentration painful and may cause serious adverse effects such as skin [6]. Couples with a history of repeated implantation inflammation and sterile abscesses, but they have been found for intrauterine adhesions, submucosal fibroids and mullerian to decrease subendometrial uterine contractility better than Y D J L Q D O S U R J H V W H U R Q H 9 3 D Q G D Q R P D O S L H V W X Q L F R H Q X D W H E L E R U Q X related to increased pregnancy outcomes and decreased rates excluded from the study. Also, couples carrying chromosomal of embryo displacement following the attachment process abnormalities and preimplantation genetic testing cycles were In the light of new technological developments, subcutaneous not included.

and absorbable state by the addition of β -cyclodextrin. Two protocols were preferred: metformin fulvate in water (100 mg) or F1FOHV FRPSDUHG WKH H1ILFDVRI 68 the Q Gor 93 day DQG the U HSPRULWVH, yohimbine RQJRLQJ SUHJQDQF\ UDWHV 235V LDQMGH DWYRNQE\ L2HMUKH WDWDHUW H/G% 5V XVLQJ . Regarding the degree of acceptance and satisfaction, the RUPRQH * RQDO) OHUFN 6HURQR * HO authors found significantly increased acceptance rates for the highly purified KXPDQ PHQRSDXVH JRQDG R WU 63 URXWH FRPSDUHG ZLWK 93 .8 OHULRQDO .% 6\$ SUHSDUDWL

were designated at the physician's preference. When the intrauterine gestational sac at 6-7 weeks of pregnancy. Missed O H D G L Q J I R O O L F O H H [F H H G H G P P D E R Q G I W D L P R H Q V H O \$ Z D V P J G R H I I L * Q B G D V D & D Q W D J R Q L V W & H W U R W L G H 6 H U R Q GestationV V W D U W H G G D L O \ X Q W L O W K H G of maturation trigger. Maturation of the oocytes was induced either with the use of 250 µg of human chorionic gonadotropin 6 W D W L V W L F D O \$ Q D O \ V L V K & * 2 Y L W U H O O H 6 H U R Q R R U P R U W K H W U Y W V W H S W K H R O P R J R U R) H U U L Q J 7 U D Q V Y D J L Q D O V R Q R J U D S K \ tests were performed to understand whether the continuous retrieval was performed 35-36 hours later. variables followed a normal distribution. Accordingly, the P H G L D O T Y D U W L O H T Y D U W L O H Y D

After the denudation process, each metaphase II oocyte median test was run to determine if there were differences in ZDV LQMHWLHG ZLWK VSHUP XVLQ ~~conWhkolds parameters between patients~~ ~~the two treatment~~ LQMHWLHQ WHFKQLTXH DQG FXOW ~~grbludsG ThQ Ghi-SquareX~~ ~~was performed~~ ~~std FtsD the S U HTXLLOEUDWHG FXOWXUH GLVK \$~~ ~~I signifiance of the difference~~ ~~David Schreiber~~ ~~David Schreiber~~ ~~World G KRXUV DIWHU LQVHPLQDWLRQ reported as percentages H S PHGLD , UYLQH 6FLHQWLILF & \$ 86\$ ZDV XVHG WKUARbharity Logistic regression model was performed regarding period. Blastocyst quality assessment was performed on day~~of~~outcomes to determine whether a patient was having a live or 6 by two senior embryologists, with the aid of a morphology-birth. In this model, female age, duration of infertility, sperm based three-part scoring system as described previously concentration, type of infertility, total number of retrieved Once the embryo reached the expansion degree of at least RRF\WHV HQGRPHWULDO WKLFNQHV YLWULILFDWLHQ ZDV SHUIRUPHG IRU FUEROSDUHWRHFUV DWTLRQO LWDW HHJ[RHD]DHWL RI EODVWRF\WVZ DV IROORZV HDPH(OODHQGWWS\\$R13RDRCGP LQLVWUDWL RU DQG \\$% \$& %\\$ %% SRRU as independent variables. The backward&conditional procedure RU & \$ was used and variables that were not statistically significant~~

\$UWLILFLDO 3UHSDUDWLRQ RI)(7 & WOH were removed from the model. The final binary logistic model reported only the statistically significant parameters. To Endometrial preparation was started on day 2 or 3 of menstrual cycle. PHDVXUH WKH HIIHFW RI HDFK VLJQLIL
EOHHGLQJ ZLWK HVWUDGLRO YDOHUDWH SLOOYV HVWURHP DQG BGMXV WHG RGV UDWLVR 1RUTGLN
'HQPDUN DW D GRVDJH RI PJ GDI \$VWDEOH GRYLQJ VFKHPHI ZDVOV implemented. Follow-up visits were performed between day 10 and 14 of treatment. Endometrial thickness was measured other factors were eliminated and only the specific variable XVLQJ 79 86* DQG EORRG ZDV GUDZQ WR GHWHFW VHUUXP HVWUDGLRO calculated when all the significant independent variables were (DQG 3 OHYHOV 7KH GRVDJH RI (SLOOYV ZDV LQFUHVHG WR P taken into account simultaneously. GD\ LI WKH WKLFNQHVZ DV PP DQG DQ DGGGLWLRQDO IROORZ XS visit was planned within the next seven days for confirmation.

visit was planned within the next seven days for confirmation. Results
\$FFRUGLQJ WR WKH SDWLHQW·V DQG SK\VLFLDQ·V SUHIHUHQFH /36 ZDV
LQLWLDWHG HLWKHU ZLWK PJ ,03 All 507 patients in our study were assigned to one of the two
) DUPD 7XUNH\ RQFH SHU GD\ RU ZLWK /36 DOWHUQD WLYHV 03 ZDV XVG L Q
, % 6\$ 6ZLW]HUODQG LQMHFWL RQV DQG SP)3 F
ZDV LQMHFWHG EHWZHHQ DQG DQG VXEVH\ XHOWGRVHV ZHUH
UHS HDWHG HYHU\ KRXUV DW WKH VDPH WLPH LQWHU YDO)RU WKH 63
LQMHFWL RQ WKH ILUVW GRVH ZDV LQMHFWHG EHWZHHQ DPDQG DP
DQG WKH VHFRQG GRVH ZDV LQMHFWHG KRXUV ODWHU 7KH VDPH
scheme was followed every day. In our daily routine, all transfers Table 2 displays the characteristics of AC-FET cycles and
are performed between 4 pm and 7 pm. Accordingly, FET was pregnancy outcomes. As shown, the only parameter to reach
performed following the 15 dose of IMP and the 11 G R V H R 63 statistical significance was the peak E2 levels, which were
DGPLQLVWUDMCG Relevante Unmeasured 12 days after measured on the day of or one day before the initiation of P
)(7 DQG OHYHOV • ,8 ZHUH DFFHSWHG DV SRVLWLYH \$IWHDUZDUGV
replacement was stopped at the 6 week of pregnancy, whereas UHSODFHPHQW S 7KHUH ZHUH Q
P was continued until 10 weeks in both arms. EHWZHHQ JURXSV UHJDUGLQJ SRVLWL

Binary logistic regression analysis was performed to determine

7 D E O H Demographics, clinical and embryologic parameters

	, 0 3 Q	6 3 Q	S Y D O X
Female age			0.305
% 0 , N J P			0.073
Duration of infertility			0.913
Previous IVF attempts			0.003
6 S H U P F R Q F H Q P W U D W L R Q			0.475
Type of infertility			
Female			
Male			0.017*
8 Q H [S O D L Q H G 8 (,			
Combined			
7 R W D O G R V H R I J R Q D G R W U R S L Q V , 8			0.850
3 H D N (O H Y H O V S J P /			
Total number of oocytes			0.002*
No. of mature oocytes			0.003*
No. of 2PN			0.001*
) H U W L O L] D W L R Q U D W H) 5			0.843
% O D V W X O D W L R Q U D W H S H U 3 1			0.687
9 D O X H V D U H U H S R Q W H G D V P H G L D Q 4			
, Q G H S H Q G H Q W V D P S O H V P H G L D Q W H V W Z D V X V H G W R W H V W W K H P H G L D Q Y D O X H E H W Z H H Q W K H , 0 3 D Q G 6 3			

*statistically significant p-value at the _ O H Y H O , 0 3 , Q W U D P X V F X O D U S U R J H M W i t h U H R L Q M O E D , W L V R Q Q \ P D V V L Q G H [, 9)

7 D E O H Properties of FET cycles and pregnancy outcomes

	, 0 3	SP	S Y D O X
(Q G R P H W U L D O W K L F N Q H V V P P			0.224
Cryopreservation day			
Day 5			0.907
Day 6			
Blastocyst Quality			
Excellent			
Good			0.301
Poor			
3 H D N (O H Y H O V L Q)(7 S J P /			0.025*
3 R V L W L Y H S U H J Q D Q F \			0.474
& O L Q L F D O S U H J Q D Q F \			0.979
0 L V V H G \$ E R U W X V			0.144
/ L Y H E L U W K			0.404

r² WHVW ZDV XVHG WR WHVW WKH SURSRUWLRQV EHWZHHQ WKH , 0 3 D Q G 6 3 J U R X S V I R U F D W H J R U L F D O Y D U

*statistically significant p-value at the _ O H Y H O

, Q G H S H Q G H Q W V D P S O H V P H G L D Q W H V W Z D V X V H G W R W H V W W K H P H G L D Q Y D O X H I R U F R Q W L Q X R X V Y D O X H

progesterone

statistically significant,r² S 7 K H a n d R C o r r e l o d y classified 62.1% of cases. As shown in Table 3, H [S O D L Q H G 21 D R J H O N K H U Y D H U & D Q F H A Q R a n d L A Y R c o n c l u d e d t h a t variables such as the total

7 D E O H / R J L V W L F U H J U H V V L R Q P R G H O R Q O L Y H E L U W K R X W F R P H

	%	Wald	S Y D O X R	&, I R U 2 5	/ R Z H U	Upper
Total no. of oocytes	0.024	4.715	0.030	1.024	1.002	1.047
Endometrial thickness	0.114	4.040	0.044	1.121	1.003	1.253
Cryopreservation day						
Day 5	Reference	---	---	---	---	---
Day 6	-0.864	7.338	0.007	0.421	0.226	0.788

A binary logistic regression model was used with a backward conditional procedure. The outcome variable was taken as having a live birth or not. Reference category on the cryopreservation day was taken as day 5.

*statistically significant p-value at the _ O H Y H O &, & R Q I L G H Q F H L Q W H U Y D O 2 5 2 G G V U D W L R

number of retrieved oocytes, endometrial thickness, and shorter duration of adverse effects, those related to hormonal cryopreservation day were statistically significant both when considered separately and when taken into analysis at the same time. AC-FET cycles using day 6 cryopreserved blastocysts resulted in a 57.9% less likely live births compared with day 5 endometrial sampling. The authors reported adequate pre-

E O D V W R F \ V W W U D Q V I H U V > \$ 2 5 decidual transplants at the time of embryo transfer. Specimens &, S @ , W L V D O V R of the new formulation total number of retrieved oocytes increased by one unit, patients were 1.024 times more likely to have a live birth, and similarly, when the endometrial thickness increased by one unit, patients interpreted with caution and further well-designed studies especially in overweight &, S D Q G \$ 2 5 and obese women.

S U H V S H F W L Y H O \ 3 D G P T h e best route of administration D F K L H Y H V W D W L V W L F D O V L J Q L I L F D of replacement in AC-FET cycles. According to a Cochrane review, there was no significant difference between VP and IMP

L Q W H U P V R I & 3 0 \$ U D R Z H V Y H D Q G W K H 5 V As far as we know, this is the first study to compare the clinical declared that the results were insufficient to draw a definite H I I L F L H Q F \ S U R I L O H V R I W K H Q R Y H onclastion due to the heterogeneity between the included IMP in AC-FET cycles. The results of our study showed nonstudies. In a more recent analysis in which VP and IMP were L Q I H U L R U S U H J Q D Q F \ R X W F R P H V R I compared in FET cycles, digital pregnancy outcomes were in women undergoing AC-FET compared with IMP. reported. By contrast, Devine et al. reported decreased

For many years, owing to its insoluble properties, the onlyOPRs only in the VP group when compared with VP plus IMP way to administer the synthetic progesterone hormone was D Q G , 0 3 R Q O \ D Q G W K H \ W H U P L Q D W H W K U R X J K L Q W U D P X V F X O D U L Q M H F W G L X R H Q W R \$ L Q M H F W G L W \$ K U D W H P D Q \ adverse effects and causes discomfort, most studies used IMP

7 K H E U R D G U D Q J H R I D J H V H as a reference when comparing other formulations due to its H D U V D Q G W K H Q L Q H G D \ X V H R I 9 3 E reliable contributions to pregnancy outcomes. The aim into account. In another study, significantly lower rates of CP R I S U R G X F L Q J D Q H Z L Q M H F W D E O H and live birth were reported in the VP group following day 3 W K H D G Y D Q W D J H R I H [L V W L Q J S D U F E T O W H U D O L Q M H F W L R Q R Q S U H J Q D Q F \ results, and to eliminate its adverse effects, complications, and the main limitations of the study were the use of the slow negative effects on patient comfort) R U W K L V S X U S U R V H V H L Q D W R H F K Q L T X H I R U F U \ S U H V H et al. D V V H V V H G W K H E L R D Y D L O D E L O L H P E R J N R W M H U D Q R V I H H Q \ 6 3 L Q R V W P H D Q D V R I L R E Q D V in comparison with oil-based IMP among postmenopausal women. Irrespective of the route of using oral dydrogesterone for FET cycles also needs further D G P L Q L V W U D W L R Q L P D Q G V F investigated on P D [L P X P F R Q F H Q W U D W L R Q V & max R I 6 3 S U R G X F W Z H U H W L P H \$ W D Q J Q X H B] W S K U D Q F W W L K A H L R Q A U V N Q R Z G I R I W K H R L O \ , 0 3 S O R U H R Y H are made throughout the stimulation period before IVF treatments.

Cmax Z D V W L P H V V K R U W H U L Q W K A K G I J H I U R U X H S S D H W D H Q W Q J D W K H I D P L O L D U safety profiles, the authors reported lower frequency and attempts and feel safe K L O H V H O I D G P M o d e l v e t V H U L C

W K H O H V V H U L Q M H F W L R Q V L W H S D B C
related to its water-soluble content Another advantage of
63 X V H L V S U H Y H Q W L Q J W K H P H V V \
application.

6WXG\ /LPLWDWL RQV
7KH PDMRU ZHDNQHVHV RI RXU VWX
DQG ODFN RI UDQGRPL]DWLRQ IRU W
retrospective nature is also the greatest obstacle to reaching
information about patient comfort. The main reason for the
VPDOO VDPSOH VL]H LV WKDW WKH 6
country approximately two years ago. We designed this study
in patients who were aged younger than 37 years to alleviate
the risk of aneuploidy, which might give rise to increased rates
RI DERUWL RQV)RXU KXQGUHG HLJKW
in the study were aged younger than 37 years. Due to the legal
restrictions in our country, we included only single blastocyst
transfers. We believe that the strict inclusion and exclusion
criteria helped us to generate homogenous groups and detailed
analysis of the variables added strength to our work.

Conclusion

This study provides clinical evidence that the newly developed
63 IRUPXODWL RQ KDV D FRPSDUDE OH
RXWFRPHV D Q G L V D VWURQJ FDQGL
Future prospective studies and RCT are needed to clarify the
best way regarding various P replacement regimens.

(WKLFW

(WKL FV & RPPLW WHH \$SSUR YDO Ethics a
IURP WKH LQVWLWXWL RQDO UHYLHZ E

, Q I R U P H G & R Q V H Q W Retrospective study.

3 H H U U H Y L H Z Externally and internally peer-reviewed

\$XWKRUVKLS & RQWULEXWLRQV

6XUJLFDO DQG 0HGLFDO 3UDFWLFHV
0 % 'DWD &ROOHFWLRQ RU 3URFHVV
RU ,QWHUSUHWDLWRQ = < /LWHU
ENT

& R Q I O L F W R I , Q W H U H V W The authors report no
) L Q D Q F L D O ' L V F O R V X U H Authors have no conflicts
 about the research.

References

- 7URXQVRQ \$ ORKU / +XPDQ SUHJQDQF\ IRWOLPZLQDJWLRQ SURHVHQYDWLRQ IHUWLQJD
thawing and transfer of an eight-cell embryo. Nature 1983;305:707-
9.
&HQWHUV IRU 'LVHDVH &RQWURO DQG 3UHKDPSQWR R%Q6 '\$(0)QHUV 6GRPDQFW7IRUDUQHU)&
Assisted Reproductive Technology 2016 Assisted Reproductive 7KRPDV 6 (YLGHQFH RI LPSDLUHG HQGRPH
7HFKQRORJ\ 1DWLRQDO 6XPPDU\ 5HSRUWV V\6P\KSDWLRQDQFLQ+YHDLWLRK IHUWLQJDW
DQG +XPDQ 6HUYLFHV KWWSV ZZERPGSDURQJD UUWHVSGIDQG IURJHQ WKDZHG H
UHSRUW \$57 1DWLRQDO 6XPPDU\ 5HSRUHWSSRGHUV)HUWLQ 6WHULO

- * D U G Q H U ' . 6 F K R R O F U D I W :% & X O W X U H 6 DDVQRGU W U 5 DQGLIUR R Q L & X B B Q H W W L % / R S U
blastocysts. Curr Opin Obstet Gynecol 1999;11:307-11. et al. Pharmacokinetics and safety profile of a novel progesterone
* D U G Q H U ' . / D Q H 0 6 W H Y H Q V - 6 F K O H ~~at nebulus formulation~~ R D R O I s t e r i d l y ths s.c. route. Gynecol
Blastocyst score affects implantation and pregnancy outcome: Endocrinol 2013;29:205-8.
W R Z D U G V D V L Q J O H E O D V W R F \ V W W U D Q V I G H U = L H I U O / H I O ' 6 W 6 D U M L R O 0 % L Q H O O L ' / H X U
< D Q X V K S R O V N \ (+ X U Z L W] 6 * U H H Q E H U J H W 5 D D F R & V U N D Q & G R P R L U Q G & W H U L Q O F R P S D U L Q J
M. Crinone vaginal gel is equally effective and better tolerated than subcutaneous administration of 25 mg and 50 mg progesterone in
intramuscular progesterone for luteal phase support in in vitro D T X H R X V S U H S D U D W L R Q) H U W L O 6 W H U L O
I H U W L O L] D W L R Q H P E U \ R W U D Q V I H U F \ F O H V O M S R U R V A N S H ' F V B I H V I F H U B Q G L R V P E J D H G Q V W X G X H O C
) H U W L O 6 W H U L O Endometrial Preparation for Women Undergoing Embryo Transfer
3 R O \] R V 13 0 H V V L Q L &, 3 D S D Q L N R O D R X: L(W K 0)D U X R U H Q (P E L U R B & V R & (P E U \ R V ' H U L Y H O
Badawy A, et al. Vaginal progesterone gel for luteal phase support in & R F K U D Q H ' D W D E D V H 6 \ V W 5 H Y &
, 9) , & 6, F \ F O H V D P H W D D Q D O \ V L V) H D W B e g e 6 B M H B H I I O s JA. Pregnancy outcomes in oocyte donation
6 L O Y H U E H U J . 0 9 D X J K Q 7 & + D Q V D U G / - U H F X I S L H I Q W V & Y D Q L V Q H D U 7 J H O Y H U V X V L Q W U
9 D J L Q D O & U L Q R Q H J H O Y V L Q W U D P X ~~replaced~~ J S A b b R t R e p o d G d d R 2012;29:23 R 42 O I R U
O X W H D O S K D V H V X S S R U W L Q L Q Y L W U R I H H W L Q H J D W 5 L R F & W D I Q D & J H L G U R V S H F O W L H Y H E W
) H U W L O 6 W H U L O transfer cycles with the use of only vaginal progesterone replacement
. D V H U ' - * L Q V E X U J (6 0 L V V P H U 6 \$ & R ~~with~~ D m e t r i n h a v D i f f e r i n g b i g g i n g & pregnancy rates: results from
Intramuscular progesterone versus 8% Crinone vaginal gel for luteal W K H S O D Q Q H G L Q W H U L P D Q D O \ V L V R I D W
S K D V H V X S S R U W I R U G D \ F U \ R S U H V H U Y H Q R Q P Q U H B L V R U D Q V V I W U L D D O U W H I Q W L V O H G M / B U L C
2012;98:1464-9. 5 D V K L G L % + * K D] L] D G H K 0 7 H K U D Q L 1
24. Zoppetti G, Puppini N, Ospitali F, Fini A. Pharmaceutics, * R U J L Q] D G H K 0 2 U D O G \ G U R J H V W H U R Q H I
S U H I R U P X O D W L R Q D Q G G U X J G H O L Y H U \ - W 8 K I D Z U H P G D F H H P X E M U 6 F L W U D Q V I H U D U W L I L F L D O
36. controlled trial. Asian Pac J Reprod 2016;5:490-4.
= R S S H W W L * 3 X S S L Q L 1 3 L] X W L 0) L Q H D I S H L * I S R Y 6 D R Q K D L 7 O & R P D Q V D Q H] K D G 0 (\$ O E
6 : D W H U V R O X E O H S U R J H o d d e r R Q H K & R J R \$ D S U L R V R Q R I I R X U S U R W R F R O V I R U O X
F R P S O H [I R U L Q M H F W D E O H I R U P X O D W L R Q K D Z H , Q F H P E 3 K I R Q W B D Q Q V A H R F F D O O H V D U D
Chem 2007;57:283-8. Gynecol Obstet 2017;295:239-46.

In vitro maturation with letrozole priming: Can it be a solution for patients with cancerophobia? A pilot study

/ HWUR]RO LOH QQYFP DQW RQD VURQ . DQV
KDVWDODUGD ELU o|]•P RODELOLU PL

- y DIDN + D W x B Q]6 D \Q X U D D W S H Q D % D O E & H . D Q D W D C h r N e M D ü
- 0 L F K D H Q D D K H D D Q Q 7 D Q

¹Medicana Samsun International Hospital, Samsun, Turkey

²McGill University Faculty of Medicine, Department of Obstetrics and Gynecology, Montreal, Quebec, Canada

³Düzce University Faculty of Medicine, Department of Obstetrics and Gynecology, Düzce, Turkey

⁴Afyon Health Sciences University Hospital, Clinic of Obstetrics and Gynecology, Afyonkarahisar, Turkey

⁵Antalya Training and Research Hospital, Clinic of Obstetrics and Gynecology, Antalya, Turkey

⁶Originelle Women's Health and Fertility Center, Montreal, Quebec, Canada

\$EVWUDFW

2EMHFVLYH 7R LQYHVWLJDWH ZKHWKHU OHWUR]ROH iSvlttoP DQW XFRXW GRQH , XVOH Q VHLRIPSHD
VWLWXODWLQJ KRUPRQH)6+ SULPLQJ
0DWHULDQV DQG OHWKRGV 7KLV LV D UHWURVSHFWLYH DQDO\VLV RI SDWLHQWV ZKR
2+66 Q FDQFHURSKRELD Q DQG GHVLUH IRU ,90 DIWHU IDLOHG LQ YLWUR IHU
SDWLHQWV UHFHLYHG OHWUR]ROH SULPLQJ
Results: 7KH SDWLHQWV ZKR KDG)6+ RU OHWUR]ROH SULPLQJ ZHUH VWDWLVWLFDOO\ VLPL
IROOLFOH FRXQW VHUXP DQWL 0•OOHULDQ KRUPRQH OHYHOV DQG ,90 LQGLFDWLRQV
JHUPLQDO YHVLFOH RRF\WHV PHWDSKDVH , DQG IHUWLOL]HG RRF\WHV ZHUH VLJQLILF
PHWDSKDVH , RRF\WHV ZDV VLJQLILFDQWO\ ORZHU LQ WKH OHWUR]ROH SULPLQJ JURXS
VLPLodu UDWHV RI LPSODQWDWLRQ YV S FOLQLFDO SUHJQDQF\ YV
&RQFOXVLRQ 3RWHQWLDO LQGLFDWLRQV IRU ,90 LQFOXGH SDWLHQWV ZLWK LQFUHDVH
FDQ EH XVHG WR SUHVHUYH WKH IHUWLOLW\ RI SDWLHQWV ZLWK HVWURJHQ VHQLWL
XQGHUJR ,90 ZLWK OLNHO\ OHVV FRVW WKDQ)6+ SULPLQJ
.H\ZRUGV Cancerphobia, *in vitro* PDWXUDWLRQ WHFKQLTXHV OHWUR]ROH RRF\WHV 2YDULDQ +\S

Öz

\$PDo % X inDoxP D W XUDV\RQD ,90 JLUHQ KDVWDODUGD OHWUR]RO NXOODQxPxQxQ HWNL
LOH NDUü XODÜWxUxOPDVxQx DUDÜWxUPD\x DPDoODPDNWDGxU
*HUHo YH <|QWHPOHU % X UHWURVSHNWLI oDOxüPD \•NVHN <XPXUWDOxN +LSHUVWLP•
W•S EHEHN WHGDYLVL VRQUDVx ,90 GHQHPN LVWH\HQ Q ,90\H JLUHQ KDVWDQxQ
|QF•OOHQPLÜWLU
%XOJXODU)6+ YHD OHWUR]RO |QF•OOHQPLÜ RODQ KDVWDODU \DÜ Y•FXW NLWOH LQGH
VHYL\HOHUL YH ,90 HQGLNDV\RQODUx DoxVxQGDQ LVWDWLVWLNHO RODUDN EHQ]HUGL
JUXSWD JHUPLQDO YH]LN•O RRVLWOHUL 0HWIDID] , YH G|OOHQPLÜ RRVLWOHULQ VD\xV
0HWIDID] , RRVLWOHULQLQ VD\xV OHWUR]RO |QF•OOHQPLÜ JUXEXQGD DQODPOx RODUD

PRECIS: / HWUR]R @MitrS UPDPM QUDWLRQ SURWRFRO KDV SURPLVLQJ UHVXOWV LQ FDVHV Z
RXWFRPHV DUH FRPSDUDEOH ZLWK)6+ SULPLQJ ,90

\$GGUHVV IRU &RUUVSRQG BODNH <DDW\WQDQD \$ GUMRE 3URI
0HGLFDQD 6DPVXQ ,QWHUQDWLRQDO +RVSLWDO 6DPVXQ 7XUNH
Phone: +90 362 311 05 05 (PDLO VDIDNKDWLUQD]#JPDL FRP 25&,' , orcid.org/0000-0001-8859-0639
5HFHLYHG *HOLÜ 7DULKL 25.06.2020 \$FFHSWHG .DEXO 7DULKL 04.10.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

RODUDN EHQJHU LPSODQWDV\ RQ RUDQODUX . H NDUÜx S NOLQLN JHEHOL
 S YH FDQOx GRýXP . H NDUÜx S J]OHQPLÜWLU
 6RQXo ,90 LoLQ SRWDQVL\HO HQGLNDV\RQODU DUWPxü 2+66 ULVNL YH KLSHULQVXOLQ
 NDQVHUOHUGH IHUWLLOLWH NRUXPD DPDoox NXOODQxODELOPHNWHGLU /HWUR]RO LOH
)6+ |QF•OOHQPLü WHGDYLGHQ RODVxOxNOD GDKD X\JXQ PDOL\HWWH ROPDNWDGXU
 \$QDKWDU . HOLPHOHU Kanserfobi, in vitro PDWXUDV\RQ WHNQLNOHUL OHWUR]RO RRVLWOHU 2Y

Introduction

In vitro PDWXUDWL RQ ,90 UHIHUV immature oocytes from antral follicles, with the final stages of meiosis completed during in vitro culture. Potential indications for IVM include patients with increased risk for breast disease Q D IDPLO\ KLVWRU\ RI E DQG IDPLO\ KLVWRU\ RI HQGRPHWULXP approved by the Institutional Review Board of the study center. DSSURYDO QR DQG FRQGXFWHG HWKLFDO SULQFLSOHV RXWOLQHG LQ participants gave written informed consent.

2YDULDQ +\SHUVWLPXODWL RQ V\QGURPH WZ\6 SSWLHQWV U\PHLYHG) limited time for ovarian stimulation, and patients with a contraindication for elevated concentrations of estradiol 2YDULDQ +\SHUVWLPXODWL RQ V\QGURPH WZ\6 SSWLHQWV U\PHLYHG) OHWUR]ROH K&* SULPLQJ &DQFHURSKR The primary benefits of IVM are the reduction in gonadotropin JURXS ZDV UHODWHG WR ILEURF\VVWLF H[SRVXUH WKH VXEVTXHQW GHFUHDPLQWLWKRULW\RN RUH\B\W DQFHU facilitation of oocyte retrieval in oncology patients who need Q 3DWLHQWV ZLWK K\SHUSURODFW to undergo gonadotoxic treatment without adequate time fomon-classic congenital adrenal hyperplasia, adrenal and ovarian ovarian stimulation . Another benefit of IVM is the avoidance androgen-secreting tumors were excluded. Women whose from ovarian stimulation-related hyperestrogenism in oncology S D UWQHUV KDG DJRRVSHUPLD FU\SW patients with hormone-sensitive tumors ROLJRDVWKHQ RWHUDWR]RRVSHUPLD ZH /HWUR]ROH LV DQ DURPDWDVH LQKLELWRU WKRW\ RQDGRWURSLQ DQG YHWUR]ROH 7KH VWDQGDUG SURWRFRO IRU ,90 LQO of androgens into estrogens in the ovarian milieu /HWUR]ROH exerts its primary action by increasing endogenous secretion RI IROOLFOH VWLWXODWLQJ KRUPRQH)6+ DQG DVHFRQGDU\ DFWLRQ the study center, as previously described ,90 ZLWK OHWU by giving rise to a hyperandrogenic microenvironment, which triggers the development of primordial follicles Therefore, it Beginning on the 3 day of a spontaneous or an induced KDV EHHQ K\SRWKHVL]HG WKDW OHWUR]ROH FBYQG E\XVHG WR DFKLH ovarian stimulation in women with hormone-sensitive tumors SDWLHQWV UHFHLHYHG U\PHFORPLEFNQ DQWR) without exposing them to sustained elevated estrogen levels *HQHYD 6ZLW]HUODQG DW D GDLO\ GR The avoidance from hyperestrogenism might also help to ,8 RI XULQDU\®, IO&g;anor, A\Hsler, about the long-term probability of developing estrogen- *HQHYD 6ZLW]HUODQG ZDV DGPLQLV sensitive cancers while they are undergoing an assisted R OOLFOH VL]H ZDV WR PP DQG HQ reproductive cycle . On the other hand, the emergence of least 8 mm on transvaginal ultrasonography in the mid-sagittal a hyperandrogenic microenvironment might be beneficial inplane. Under the guidance of transvaginal ultrasonography, cases of oocyte maturation arrest. oocyte pickup was performed using a 17-gauge double-lumen 7KLV VWXG\ DLPHG WR LQYHVWLJDWHS LZKDHWLKRHQ QOHHW\ORI] R\OWKS\QPD\QS LUD could be used efficiently for patients who were to undergo IVM 38 hours after hCG administration. WUHDWPHQW GXH WR D KLJK ULVN RI 2+66 GHWBLWLRQ ,90 RU IHDU IRU Materials and Methods

Materials and Methods

This is a retrospective analysis of 63 patients who underwent IVM. This study was approved by the Institutional Review Board of the study center. All procedures were conducted in accordance with the Declaration of Helsinki and the principles of the International Conference on Harmonization Good Clinical Practice. The study was registered at ClinicalTrials.gov (NCT02800001). All procedures were conducted in accordance with the Declaration of Helsinki and the principles of the International Conference on Harmonization Good Clinical Practice. The study was registered at ClinicalTrials.gov (NCT02800001).

D Q G W K H Q L Q F X E D W H G a n d M % Q. A f t e r D Q 6 W D W & L V W L F D O \$ Q D O \ V L V
L Q F X E D W L R Q L Q / \$ * P H G L X P R R F \ W H & R Z H H H S O D F H G H T X D Q Q \ B Q D W K H G X
Z H O O V R I D I R X U Z H O O G L V K 1 X Q F 5 R V N L O G H P H Q R D J N F R Q W D \ Q L Q J P O

incubated for 26-28 hours. Nuclear maturity of oocytes was not assessed any further.

denoted as numbers or percentages. Continuous variables were categorical variables were compared using the *t*-test or ANOVA. A post hoc analysis was performed to determine significance level.

\$OO ,&6, SURFHGXUHV ZHUH SHURUPHG LQ)DOFRQ 3HWUL GLVK ZLWK
GURSOHWV RI 393 FROWDILQLQJ PHGTXRUVSHUPV 9LWUROLIH &RGH
Results

Table 4 compares the baseline characteristics of the 21 patients who received heparin for oocytes.

presence of two distinct pronuclei and two polar bodies within
 WKH RRF\WHV LQ , 60 PH G L X P W K U R ~~X~~ D E K O B Q Base Methylation Status of the Promoter Regions S H

at x200 magnification. This was repeated 24 hours later. The classification system introduced by Veeck was used for

The embryos were graded as follows: Grade 1 - embryo with

The embryos were graded as follows. Grade 1 = embryos with EODVWRPHUHV RI HTXDO VL]H QR F % RG\ PDVV L²Q GH [27.07±6.02 25.16±4.35 0.159 HREUVR ZLWK EODVWRPHUHV RI HTXDO DVWVRDHR LBLQH RIWAQ DWWK 16.2019 DVWVRZ

fragments or blebs: Grade 3 - embryo with blastomeres o \$ Q W U D O I R O O L F O 1 5 . 7 E R 1 X Q W 7 ± 6 6 0 . 1 9 8
G L V W L Q E W Q Y Q U T X D C V I I I I I G R O U I

Embryo transfer was performed using a Wallace embryo transfer gun. The transfer rate was 5.56±1.35% (n=13), 6.04±1.36% (n=13) and 0.191% (n=1).

guidance and placed 1.5 to 2.5 cm from the fundus. Women deviation

aged younger than 35 years could only have a single embryo transferred, and a maximum of two embryos could be transferred.

to women aged over 35 years. Taking endometrial thickness into consideration, fresh embryo transfers were performed on day 6 + Letrozole.

3 or day 5. To prepare the endometrium for embryo transfer, an oral estrogen tablet was administered at a daily dosage of 400 micrograms. This was continued until the day of transfer. On the day of transfer, a dose of 200 micrograms was given. The purpose of this treatment was to prevent oocyte maturation arrest.

P J (V W^U R I R H P R 1 R U G L V N % D J V Y U G 3 & 2 6 S D W L H Q W V Z L W K 0.306 J W
I U R P W K H W K L U G G D \ R I P H Q V W U X E cancerophobia

was begun the day following OPU, which was provided with , Q F U H D V H G U L V N I R U 2 + 6 6 0.099 a vaginal progesterone capsule at a daily dosage of 200 n

and progesterone capsules were continued until the first fetal 3R0\|VWLF RYDULHV RQ 79 86* 0.338

Clinical pregnancy was defined as the presence of at least one 3 U H Y L R X V 2 + 6 6 0.838

Clinical pregnancy was defined as the presence of at least one gestational sac in the uterus. No IVM cycles were cancelled in 3 R0\1 F\1 VVLF 2 YDU\1 V\QGURPH 2+66 2 YDULDQ +\SHUV Transvaginal ultrasonography

this study. Transvaginal ultrasonography 249

ZKR KDG UHWURJRUH SULPLQJ DQG
B&OHWUWHG WKH B&E\WHV ZHJLH

\$J\ H\ \backslash H\ D\ U\ V\ 29.2\pm4.8\ 31.1\pm4.2\ 0.129

% R G \ P D V V L²Q G H [27.47±6.02 25.16±4.35 0.159
 T X D D O W V R P H R I P L Q Q R D W V E D W V R 1 S C Q H D V U B 1 S F
 \$ Q W U D O I R O O L F O 1 5.7 E R I X Q W 7 ± 6.6 0.198
 R U I H 2 F W K R S O D V P L F I U D J P H Q W V
 \$ Q W L 0 • O O H U L D Q K R U P R Q H Q J 5.56 ± 1.35 6.04 ± 1.36 0.191
 P / D E C P R P L Q D O X Q W U D V P O R U D S K I
 9 D O X H V D U H J L Y H Q D V P H D Q " 6') 6+) R O O L F O H V W
 deviation

Indications for in vitro maturation	
	Q J W
Qocyte maturation arrest	0.285
3 & 2 6 S D W L H Q W V Z L W K cancerophobia	0.306
, Q F U H D V H G U L V N I R U 2 + 6 6	0.099

BY-NC-SA 3.0 DE | <https://creativecommons.org/licenses/by-nc-sa/3.0/de/>

<RXQJ DJH \HDUV -	0.209
\3RO\ F\VWLFRYDULHV RQ 79 86*	0.338
3UHYLRXV 2+66	0.838

Comparison of pregnancy outcomes of two groups	
7DEOH JURXS V ZHUH VWDWLWLFDO O\) 6+ Letrozole p
similar concerning the endometrium thickness on the hCG day time to oocyte pick up, retrieved oocytes counts, and single) 6+ SULPLQJSULPLQJ
RU GRXE OH HPEU\ R WUDQVIHUV S! T RU DOO :KHZ FRPSDUHG	Implantation rate per transfer 0.709
ZLWK WKH) 6+ SULPLQJ JURXS D VL LDOU FDOVW KLIKII QXPFHIP	Clinical pregnancy rate per transfer 0.848 \ WHV
JHUPLQDO YHVLF OH RRF\WHV PHW UHVSHFWLYH	lower number of metaphase I oocytes and grade 3 embryos 6LQJOHWRQ SUHJQDQF\ UDWH SHU
S S S UHVSHFWLYHO\ 7KH QXP EHI Twin pregnancy rate per transfer 0.611 KHZ	ZHUH GHWHFWHG LQ WKH OHWURJDO SULPLQJ JURXS S
DOVR VLJQLILFDQWO\ ORZHU LQ WK transfer	SDWLHQWV ZKR UHFHLYHG) 6+ DQG CWWKJRUH SULPLQJ RDS VWDWLWLFDO
FRPSDUHG ZLWK WKH) 6+ SULPLQJ JURXS S	VLPLODU UDWHV RI LPSODQWDWLRLQ culture media. Thus, hormones are not administered to patients undergoing IVF treatment + RZH YHU WKH JHQH DEXW ,90 EV WKDW D VKRUW SULPLQJ increases the chance for oocyte maturation and implantation in
YV S DQG OLYH ELUWK	SDWLHQWV ZLWK 3&26 7KLV VKRUW SUHJQDQF\ YV S WZLO SULPLQJ
Table 4 shows the pregnancy outcomes of the patients. Th	9DOXHV DUH JLYHQ DV QXP EHU SHUFHQWDJH) 6+ DQG CWWKJRUH SULPLQJ RDS VWDWLWLFDO
SDWLHQWV ZLWK 3&26 7KLV VKRUW SUHJQDQF\ YV S WZLO SULPLQJ	YV S WZLO SULPLQJ
YV S DQG OLYH ELUWK	undergoing IVF treatment + RZH YHU WKH JHQH DEXW ,90 EV WKDW D VKRUW SULPLQJ increases the chance for oocyte maturation and implantation in
Discussion	SDWLHQWV ZLWK 3&26 7KLV VKRUW SUHJQDQF\ YV S WZLO SULPLQJ
By definition, IVM refers to the maturation of collected immature oocytes under the influence of hormones that exist within the	9DOXHV DUH JLYHQ DV QXP EHU SHUFHQWDJH) 6+ DQG CWWKJRUH SULPLQJ RDS VWDWLWLFDO
7DEOH /DERUDWRU\ ILQGLQJV RI WKH SDWLHQWV	YV S WZLO SULPLQJ
Endometrial thickness at hCG 9.07±1.25 9.63±1.68 0.138	clinical pregnancy rates in IVM cycles . Accordingly, this
GD\ PP 9.07±1.25 9.63±1.68 0.138	study adopted an IVM protocol indicating the administration of
7LPH WR RRF\WHV 13.2±1.8N X450±18D \M123	UHFRPELQDQW) 6+ DW D GRVH RI ,8 I
5HWULHYHG RRF\W2B\6.8Q 14.6±3.6 0.273	, Q WKLV VWXG\ SDWLHQWV ZLWK 3&26
HUPLQDO YHVLF Q814±18R F\8M±6.5 QD.003	priming because they had cancerophobia due to fibrocystic breast disease and a positive family history for breast and endometrium cancer. Therefore, priming was performed using
0HWDSKD VH , RRF\WHV 14.6±0.7 0.002*	DQ DURPDWDVH LQKLELWRU QDPHO\ O
0HWDSKD VH , RRF\WHV 9.04±2.7 0.001*	3&26
)HUWLOL]HG RRF\W5H2/8 Q 6.8±1.5 0.016*	In this study, the primary indications for IVM treatment
(PEU\ R WUDQVIHU Q 0.621	ZHUH WKH DYRLGDQFH IURP 2+66 DQG
6LQJOH HPEU\ R	desiring IVM. It is well known that IVM is the only assisted reproduction technique that has been proved to be devoid of
Double embryo -	2+66 ULVN 5HFHQW PHWD DQDO\VHV U
(PEU\ R JUDGH Q 0.007*	with IVM had significantly higher implantation and clinical pregnancy rates, as well as significantly lower miscarriage and cycle cancellation rates . The maturation of human oocytes is naturally arrested at the germinal vesicle stage when the oocytes need gonadotropin stimulation and the metaphase II
Grade 1 -	VWDJH ZKHZ RRF\WHV DUH ZDLWLQJ IF approach for failed IVF could be the IVM of immature oocytes within culture media enriched with factors necessary for oocyte maturation , if compromised in vivo.
Grade 2 -	Due to the wide variations in priming protocols, varying numbers between 8% and 40% have been specified as the clinical pregnancy rates and live birth rates in IVM cycles
Grade 3 -	6LPLODUO\ RXU SUHYLRXV VWXG\ UHS of 44.6% and 44.7% and live birth rates of 34.9% and 34.2% for single embryo transfer and double embryo transfers in
(PEU\ R TXDOLW\ Q 0.007*	KRUPRQH K&* +XPDQ FKRLRQLF JRQDGFMUFRQIHQV ZLWV KF. As for the present study, the clinical pregnancy and live birth rates were respectively 31.5%
One-cell embryo -	6WDQGDUG GHYLDWLQR
Two-cell embryos -	
Three-cell embryos -	
Four-cell embryos -	

9DOXHV DUH JLYHQ DV PHDQ " 6' RU QXP EHU SHUFHQWDJH) 6+ DQG CWWKJRUH SULPLQJ RDS VWDWLWLFDO

and 24.1% in IVM cycles with gonadotropin priming. Although clinical pregnancy and live birth rates tended to be higher in IVM cycles with letrozole priming (33.3% and 29.6%), there were no statistically significant differences.

A new indication for IVM has been defined as a convenient therapeutic approach for infertile patients who have been diagnosed as having malignancies and scheduled for oncofertility treatment. The basic rationale for this definition is the feasibility of IVM for preserving oocytes and embryos and thus, future fertility, whenever conventional in vitro fertilization is not an option. A potential factor that might delay the oncology treatment can also be avoided because IVM prevents the risk of OHSS. Additionally, this technique can be used to replace an IVF cycle that would otherwise end up with excessive follicular growth and subsequent cycle cancellation^(25,26).

Another advantage of IVM treatment is that it can be started immediately at any time of the menstrual cycle without stimulating ovaries. Therefore, IVM emerges as an appropriate technique for preserving the fertility of oncology patients in whom the initiation of chemotherapy, radiotherapy or surgical treatment cannot be delayed^(1,2). Another advantage of this assisted reproduction technique is that serum estrogen concentrations remain low throughout an IVM cycle. Therefore, IVM has been established as a safe and effective method for fertility preservation in patients with estrogen-sensitive tumors^(25,26).

It is also well known that aromatase inhibitors can be used as single agents or adjuncts to FSH-containing ovulation induction regimens for preserving the fertility of patients with estrogen-sensitive breast cancer. Aromatase inhibitors would reduce supra-physiologically serum concentrations of estradiol, suppress local production of estrogen within the tumor tissue, and induce follicular growth in women with estrogen-sensitive malignancies. Combining gonadotropins with aromatase inhibitors would augment the ovarian stimulation without a profound increase in serum estradiol levels^(27,28).

Conclusion

The findings of this study suggest that IVM treatment with letrozole priming might be an efficient approach for patients who have a high risk for OHSS or fear for estrogen-sensitive tumors. However, these findings should be interpreted carefully as their power is limited by its retrospective design, small cohort size, technical inadequacy for cryopreservation, and lack of long-term data. Further research is warranted to clarify the clinical implications of letrozole priming in IVM cycles. A prospective study of letrozole-primed IVM should be considered.

Ethics

Ethics Committee Approval: This study was approved by the Institutional Review Board of the study center (approval no: 3/2020).

Informed Consent: All participants gave written informed consent.

Peer-review: Externally and internally peer-reviewed.

Authorship Contributions

MDODDOLFIWBY

MDK

DVZ

SMA

MKBGK

M.K.P.

Conflict of Interest: The authors report no conflict of interest.

Financial Disclosure: Authors have no financial interests about the research.

References

1. RJ. In vitro maturation. Best Pract Res Clin Obstet Gynaecol 2018;53:60-72.
2. Sauerbrun-Cutler MT, Vega M, Keltz M, McGovern PG. In vitro maturation and its role in clinical assisted reproductive technology. Obstet Gynecol Surv 2015;70:45-57.
3. Khalili MA, Shahedi A, Ashourzadeh S, Nottola SA, Macchiarelli G, Palmerini MG. Vitrification of human immature oocytes before and after in vitro maturation: a review. J Assist Reprod Genet 2017;34:1413-26.
4. Sonigo C, Grynberg M. In vitro oocyte maturation for female fertility preservation. Gynecol Obstet Fertil 2014;42:657-60.
5. Grynberg M, El Hachem H, de Bantel A, Benard J, le Parco S, Fanchin R. In vitro maturation of oocytes: uncommon indications. Fertil Steril 2013;99:1182-8.
6. Nguyen TT, Doan HT, Quan LH, Lam NM. Effect of letrozole for ovulation induction combined with intrauterine insemination on women with polycystic ovary syndrome. Gynecol Endocrinol 2020;36:860-3.
7. Tanbo T, Mellembakken J, Bjercke S, Ring E, Åbyholm T, Fedorcsak P. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand 2018;97:1162-7.
8. KHDLD1.OLPDQXQWRSDDP5:DKPDQQ%5RVHQZDNV
Z. Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer. Gynecol Endocrinol 2019;35:214-6.
9. Sonigo C, Sermonade N, Calvo J, Benard J, Sifer C, Grynberg M. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients. Eur J Obstet Gynecol Reprod Biol X 2019;4:100049.
10. KDJQJ*KDJQJ*HQJ) :DQJ - KHQJ1 \$LORWMGR
gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer. J Gynecol Oncol 2019;30:e61.
11. Sánchez F, Lolicato F, Romero S, De Vos M, Van Ranst H, Verheyen G, et al. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. Hum Reprod 2017;32:2056-68.
12. DQWTXHWUHQH%HFNHU%DULHOG-36FKRROFDIV%
Krisher RL. A pre-in vitro maturation medium containing cumulus oocyte complex ligand-receptor signaling molecules maintains meiotic arrest, supports the cumulus oocyte complex and improves

- oocyte developmental competence. Mol Hum Reprod 2017;23:594-606.
13. Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol 2012;10:32.
 14. Hatirnaz S, Hatirnaz E, Dahan MH, Tan SL, Ozer A, Kanat-Pektas M, et al. Is elective single-embryo transfer a viable treatment policy in in vitro maturation cycles? Fertil Steril 2016;160:1691-5.
 15. Hossain A, Phelps J, Agarwal A, Sanz E, Mahadevan M. A Review of The Society for Assisted Reproductive Technology Embryo Grading System and Proposed Modification. Int J Fertil Steril 2016;10:141-7.
 16. DKDQ07DQ6/KXQJ-6RQ:@LQLFDOGHILQLVRQSDSHBQ in vitro maturation of human oocytes. Hum Reprod 2016;31:1383-6.
 17. De Vos M, Smitz J, Thompson JG, Gilchrist RB. The definition of IVM is clear-variations need defining. Hum Reprod 2016;31:2411-5.
-XQN60HDS'PSEMGGLPSODOQWQRDQGRQJRLQJSUJQDQF\ rates after single-embryo transfer with an optimized protocol for in vitro oocyte maturation in women with polycystic ovaries and polycystic ovary syndrome. Fertil Steril 2012;98:888-92.
:DOOV0/XQWU5DQ-3.HHODQ-\$DWDQ(BW,Q
vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes. Hum Reprod 2015;30:88-96.
 20. De Vos M, Ortega-Hrepich C, Albuz FK, Guzman L, Polyzos NP, Smitz J, et al. Clinical outcome of none hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome. Fertil Steril 2011;96:860-4.
 21. Lindenberg S. New approach in patients with polycystic ovaries, lessons for everyone. Fertil Steril 2013;99:1170-2.
 22. Siristatidis C, Sergentanis TN, Vogiatzi P, Kanavidis P, Chrelias C, Papantoniou N, et al. In vitro maturation in women with vs. without polycystic ovarian syndrome: a systematic review and meta-analysis. PLoS One 2015;10:e0134696.
 23. H FMUOKD]RH &XSND 06 :OV &RFDOX (Motrenko T, et al. ART in Europe, 2014: results generated from European registries by ESHRE: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2018;33:1586-601.
 24. 6KLDVDZD 7HDGD <Q KMPDXWLRQ RI KXPDQ LPPDXH oocytes for fertility preservation and research material. Reprod Med Biol 2017;16:258-67.
 25. 6KRKD P HYROHGDQR 5 /HRQJ 0 :HLVVPDQ \$BQ < Shoham Z. Oncofertility: insights from IVF specialists-a worldwide web-based survey analysis. J Assist Reprod Genet 2019;36:1013-21.
 26. Fatum M, McVeigh E, Child T. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate. Hum Fertil (Camb) 2013;16:235-40.
 27. Comtet M, Sonigo C, Valdelliévre C, Sermonnade N, Sifer C, Grynberg M. Fertility preservation in breast cancer patients: the state of art in 2014? Bull Cancer 2015;102:443-53.
 28. 7DNDL 5HFHQWGDQFHV LQ RQFRIHWOLWDH ZROGZLGH DQG LQ Japan. Reprod Med Biol 2018;17:356-68.

Introduction

Infertility affects approximately 15% of the general population worldwide and 40-50% is attributed to female infertility. It is caused by many factors, and fallopian tube abnormalities cause about 30-35% of cases of female infertility. The method used in the determination of both tubal pathologies and tubal patency, and uterine and peritoneal pathologies in the investigations into the etiology of infertility. Although general anaesthesia, the procedure can be painful. Up to 72% of patients complain of pain from the procedure.

The mechanisms causing pain may include cervical instrumentation, and irritation of contrast medium in uterine cavity distension, and peritoneal irritation of contrast medium that has spread to the abdomen. In addition, taking the uterus into traction by holding the cervix with a tenaculum increases local prostaglandin synthesis and can lead to uterine contractions and pain. Patients think that this procedure will be painful and are reluctant to have the test, which also causes anxiety. Many different randomised controlled studies have investigated many different agents and different applications in literature that have evaluated these studies.

Therefore, no optimal method has been found as yet, which can complement treatments have started to be more widely used in modern medicine, and of these, acupuncture applications have shown efficacy, especially in acute pain syndromes and chronic pain. Kiran et al. determined that acupuncture

similar effects in patients with primary dysmenorrhea. In recent acupuncture decreased anxiety and increased quality of life in patients applied with in vitro Therefore, the aim of this study was to investigate, for the first time in literature, the effect of acupuncture in reducing pain.

D Q G D Q [L H W \ L Q S D W L H Q W V X Q G H U J R L Q J + 6 *

Materials and Methods

Approval for the study was granted by the Clinical Research

(W K L F V & R P P L W W H H R I . D K U D P D Q P D U D ü 6 • W o • p P D P 8 Q L Y H U V L W \ G H F L V L R Q Q R V H V V L R Q 3 D W L H Q W V Z K R D G P L W W H G W R our Assisted Reproductive Techniques clinic with the desire

vagina, and following observation of the cervix, local cleaning was applied with 3% povidone-iodine. Then, depending on the cervix position, the anterior or posterior cervical lip was held

Z L W K D W H Q D F X O X P D Q G D 5 X E L Q + 6 * F D Q Q X O D Z D V J H Q W O \ S O D F H G
in the cervical canal. The speculum was removed and 10-20

P / Z D W H U V R O X E O H U D G L R R S D T X H V R O X W L R Q 8 U R J U D I L Q Š

P / % D \ H U \$ * 7 X U N H \ Z D V X V H G D V D F R Q W U D V W P H G L X P D Q G

L Q M H F W H G V O R Z O \ X Q G H U V S R W I O X R U R V F R S \ \$ I W H U F R P S O H W L R Q R I W K H
procedure, all the instruments were removed and the patient was transferred to a bed.

\$ 9 L V X D O \$ Q D O R J V F D O H 9 \$ 6 Z D V X V H G L Q W K H H Y D O X D W L R Q R I S D L Q
V H Y H U L W \ D Q G W K H 6 W D W H W U D L W \$ Q [L H W \ L Q Y H Q W R U \ V W D W H 6 7 \$, 6
L Q W K H H Y D O X D W L R Q R I S D W L H Q W D Q [L H W \ \$ O O W K H 9 \$ 6 D Q G 6 7 \$, 6
V F R U L Q J Z D V S H U I R U P H G E \ D V L Q J O H S K \ V L F L D Q \$ 8 E O L Q G H G
W R W K H J U R X S V , Q W K H 9 \$ 6 V \ V W H P W K H S D W L H Q W L V L Q V W U X F W H G W R
S O D F H D P D U N R Q D P P K R U L] R Q W D O O L Q H F R U U H V S R Q G L Q J W R W K H
O H Y H O R I S D L Q I H O W Z K H U H Q R S D L Q D Q G L Q W R O H U D E O H S D L Q
7 K H T X H V W L R Q V R Q W K H 6 7 \$, 6 I R U P Z H U H D V N H G G L U H F W O \ W R W K H

patients and the results were recorded. Both evaluations were

D S S O L H G D W P L Q D Q G P L Q E H I R U H W K H + 6 * S U R F H G X U H D Q G D W
minutes after the procedure and all the results were recorded.

In the evaluation of anxiety, the changes over the specified time period were evaluated.

6 W D W L V W L F D O \$ Q D O \ V L V

Data obtained in the study were analysed statistically using

6 3 6 6 Y Q V R I W Z D U H , % 0 6 W D W L V W L F V I R U : L Q G R Z V
Y H U V L R Q , % 0 & R U S R U D W L R Q \$ U P R Q N 1 < 8 6 \$ D Q G 3 \$ 6 7
V R I W Z D U H Ø + D P D P H U S H U ' \$ 7 5 \ D Q 3 '

3 D O H R Q W R O R J L F D O V W D W L V W L F V 7 R D V V H V V W K H F R Q I R U P L W \ R I G D W D
Q R U P D O G L V W U L E X W L R Q W K H 6 K D S L U R : L O N W H V W Z D V D S S O L H G W R G D W
Z L W K V L Q J O H Y D U L D E O H V D Q G W K H 0 D U G L D W H V W ' R U Q L N D Q G + D Q V H Q
R P Q L E X V W R G D W D Z L W K P X O W L S O H Y D U L D E O H V 7 K H / H Y H Q H W H V W Z D V

used to evaluate variance homogeneity. Parametric methods were used in the analyses of variables with homogenous variance and normal distribution and non-parametric methods were used for variables not showing homogenous variance and normal distribution. In the comparisons of independent multiple groups with each other, the One-Way ANOVA

5 R E X V W W H V W % U R Z Q) R U V \ W K H D Q G . U X V N D O : D O O L V W H V W V Z H U H
used, and for the post hoc analyses, the non-parametric post

K R F W H V W 0 L O O H U 7 R H [D P L Q H W K H L Q W H U D F W L R Q R I U H S H D W H G
measurements of dependent variables according to the groups,

uS 7 Å e 2 E P Ê Ò E P Ä • B S e 2 E P Ä E ^ Q e 2 E P Ä E 2 E P Ä Å í \$ U L \$ U L P W Ó U L z € Q e 2 E D T % Ä = ö 2 E P Ê Ò E D € 0 € @ 0 m e a s u

LQFUVHDVHG LQ WKH ,0'6 DQG FRQWURO JURXS VDQGWFRHQ WRUSR Q JURXS Z
 VFRUHV PLQXWHV DIWHU WKH +6GHSWRERGQH EHWZHQQ PWKHG, 0'6 DQG
 the valuesin the ACU group were found to be statistically S YH S UHVSHFWLYHO\ 7DEO
 VLJQLILFDQWO\ ORZHU WKDQ WKH ,0'6 DQG FRQWURO JURXS VLPLODU WR
 the 5th minute before the procedure, but this difference was not Discussion

Discussion

G H W H U P L Q H G E H W Z H H Q W K H , 0 ' 6 D The results of this study showed that SCU reduced the pain 7 D E O H K H Q W K H F K D Q J H V L Q W K H 6 7 \$ R 6 H M F R E W H H R U H E H D V Q Z H H D Q W H U W K H + 6 * 1 hour before-5 minutes ago, 1 hour before-30 minutes later W K H 16 \$, ' G L F O R I H Q D F , W Z D V D O V R D Q G P L Q X W H V E H I R U H P L Q X W H v i d o r f a n d A C W h a d t h e s i g n i f i c a n t l y r e d u c i n g anxiety related to D Q D O \] H G W K H F K D Q J H V L Q 6 7 \$, 6 t h e p r o b l e m w e l q W K H \$ & 8 J U R X S Z H U H found to be statistically significant for all three change values? K H U H D U H P D Q \ V W X G L H V R Q W K H V X



)LJXUH 9\$6 VFRUHV PLQXWH EHIRUH WKHQH ZDQWHLURDWHU WR EH QR EHQI 9\$6 9LVXDO \$QDORJ VFDOH +6* +VWHURWDQSLRJUDSK procedure, but when local

that have investigated the types of pharmacological drugs used and the methods of use. A systematic Cochrane review in 2015 randomised studies. Although the level of evidence was low, it was concluded that topical anaesthetics and intravenous opioids could be effective in reducing pain during the procedure, but this effect was not seen after the procedure. It was reported that there was not sufficient evidence that other analgesic methods could be effective. In a review by Ahmad et al. R Q W K H V X E I of pain-relief in office-setting gynaecological interventions, U H D Q U H Z P D - Q X W H S R D W H G W R E H Q R E H Q I first 30 Mins and 30 Mins after the procedure, but when local anaesthetics were used, it was shown that even if not in the first 30 mins, there could be beneficial effects after 30 mins.

with non-pharmacological methods are studies where catheters have been used. It has been suggested that catheters used during + 6 * FR X O G K D Y H G L I I H U H Q W H I I H F W V R al. and Varpula , it was determined that the use of flexible balloon catheters instead of a traditional metal cannula was not effective in reducing pain, while De Mello et al reported in a study published in 2006 that the use of flexible balloon F D W K H W H U V U H V X O W H G investigated the S D L G efficacy of fast-release orodispersible tramadol, as a different D analgesic method, in cases where traditional metal cannula and S balloon catheter were used and reported that it was effective independently of the type of catheter used.

) LJXUH 67\$, 6 VFRUHV PLQXWHV D ~~W~~
+ 6* + \VWHURVDOSLQRJUDSK\ 67\$, 6 b~~o~~
-state ~~DDA~~ ~~the catheter was used~~ and reported that it was effective
independently of the type of catheter used.

7DEOH 67\$, 6 YDOXHV DW KRXU DQG PLQXWHV EHIRUH DQG PLQXWHV DIWHL

ACU is a complementary medicine application with increasingly widespread use. There have started to be wide areas of use especially in the elimination of pain symptoms. Previous studies have shown that the effect mechanisms of ACU are formed on

D E L R O R J L F D O E D V L V S D P H D J h a D t Q e G 3 R P H U D Q]

analgesic efficacy of ACU occurred by increasing endogenous opioids and demonstrated that this effect could be removed with naloxone, which is an opioid antagonist. Using functional magnetic imaging technology, another study showed that the stimulation of ACU points affected the limbic system and structures in both the cortical and subcortical areas in the brain . In a clinical study, Cho et al. determined activity signals in the cingulate gyrus and thalamic region with pain stimuli, and following ACU, reported a decrease both in the signals and in the pain felt by the patient.

Although there are no studies in literature examining the effect

R I \$ & 8 R Q D Q [L H W \ H Q J H Q G H U H G E \ W K H D S S O L F D W L R Q R I + 6 *

there are studies related to the effect of lowering anxiety in general. The hypotheses of some of these studies are explained by biochemical mechanisms and some by physiological

S D U D P H W H U V investigated changes in plasma

D G U H Q R F R U W L F R W U R S L F K R U P R Q H F R U W L F R V W H U R L G D Q G S O D W H O H W + levels in response to anxiety treatment. Comparisons were made of ACU, pharmacological treatment and combined treatment groups, and similar results were found in the ACU group and the pharmacological treatment group. That the side-effects seen in the pharmacological treatment group were not seen in the ACU group was emphasised as a positive aspect. The effects of ACU on anxiety were investigated by observing changes in the parameters of oxygen saturation and heart rate by Karst et al.

D Q G L Q K H D U W U D W H D Q G V N L Q F R Q G X F W L Y L W \ E \ 6 K D \ H V W H K I D U H W D O

As ACU reduced heart rate in both groups, it was concluded to be effective on anxiety.

To the best of our knowledge, this is the first study in literature

W R K D Y H L Q Y H V W L J D W H G \$ & 8 R Q W K L V V X E M H F W + R Z H Y H U W K H U H were some limitations to the study, the first of which is that

W K H G L I I H U H Q W V W D J H V R I + 6 * V S H F X O X P S O D F H P H Q W W H Q D F X O X P S O D F H P H Q W R S D T X H P H G L X P D G P L Q L V W U D W L R Q Z H U H Q R W H Y D O X D W H G Z L W K 9 \$ 6 , Q D G G L W L R Q W K H V L G H H I I H F W V R I 1 6 \$, ' V D Q G \$ & 8

were not examined, and when examining the pain scores, the

+ 6 * U H V X O W V Z H U H Q R W W D N H Q L Q W R F R Q V L G H U D W L R Q

- DQ[LHW\ DQG TXDOLW\ RI OLIH IRU ZRPHQ&KQHQH U5J R3RQH, 9 DQS 1%D QQR P W]WGD F X S X Q F W
 FR QWUROOHG WULDO \$FWD 2EVWHW * \Q Hetero-specific receptors and is reversed on antagonists of type
 <XTLQJ = 4LDQJOL &)XQGDPHQWDOV, RHFA5WQXQFWX4H6PDQG
 0R[LEXVWLRLQ 7LDQMLQ 6FLHQFH 7HFKQRLORJ\LX7UDQVQDWM-R1Q * ROOXE 5/ & K
 Publishing Corporation, 1994.
- .D\QDU 0 .R\XQFX) %XOGX b 7HNLQDUVODQ (7HSHOHU \$ DUDWDY
 T, et al. Comparison of the efficacy of diclofenac, acupuncture, and acetaminophen in the treatment of renal colic. Am J Emerg Med 2015;33:749-53.
 \$XVWLQ 5 6DFNV % 1RZHOO 0)HLWDO & Acupuncture mechanisms Med Acupunct 2002;14:1628-K
 Radiology 1984;151:249.
 9DUSXOD 0 + \VWHURV DOSLQJ R JUDSK\ ZLW Kplasma DcQnQnRd,F dW16dMcbldphYchNdnMdné End
 cannula: evaluation of patient pain. Radiology 1989;172:745-7.
 20. De Mello J, Abrao M, Cerri G, de Barros N. Evaluation of pain in three hysterosalpingography techniques: metal cannula with and without paracervical blockage and balloon catheter. Am J Roentgenol 2006;187:86-9.
 6WRRS ' 'H %UXFNHU 0 + DHQWMHQV Devroey P. Fast-release orodispersible tramadol as analgesia in hysterosalpingography with a metal cannula or a balloon catheter.
 +XP 5HSURG
 Acupuncture modulates the limbic system and subcortical gray structures of the human brain: evidence from fMRI studies in QRUPDO VXEMHFVW +XP %UDLQ 0DSS &KR =+ 6RQ < +DQ -< 105, 1HXURSK\VL
 <XDQ 4 /L -1 /LX % :X =) -LQ 5 (IIHFWR
 SODWHOHW +7 OHYHOV LQ SDWLHQWV Chin J Integr Med 2007;13:264-8.
 .DUVW 0 :LQWHUKDOWHU 0 0•QWH 6)
 A, Eckardt A, et al. Auricular acupuncture for dental anxiety: a JJDQGRPLIHG F RQWUROOHG WULDO \$QHVV
 3JDOHELDQ \$GH0H 6KD\HVWHKIDU 0 6HLI %DUJKL 7 =DULH Anxiolytic Effects on Physiological and Psychological Assessments
 IRUD &OLQLFDO 7ULDO 6FLHQWLILFD &D

Antenatal pentoxifylline therapy to prevent endotoxin-induced fetal injury in the preterm goat model

3 U H W H U P J H E H N H o L P R G H O L Q G H H Q C
K D V D U x Q | Q O H Q P H V L Q G H D Q W H Q D W D

① 0 H N L Q 16H \$U N L Q ? | ② H D U O H P g] ③ D H Q H K P H W + ④ O X U J X . D ü ⑤ N \$F k P H W \$ \ G R ý D
⑥ 2 U K D Q g] D W L N

¹Süleyman Demirel University Faculty of Medicine, Department of Obstetrics and Gynecology, Isparta, Turkey

²Burdur Mehmet Akif Ersoy University Faculty of Veterinary Medicine, Department of Obstetrics and Gynecology, Burdur, Turkey

³Burdur Mehmet Akif Ersoy University Faculty of Veterinary Medicine, Department of Pathology, Burdur, Turkey

⁴Cukurova University Faculty of Ceyhan Veterinary Medicine, Department of Pathology, Adana, Turkey

⁵Isparta University of Applied Sciences Faculty of Agriculture, Department of Animal Science, Isparta, Turkey

⁶Kütahya Health Sciences University Faculty of Medicine, Department of Histology and Embryology, Kütahya, Turkey

\$ E V W U D F W

2 E M H F W L Y H 3 H Q W R [L I \ O O L Q H 37; K D V L P P X Q R P R G X O D W R U \ S U R S H U W L H V D Q G L V N Q F P D W H U Q D O R U D O D Q G L Q W U D D P Q L R W L F D G P L Q L V W U D W L R Q R I 37; I R U W K H S U Y H Q W L R 0 D W H U L D O V D Q G 0 H W K R G V , Q I O D P P D W L R Q P H G L D W H G I H W D O L Q M X U \ Z D V L Q G X F H G Z L W D W R I J H V W D W L R Q L Q G D W H P D W H G S U H J Q D Q W J R D W V (L J K W J U R X S V Z H U H I R U P H G I R U G D \ V I H W D O L Q M X U \ L Q W U D D P Q L R W L F P J N J D Q G P J N J H V W L P D W H G I H W D by hysterotomy was performed at 0.80 of gestation to evaluate the fetal and placental effects. Immunochemistry for various markers including interleukins, caspases, cyclooxygenases, vimentin, myelin basic protein, and surfactant proteins were carried out in the fetal lungs, fetal brain, and placenta. Fetal plasma D Q G D P Q L R W L F I O X L G L Q W H U O H X N L Q V Z H U H D O V R H Y D O X D W H G . U X V N D O : D O O L V + W H V Results: + L J K G R V H P J N J G D \ P D W H U Q D O S U R S K \ O D F W L F R U D O W U H D W P H Q W D W W H Q X L Q I O D P P D W R U \ P D U N H U H [S U H V V L R Q V F R P S D U D E O H W R W K H F R Q W U R O V S ! H [F H S W F D P Q L R W L F I O X L G O H Y H O V R I W K H V W X G L H G L Q W H U O H X N L Q V Z H U H D O V R O R Z H U W K D Q W K P T X was associated with inconsistent results and increased inflammatory markers in some fetuses.

& R Q F O X V L R Q Oral PTX before preterm birth mitigates intrauterine inflammation with neuroprotective effects in the fetus. PTX can be considered as a promising drug for the prevention of preterm birth-associated complications. F D Q G L G D W H G U X J I R U I H W D O E U D L Q L Q M X U \ S U Y H Q W L R Q L Q W K H S U W H U P S H U L R G . H \ Z R U G V \$ Q L P D O P R G H O H Q G R W R [L Q V I H W D O E U D L Q L Q M X U \ Q H X U R S U R W H F W L R Q S H

Öz

\$ P D o 3 H Q W R N V L I L O L Q 37; L P P • Q G •] H Q O H \ L F L [] H O O L N O H U L V D K L S W L U Y H V H S V L V H E H Q I O D P D V \ R Q Y H K D V D U x Q | Q O H Q P H V L Q G H P D W H U Q D O R U D O Y H L Q W U D D P Q L \ R W L N 37; M * H U H o Y H < | Q W H P O H U \$ \ Q x J • Q G H o L I W O H ü W L U L O H Q N H o L O H U G H P D W H U Q D O J U D Q • O R V I H W D O K D V D U J H V W D V \ R Q G D W H W L N O H Q G L 6 H N L] J U X S R O X ü W X U X O G X K H U E L U L Q G I 37; I H W D O K D V D U I H W D O K D V D U O x Y H \ D K D V D U V x] W H N G R] L Q W U D D P Q L \ R W L N P J N I H W D O Y H S O D V H Q W D O H W N L O H Q P H Q L Q G H ý H U O H Q G L U L O P H V L D P D F x L O H S U W H U P G R ý R N V L M H Q D] O D U Y L P H Q W L Q P L \ H O L Q E D] L N S U R W H L Q Y H V X U I D N W D Q S U R W H L Q O H U L J L L Q W H U O | N L Q O H U G H ý H U O H Q G L U L O G L . D U ü x O D ü W x U P D O D U G D . U X V N D O : D O O L V + W H V W L

PRECIS: 8 V L Q J D Q L Q I O D P P D W L R Q P H G L D W H G I H W D O L Q M X U \ F D S U L Q H P R G H O Z H G H preterm delivery.

\$ G G U H V V I R U & R U U H V S R Q Q H Q E Q G B] & N P D \$ G U H V L

6 • O H \ P D Q ' H P L U H O 8 Q L Y H U V L W \) D F X O W \ R I 0 H G L F L Q H ' H S D U W P H Q W R I 2 E V W H W U L F V D Q G * \ Q H F R O R J \ , V S D U W D

Phone: +90 246 211 92 39 (P D L O P V H] L N # \ D K R R F R P 25 & , ' , ' orcid.org/0000-0002-6989-081X

5 H F H L Y H G * H O L ü 7 D U L K L 29.06.2020 \$ F F H S W H G . D E X O 7 D U L K L 01.09.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

%XOJXODU <•NVHN GR] PJ NJ J•Q PDWHUQDO SURILODNWLN RUDO WHGDYL HQGR HQIODPDWXYDU EHOLUWHoOHUGH NRQWURO VHyl\HOHULQH EHQ]HU S! G•JHOPHOHU SUR HQIODPDWXYDU LQWHUO|NLQOHU GH VDGHFH HQGRWRNVLQH PDUX] NDODQODUGDN 37; ED]x IHW•VOHUGH HQIODPDWXYDU EHOLUWHoOHUGH DUWxüODU YH GHylLÜNHQ ELU H 6RQXo 3UHWHP GRyXP |QFHVLQGH RUDO 37; LQWUDXWHULQ HQIODPDV|RQX D]DOWDUD EH\LQ KDVDUXxQx |QOH\HELOHFHN ELU LODo DGD\x RODELOLU \$QDKWDU .HOLPHOHU +D\YDQ PRGHOL HQGRWRNVLQOHU IHWDO EH\LQ KDVDUX Q|URNI

Introduction

Preterm birth is the most important cause of perinatal morbidity and mortality. There is growing evidence that subclinical intrauterine inflammation is responsible for a significant number of preterm deliveries. Up to 40% of pregnancies that resulted in preterm deliveries were found to have positive inflammatory markers in the second-trimester amniotic fluid. Moreover, increased subclinical IA inflammation is suggested to affect the fetus, with the inflammation probably commencing from the lungs and then propagating to the vulnerable fetal brain. This condition has most likely in an ascending manner through the cervix peripartum hypoxia has conventionally been accused for the development of neonatal encephalopathy, data controlling for confounders show that most cases are indeed associated with antenatal insults to the developing fetal brain.

Given the medical and social negative consequences of fetal brain sulfate has been shown to have neuroprotective effects. Some recent data have also indicated that magnesium sulfate may not be neuroprotective in the setting of chorioamnionitis + HQFH WD U J H W H G W K H U D S L H V W K D W , and IA administration of PTX for the prevention of fetal fluid and the chorioamniotic membranes may be required to inhibit initial steps of the inflammatory cascades in the amniotic fluid and the chorioamniotic membranes may be required to agents in a combined form in relatively low cumulative doses, may demonstrate a cocktail effect, decreasing the overall side effects to the fetus, and with various therapeutics acting on different steps of inflammation.

3HQWR[LI\OOLQH 37; LV D V\QW K H W L F PHWK\O[DQWKLQH GHULYDWLYH that competitively inhibits phosphodiesterases with Materials and Methods nonsteroidal immunomodulatory activities. Phosphodiesterase

inhibition is believed to be associated with an anti-inflammatory effect, leading to decreased proinflammatory cytokine6• OH\PDQ 'HPLUHO 8QLYHUVLW\ \$QLP D F W L Y L W\ LQFOXGLQJ W X P R U Q H F U(RWKLVFVD &WIRPLWONSHKD D TS)UR Y B Q GWKH L Q W H U I H U RQ\this , basis, PTX is presently under Q X P E H U G D W H clinical investigation against neonatal sepsis, and a Cochrane meta-analysis has shown decreased sepsis-associated neonatal mortality. A priori power analysis was conducted to test the

PHWD D Q D O \V L V K D V D O V R F R Q I L U P H G U L V N D Q G F R Q I L G H Q F H L Q W H U Y

following neonatal PTX treatment Therefore, maternal use of PTX for inflammation-driven pregnancy complications that might have effects on the fetus seems plausible, considering likely negligible toxicity to the preterm fetus.

In the sheep model, PTX was reported to decrease serum proinflammatory cytokines following experimentally induced endotoxemia . Another experimental study revealed that

PTX was partly effective against pre-eclamptic-like symptoms in ewes . Considering these preliminary animal data, PTX can be considered to have fetal neuroprotective effects by

PLWLJ D W L Q J \$ L Q T Q D P P D W L R Q 0 R U H R E H K\SRWKHVLFHG W R GHOLYH W K H G to act on the fetal alveolar capillary bed and the gastrointestinal system by fetal swallowing.

The experimental ovine and caprine pregnancy models have been in use for translational research due to the physiological similarities with the human pregnancy, avoidance of multiple pregnancies with proper mating strategies, feasibility of IA administrations and sampling, and availability of adequate

D P R X Q W R I I H W D O E O R R G D Q G W L V V X H L Q M X U\ H I I H F W L Y H D Q W H Q D W D O W U H D W P H Q W D U H Q H G H G Q D Q G L Q M X U R Z H Y H U may offer some advantages for experimental obstetric research.

The aim of the current study was to evaluate maternal oral and IA administration of PTX for the prevention of fetal

W U H D W P H Q W E H I R U H L P P L Q H Q W H D U Q O S U H W H U P G H Q Y H U M X U R Z H Y H U D F S U that both oral and IA routes of PTX therapy were effective

+ D J D L Q V W L Q I O D P P D W L R Q P H G L D W H G I period, particularly in the developing lung and brain tissues. To

test this hypothesis, we used the small ruminant experimental

P R G H O W K D W X W L O L I H G P D W H U Q D O J G H F U H D V H I H W D O E U D L Q L Q M X U\ O R U H R Y H U X V H & 6 R I I H W D Q O H X U R S U R W H E F G

agents in a combined form in relatively low cumulative doses, aggravate intrauterine inflammation. We then evaluated various

L Q I O D P P D W R U\ D S R S W R W L F D Q G L Q M X fluid, fetal blood plasma, placenta, fetal lungs, and fetal brain of

the preterm goat fetuses.

3HQWR[LI\OOLQH 37; L Q I O D P P D W R U\ D S R S W R W L F D Q G L Q M X

decrease or increase in the mean, using a two-tailed test and Q E R W K R I W K H V H J U R X S V Q H D F K an alpha of 0.05. Result showed that 4 animals in a group at day 100, and daily treatment continued for 15 days from were required to achieve a power of 80%. Therefore, the gestation day 100 to 114 at a daily dose of 30 mg/kg maternal experimental preterm goat model included 32 date-mated Z H L J K W O R Z G R V H D Q G P J N J P D W H V L Q J O H W R Q S U H J Q D Q W K D L U J R D W R T X , & specifically KA betha V and Zeta V were used to find Q H D F K I R U P H G D W G D \ R I J H F R M P D P M H L R F Q D O V O H U D Y S W B D C D Q I F W D E O H W V D S S U R [L P D W H O \ G D \ V 7 K H D Q L P D D O Q / R Z L H U H Q M D U V H G , R W D S Q D E X W O X U T H X U N H and/or standard food, given water and mineral salts ad libitum After weighing on precision scales to calculate the dose, the and were sheltered in a semi-open pen. All experiments were 7 ; S R Z G H U Z D V G L V V R O Y H G L Q P / carried out at the Faculty of Veterinary Medicine, Mehmet Akif administered to the does via an oral feeding catheter connected Ersoy University. Maternal age and prepregnancy body weight W R D P / V \ U L Q J H 7 K H G R H V Z H U H R was 4-5 years and 40±5 kg, respectively.

([S H U L P H Q W D O * U R X S V

The experiments were carried out in 2 phases. The first phase included validation of inflammation-mediated preterm fetal L Q M X U \ H [S H U L P H Q W D O P R G H O L Q G X F H I H W D O L Q M X U \ V L P L O D U W

D Q L P D O \$ Q L P D O V L Q R W K H U W U H D W P J L Y H Q P / R I V W H U L O H Z D W H U Z L W K R included validation of inflammation-mediated preterm fetal daily low- and high-doses of oral PTX, depending on previous L Q M X U \ H [S H U L P H Q W D O P R G H O L Q G X F H I H W D O L Q M X U \ V L P L O D U W pharmacokinetic data from large animals, Group 3 and 4 J U R X S Q D Q G W K H S R V L W L Y H F R Q W U R O J U R X S Q D Q G J U R X S V D Q L P D O V D O Y R U H F H L Y M G * & 6) G D \ V

Details and results of these first 2 groups with proper validation of the novel modified experimental model initially defined by Watanabe et al. have been described previously

5 H F R P E L Q D Q W * & 6) D W D G D L O \ G R V H R I P L F U R J G L V Y R O Y H G L Q P H G L D W P / Q R U P D O V D O L Q H 1 H X S R J H Q 5 R F K H G R H V L Q J U R X S Q D 5 B F K H / W G % D V H O 6 Z L W] H U O D Q G W R L Q G X F H Q R & 6) U H F L P H Q D Q G Q L Q I Q P P D W L R Q Z D V L Q M H F W H G L Q W R P D W H U Q D O M X J X Q D U Y H I Q J R U F R Q V H F X W I Y H G D \ V

Z D V L Q M H F W H G L Q W R P D W H U Q D O M X J X Q D U Y H I Q J R U F R Q V H F X W I Y H G D \ V

J H V W D W L R Q D O G D \ V Z L W K F R Q W U R Q D O J H V W D W L R Q D O G D \ V

normal saline. At gestational day 115, amniocentesis with

D J D X J H D P Q L R F H Q W H V L V Q H H G Q H

8 Q L W H G 6 W D W H V Z D V S H U R U P H G

(F K R & D P H U D 6 6 ' \$ O R N D 7 R N \ R W \ S L P D O O F R Q V L G H U H G D V N J F R

of inappropriate allantoic entry by the color and viscosity of

the fluid . Amniotic fluid, watery in consistency and pale

amber in color was aspirated from the inner amniotic sac close

to the fetus. Using the amniocentesis needle in the amniotic

V D F K L J K G R V H P J , \$ H Q G R W R [L Q Q L S R S R O V D F F K D U L G H V J U R P

(V F K H U L F K L D F R O L 2 % / 6 L J P D \$ O G U I F K Q L V V R X U L 8 6 \$

was used to induce IA and fetal inflammation in group 1, while

normal saline through amniocentesis. Validation of the model

Z L W K U H V X O W D Q W Q H F U R W L] L Q J I X Q U V I W L V D V V R F L D W H G Z L W K D F X Q G D G

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \ W K D W L V H Y L G H Q W I R O O R Z L Q J H Q G R W R

exposure .

The second phase of the experiments included treatment

37 ; J U R X S V W R W H V W W K H R U D O D L V Q Z M E D H Q D M Q , \$ D B A I L R D F W K D H Q G U V H D I Q H D N Q W

of antenatal PTX therapy. Group 3 and group 4 were designed

to assess the prophylactic use of oral PTX at 2 different doses

postadministration, and the procedure was repeated if the

solution was not properly swallowed or spitted out by the

D Q L P D O \$ Q L P D O V L Q R W K H U W U H D W P

J L Y H Q P / R I V W H U L O H Z D W H U Z L W K R

daily low- and high-doses of oral PTX, depending on previous

pharmacokinetic data from large animals, Group 3 and 4

J U R X S Q D Q G W K H S R V L W L Y H F R Q W U R O J U R X S Q D Q G J U R X S V D Q L P D O V D O Y R U H F H L Y M G * & 6) G D \ V

Group 5 and group 6 aimed to examine the therapeutic effectiveness of single-use IA PTX at 2 different doses against

5 H F R P E L Q D Q W * & 6) D W D G D L O \ G R V H R I P L F U R J G L V Y R O Y H G L Q P H G L D W

P / Q R U P D O V D O L Q H 1 H X S R J H Q 5 R F K H G R H V L Q J U R X S Q D 5 B F K H / W G

% D V H O 6 Z L W] H U O D Q G W R L Q G X F H Q R & 6) U H F L P H Q D Q G Q L Q I Q P P D W L R Q

Z D V L Q M H F W H G L Q W R P D W H U Q D O M X J X Q D U Y H I Q J R U F R Q V H F X W I Y H G D \ V

defined. Additionally at day 115, either single low-dose

J H V W D W L R Q D O G D \ V Z L W K F R Q W U R Q D O J H V W D W L R Q D O G D \ V

normal saline. At gestational day 115, amniocentesis with

H V W L P D W H G I H W D O Z H L J K W 3 7 ; Z D V L Q J U R X S Q D Q G J U R X S V D Q L P D O V D O Y R U H F H L Y M G * & 6) G D \ V

following endotoxin administration using an amniocentesis

needle under ultrasound guidance. Estimated fetal weight was

(F K R & D P H U D 6 6 ' \$ O R N D 7 R N \ R W \ S L P D O O F R Q V L G H U H G D V N J F R

of inappropriateness of allantoic entry by the color and viscosity of

the fluid . Amniotic fluid, watery in consistency and pale

amber in color was aspirated from the inner amniotic sac close

to the fetus. Using the amniocentesis needle in the amniotic

V D F K L J K G R V H P J , \$ H Q G R W R [L Q Q L S R S R O V D F F K D U L G H V J U R P

(V F K H U L F K L D F R O L 2 % / 6 L J P D \$ O G U I F K Q L V V R X U L 8 6 \$

was used to induce IA and fetal inflammation in group 1, while

normal saline through amniocentesis. Validation of the model

Z L W K U H V X O W D Q W Q H F U R W L] L Q J I X Q U V I W L V D V V R F L D W H G Z L W K D F X Q G D G

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \ W K D W L V H Y L G H Q W I R O O R Z L Q J H Q G R W R

exposure .

The second phase of the experiments included treatment

37 ; J U R X S V W R W H V W W K H R U D O D L V Q Z M E D H Q D M Q , \$ D B A I L R D F W K D H Q G U V H D I Q H D N Q W

of antenatal PTX therapy. Group 3 and group 4 were designed

to assess the prophylactic use of oral PTX at 2 different doses

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \ W K D W L V H Y L G H Q W I R O O R Z L Q J H Q G R W R

exposure .

The second phase of the experiments included treatment

37 ; J U R X S V W R W H V W W K H R U D O D L V Q Z M E D H Q D M Q , \$ D B A I L R D F W K D H Q G U V H D I Q H D N Q W

of antenatal PTX therapy. Group 3 and group 4 were designed

to assess the prophylactic use of oral PTX at 2 different doses

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \ W K D W L V H Y L G H Q W I R O O R Z L Q J H Q G R W R

exposure .

The second phase of the experiments included treatment

37 ; J U R X S V W R W H V W W K H R U D O D L V Q Z M E D H Q D M Q , \$ D B A I L R D F W K D H Q G U V H D I Q H D N Q W

of antenatal PTX therapy. Group 3 and group 4 were designed

to assess the prophylactic use of oral PTX at 2 different doses

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \ W K D W L V H Y L G H Q W I R O O R Z L Q J H Q G R W R

exposure .

The second phase of the experiments included treatment

37 ; J U R X S V W R W H V W W K H R U D O D L V Q Z M E D H Q D M Q , \$ D B A I L R D F W K D H Q G U V H D I Q H D N Q W

of antenatal PTX therapy. Group 3 and group 4 were designed

to assess the prophylactic use of oral PTX at 2 different doses

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \ W K D W L V H Y L G H Q W I R O O R Z L Q J H Q G R W R

exposure .

The second phase of the experiments included treatment

37 ; J U R X S V W R W H V W W K H R U D O D L V Q Z M E D H Q D M Q , \$ D B A I L R D F W K D H Q G U V H D I Q H D N Q W

of antenatal PTX therapy. Group 3 and group 4 were designed

to assess the prophylactic use of oral PTX at 2 different doses

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \ W K D W L V H Y L G H Q W I R O O R Z L Q J H Q G R W R

exposure .

The second phase of the experiments included treatment

37 ; J U R X S V W R W H V W W K H R U D O D L V Q Z M E D H Q D M Q , \$ D B A I L R D F W K D H Q G U V H D I Q H D N Q W

of antenatal PTX therapy. Group 3 and group 4 were designed

to assess the prophylactic use of oral PTX at 2 different doses

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \ W K D W L V H Y L G H Q W I R O O R Z L Q J H Q G R W R

exposure .

The second phase of the experiments included treatment

37 ; J U R X S V W R W H V W W K H R U D O D L V Q Z M E D H Q D M Q , \$ D B A I L R D F W K D H Q G U V H D I Q H D N Q W

of antenatal PTX therapy. Group 3 and group 4 were designed

to assess the prophylactic use of oral PTX at 2 different doses

leukocyte infiltration leading to necrotic arc formation in the

vascular wall of the umbilical vessel and secondary fetal brain

L Q M X U \ Z D V V K R Z Q L Q D O O R I W K H I H W X V H V Q I Q W K H H I S H U I P H Q W D O

J U R X S J U R X S S R . V P r i m i n g w i t h f r e t a l u r o

* & 6) I R O O R Z H G E \ K L J K G R V H P J H Q G R W R [L Q F O R V H O P L P L F V

W K H), 56 L Q Z K L F K O R Z J U D G H S U H F O L Q L F D O Y V W H P L F P D W H U Q D O D Q G N J

IA inflammation is followed by a relatively abrupt insult that

O H D G V W R I H W D O E U D L Q L Q M X U \

sacrococcygeal epidural anesthesia into the sacrococcygeal D Q W L Q H X U R I L O D P H Q W S U R W H L Q V S D F H Z L W K D F P J D X J H V S L Q D P H Q C H L H Q G D B V K F L S Q U R M Q H N L Q F W P R S Q \$ E I F D P 25 mg lidocaine hydrochloride and 0.016 mg epinephrine wereDegree of immunostaining was assessed by the pathologists performed. Then, the whole abdominal area was cleansed with blindly, concerning experimental groups with an arbitrary 10% povidone iodine solution. A paralumbar skin incision of visual scale that graded the immunoreaction as 0, no staining; approximately 10 cm in length was used to reach the uterus, weak staining; 2, moderate staining; and 3, diffuse staining. which was opened from its dorsal curvature with extension) R U V H P L T X D Q W L W D W L Y H H Y D O X D W L R C of the uterine incision using scissors as necessary. Before L I H 6 F L H Q F H , P D J L Q J 6 R I W Z D U H 6 \ V W H D P Q L R W R P \ D P / V W H U L O H V \ U L Q J R H N Z P D V - D S B I Q W L R W D V H S G L Z D W K D V K O H L J K W amniotic fluid for sampling. Then, the fetus and the placenta Z D V X W L O L] H G were delivered, and an intact placentome was dissected and sampled. The uterus was comprehensively lavaged with sterile saline solution to clean of all blood clots and membranes. Then, the uterus and the abdominal wall were closed with polyglactin: Data were expressed as mean and standard deviations. Kruskal-Wallis test was used for between-group comparisons. Mann-Whitney U test results for between-group comparisons were given in the text in more detail.

Results

7 K H Q H R Q D W H N L G V Z H U H G U L H G Z H L J K H G D Q G V X E M H F W H G W R
euthanasia with 50 mg/kg of intraperitoneal sodium thiopental. The mean neonatal weight was 1.453±260 g, and was similar
3 H Q W D O 6 R G \ X P , (8 O X J D \ , V W D Q D F X U R V \ X W N K I H \ J W R O X S R Z H S G E \ 6 L P L O D U
transthoracic intracardiac blood sampling. Then, neonatal G L V W U L E X W H G H T X D O O \ D F U R V V W K H
chest and skull were opened for en bloc dissection of the lung R I J U R X S Y H K L F O H F R Q W U R O D Q G
and brain. Parenchymal tissue from the lungs and white matter E \ P D W H U Q D O * & 6) D Q G K L J K G R V H , \$
from the brains were sampled. Tissue samples were fixed in specified in detail in our previous publication with validation
10% buffered formaldehyde and embedded into paraffin. of the current model of intrauterine inflammation. Briefly,
(Y D O X D W L R Q R I W K H 6 D P S O H V D Q G P D W H U Q D O * & 6) D Q G \$ H Q G R W R [L Q O H
' R X E O H D Q W L E R G \ V D Q G Z L F K H Q] P H U P X Q R K L V W R F K H P L Y W U \ I F N - and I F N - , COX-1, COX-2, caspase 3, 5, and 7, and
D V V D \ Z D V X V H G W R H Y D O X D W H L Q W H U O H N R D O R Q J H Z N W R G H F U H D V H G S X O P R Q D U \ 6
and TNF- _ levels in the amniotic fluid and neonatal plasma 6 3 % D Q G G H F U H D V H G E U D L Q Y L P H Q W
V D P S O H V X V L Q J F R P P H U F L D O N L W V I B U J R P W U V H U O D P H Q W W E U R S K D H P 1) 3
+ D Q J] K R X & K L Q D 5 H V X O W V Z H U H H Y D O X D W H G O D W S H [S U H V D Q R Q S W L F
G H Q V L W \ Y D O X H V Z H U H F D O F X O D W H G D Q G V W D Q G D U G L J H G D F F R U G L Q J O
Immunochemical staining on fetal lung, fetal brain and placental \$ P Q L R W L F) O X L G , Q I O D P P D W R U \ O D U N H


tissues were carried out using a routine streptavidine-biotin-peroxidase technique. After primary antibody incubation, streptoavidine peroxidase incubation of the slides for 20 minutes was carried out followed by washing with phosphate-buffered TNF- α rinse the slides, and a peroxidase substrate solution containing interleukins was more efficiently suppressed with high-dose oral 3,3'-bis(2-hydroxyethyl)-2-hydroxypropylidene bisacrylamide. ZDV and Xvhg were administered orally at a dose of 30 mg/kg, and mounting of the slides were performed.

7DEOH & RPS DULVRQV RI DPQLRWLF IOXLG DQG QHRQDWDO SODVPD LQIODPPDWRLQ caprine pregnancies

	QIODPPDWRLQ	Group 1	NH	Group 2	Group 3	*URXS	*URXS	Group 6	*URXS	*URXS	p
\$PQLRWLF IOXLG											
, QWHUOHXNLQ 95.0	\$82 P	/217.5±27.3	145.0±41.6	107.7±8.1	166.0±50.9	120.0±12.3	101.0±7.2	94.0±13.9	0.017		
, QWHUOHXNLQ 110.	\$132 P	/505.5±70.2	380.0±21.3	299.0±3.5	410.0±47.5	395.0±43.9	110.0±19.4	175.0±35.1	0.006		
, QWHUOHXNLQ 63.7	\$15.0 P	/196.2±37.7	109.0±10.4	86.3±8.1	133.0±4.0	113.0±16.1	109.0±11.9	92.0±10.1	0.008		
71) DOSKD SJ P12.7±5.4	299.7±5.2	150.0±21.5	133.3±11.5	195.0±12.2	190.0±13.4	110.0±69.1	109.0±40.6	0.009			
1HRQDWDO SODVPD											
, QWHUOHXNLQ 70.0	\$20.3 P	/142.2±20.0	115.0±7.0	93.3±11.5	132.0±15.6	100.0±6.2	80.1±9.1	75.0±8.2	0.008		
, QWHUOHXNLQ 87.5	\$10.4 P	/485.2±489	325.0±27.0	259.3±28.9	388.0±31.2	369.0±40.0	159.0±27.4	149.0±46.5	0.006		
, QWHUOHXNLQ 44.7	\$30.0 P	/156.0±30.1	68.0±4.6	59.0±3.5	112.0±14.0	105.0±4.6	109.0±9.4	75.0±17.7	0.007		
71) DOSKD SJ P9/1±14.2	160.5±22.1	120.0±24.0	110.3±8.1	159.0±47.8	129.0±20.9	90.0±23.5	85.0±5.3	0.012			

*URXS 1HJDWLYH FRQWUROV *URXS 3RVLWLYH FRQWUROV ZLWK LQIODPPDWLRQ PHGLDWHG IHWDOLQMXU\ IHWDOLQMXU\ *URXS /RZ GRVH LQWUD DPQLRWLF SHQWR[LI\OOLQH IHWDOLQMXU\ *URXS +LJK GRVH ZLWKRXW IHWDOLQMXU\ *URXS +LJK GRVH LQWUD DPQLRWLF SHQWR[LI\OOLQH ZLWKRXW IHWDOLQMXU\

all parameters between IA PTX treatment groups and vehicle VVRFLDWG ZLWK GHFUHDVHG ,/ FRQWUROV VKRZHGVWDWLWLDOSOIVYBQLISFDQWI RQJIDHOQFDO/WKSRXJK IRU DOO 6WDQGDORQH , \$ 37; WUHDWPHQWZKUHQX\$RPSQGHJURZLSWK YHKL was generally associated with similar IA inflammatory marker +LJK GRVH RUDO 37; VHHPHG PRUH YDOXHV S! H[FHSW LQFUHDVHG FJUFXSODWLQWKBORDPGRWU\ PDUNHU\ 37; JURXS FRPSDUHG WR JURXS and TNFWRVQQLILFDQWO\ OHVV WKDQ W The current data underpinned the anti-inflammatory effects of IRU DOO FRPSDULVRQV +RZHYHU RQ both prophylactic oral and therapeutic IA PTX, although high-dose oral protocol showed a more robust activity to alleviate indicating a partial reversal of inflammation following the high-dose oral regimen HQGRWR[LQ LQGXFHG , \$ LQIODPPDWLRQ]LJXUH)RU , \$ WUHDWPHQW ZLWK 37; KLJK GRV 1HRQDWDO 3ODVPD , QIODPPDWRLQ OVKHNUWXGLHG QHRQDWDO SODVPD ,/ Comparisons of the studied inflammatory parameters in the but not TNF- S FRPSDUHG WR HQGRWR[neonatal blood plasma obtained following preterm delivery are +RZHYHU RQO\ PHDQ ,/ OHYHO ZD VXPPDUL]HG LQ 7DEOH DQG)LJXUH of group 1 controls, indicating a partial reversal of inflammation ZLWK WKH KLJK GRVH DGPLQLVWUDWLR ZDV OHVV HIIHFWLHY ZLWK RQO\ ,/ O S LQ WKH QHRQDWDO SODVPD controls. Despite these positive effects, standalone IA PTX was DVVRFLDWG ZLWK LQFUHDVHG ,/ SONERWK ORZ GRVH DQG KLJK GRVH , \$ 37 UHVSHFWLYHO\ FRPSDUHG WR YHKLFO As a result, both high-dose oral and high-dose IA PTX effectively reduced the studied inflammatory markers in the neonatal plasma, but did not completely reverse the fetal inflammation back to control levels. A possible adverse effect of IA PTX may EH VWLPXODWLRQ RI DQ LPPXQH UHDFV)LJXUH




)LJXUH Fetal blood plasma and amniotic fluid interleukin-1, interleukin-4, interleukin-6, and tumor necrosis factor-alpha measurements obtained at preterm delivery in experimental study was associated with profound placental inflammation and apoptosis, as previously reported /RZ GRVH RUDO 37;

7DEOH	& RPS DULVRQV RI SODFHQWDO LPPXQRVWDLQLQJ LQWHQVLWLHV EHWZHHQ	0DUNHU	Group 1	Group 2	Group 3	*URXS	*URXS	Group 6	*URXS	*URXS	\$p
Interleukin-1	0.25±0.5	3.0±0	1.3±0.6	0.3±0.6	1.0±0.0	1.3±1.5	1.0±0.8	1.3±1.1	1.0±0.8	1.3±1.1	0.012
Interleukin-4	0.5±0.6	2.75±0.5	1.0±1.0	0.7±0.6	1.3±1.1	1.7±1.5	1.2±0.9	1.3±1.1	1.2±0.9	1.3±1.1	0.035
Interleukin-6	0.25±0.5	2.75±0.5	1.0±1.0	0.3±0.6	0.7±1.1	1.3±1.5	1.5±1.0	1.0±1.0	1.0±1.0	1.0±1.0	0.026
Interferon-alpha	0.25±0.5	2.75±0.5	1.3±1.5	0.7±0.6	1.0±0.0	1.0±1.7	1.0±0.5	1.0±1.0	1.0±0.5	1.0±1.0	0.044
Interferon-beta	0.25±0.5	2.75±0.5	0.7±1.1	0.7±0.6	2.3±0.6	1.0±1.7	1.2±0.5	0.3±0.6	1.0±0.8	0.3±0.6	0.032
Tumor necrosis factor-alpha	0.25±0.5	2.5±1.0	1.0±1.7	0.3±0.6	1.3±1.5	1.7±1.5	1.0±0.8	1.0±1.0	1.0±0.8	1.0±1.0	0.081
Cyclooxygenase-1	0.75±0.5	2.5±0.6	1.3±1.1	0.7±1.1	2.0±1.7	1.0±1.0	1.0±0.8	1.7±0.6	1.0±0.8	1.7±0.6	0.071
Cyclooxygenase-2	0.0±0.0	2.75±0.5	0.7±1.1	1.0±0.0	0.7±1.1	1.7±0.6	1.0±1.1	0.7±1.1	1.0±1.1	0.7±1.1	0.014
Caspase 3	0.25±0.5	3.0±0.0	1.0±1.0	0.3±0.6	1.3±1.5	1.3±1.5	1.0±0.0	1.3±0.6	1.0±0.0	1.3±0.6	0.021
Caspase 5	0.25±0.5	2.5±0.6	0.7±1.1	0.3±0.6	0.7±1.1	1.7±1.6	1.0±1.1	1.0±1.0	1.0±1.0	1.0±1.0	0.036
Caspase 7	0.25±0.5	2.5±0.6	1.7±0.6	1.0±0.0	1.3±0.6	1.0±1.0	1.5±0.6	1.3±0.6	1.0±0.6	1.3±0.6	0.012

*URXS 1HJDWLYH FRQWUROV *URXS 3RVLWLYH FRQWUROV ZLWK LQIODPPDWLRQ PHGLDWG IHWDO LQM
IHWDO LQMXU\ *URXS /RZ GRVH LQWUD DPQLRWLF SHQWR[LI\OOLQH IHWDO LQMXU\ *URXS +LJK GRVH
ZLWKRXW IHWDO LQMXU\ *URXS +LJK GRVH LQWUD DPQLRWLF SHQWR[LI\OOLQH ZLWKRXW IHWDO LQMXU\

1, weak staining; 2, moderate staining; and 3, diffuse staining

SDUWLDOO\ UHYHUVHG WKH ILQd
,/ S ,/ S FDVSDVH
S H[SUHVVLRQV FRPSDUHG WR
JURXS +LJK GRVH RUDO 37; JU
inflammation and apoptosis to a great extent with return to
EDVHOLQH H[SUHVVLRQV S! H[F
DQG JURXS FRPSDULVRQ
\$OWKRXJK ORZ GRVH , \$ 37; JURXS OHG WR GHFUHDVHG



expressions of some inflammatory parameters in the placenta L J X U H 3 O D F H Q W D O F D V S D V H L P P
,/ ,/ ,)1 _ D Q G & 2; Z L W K S D Q G % S J U R X S W K D W U H F H L Y H G L
D Q G S U H V S H F W L Y H O \ F R P S D U H G with or without intramniotic endotoxin respectively.
K L J K G R V H , \$ 37; J U R X S V H H P H G Administration of pentoxifylline directly into the amniotic
F R P S D U L V R Q V E H W Z H H Q J U R X S D Q G J U R X S fluid could trigger apoptosis in the placenta
and high-dose IA PTX was associated with increased caspase D Q G L Q F U H D V H G 16(S V W D L Q L Q
S D Q G S U H V S H F W L Y H O \ D Q G F D V S D V H J U R X S D Q G W K H R W K H U
S U H V S H F W L Y H O \ H[SUHVVLRQVJ\QXWKH KSDQD BHQNUH \$ Q R I L F D Q G Q J I H F

a possible apoptotic process in the placenta following PTX L P S U R Y H G H[SUHVVLRQV S R I D O C
L Q M H F W L R Q L Q W R W K H D P Q L R W L F I Q X L G S L J X U H *)\$3 S D Q G 0 % 3 S
These results revealed that prophylactic oral PTX prevented Z H U H Q R V L J Q L I L F D Q W G L I I H U H Q F H V
placental inflammation and apoptosis, and high-dose oral E H W Z H H Q J U R X S D Q G Y H K L F O H F R Q V
regimen was probably more effective with return to baseline U H Y H U V D O R I W K H E U D L Q L Q M X U \ Z L W K
levels except COX2. On the other hand, IA PTX was less R Z G R V H , \$ 37; J U R X S O H G W R G H F
effective and may be associated with placental apoptosis. IFN- S ,)1 ` S D Q G 71) _

) H W D O % U D L Q , P P X Q R K L V W R F K H P L F In our study, the fetal brain compared to endotoxin
7DEOH V X P P D U L] H V W K H L P P X Q R V W D R Q L Q W H Q R V L S W L H V) R Q Q R Z H Q H W d h
brain white matter. As previously shown, inflammatory and R Q O \ ,/ S D Q G ,)1 ` S V W D L
D S R S W R W L F P D U N H U V Z H U H L Q F U H D R Q L Q W H Q R V L S W L H V) R Q Q R Z H Q H W d h
E U D L Q L Q M X U \ D S S D U H Q W Z L W K G H F U H D V H I G U 6 D O D) F R P S D B Q V G R Q % 3 F R Q V L G
V W D L Q L Q J L Q H Q G R W R [L Q H [S R V H G Case PTW administration into the amniotic fluid without fetal
G R V H R U D O 37; J U R X S Z D V D V V R L F Q D X U H G Z L W K S G H F U H D V D V H G R / F L D W H G
S ,)1 ` S F D V S D V H S S & 2; D Q G F D V S D V H S D Q G G H F

7DEOH	&RPSDULVRQV RI IHWDOLQ	EUDLQ	ZKLWH	PDWWHU	LPPXQRVWDLQLQJ	LQWHQ			
0DUNHU	Group 1	Group 2	Group 3	*URXS	*URXS	Group 6	*URXS	*URXS	\$p
Interleukin-1	0.25±0.5	3.0±0	1.7±0.6	0.3±0.6	1.3±0.6	1.3±0.6	1.2±0.9	1.0±1.0	0.010
Interleukin-4	0.25±0.5	2.25±0.5	0.7±0.6	0.7±0.6	1.0±1.0	1.0±1.7	1.2±0.9	1.0±1.0	0.023
Interleukin-6	0.25±0.5	2.5±1.0	0.7±1.1	0.3±0.6	0.7±1.1	1.0±1.0	1.0±0.8	0.7±1.1	0.053
Interferon-alpha	0.25±0.5	2.75±0.5	1.3±1.5	0.3±0.6	1.0±1.0	1.0±1.7	1.0±0.8	0.7±0.6	0.041
Interferon-beta	0.25±0.5	3.0±0	2.0±1.0	0.3±0.6	1.0±0.0	1.0±1.7	1.2±0.5	0.3±0.6	0.013
Tumor necrosis factor-alpha	0.25±0.5	2.75±0.5	0.7±0.6	0.3±0.6	0.7±1.1	1.0±1.0	1.5±1.3	1.0±1.0	0.024
Cyclooxygenase-1	0.5±0.6	2.5±0.6	1.0±0.0	0.3±0.6	1.3±1.1	1.3±1.1	1.0±0.8	1.7±0.6	0.018
Cyclooxygenase-2	0.25±0.5	2.25±0.9	1.3±1.5	0.7±0.6	1.3±1.5	1.3±1.5	0.5±0.6	1.0±1.0	0.088
Caspase 3	0.25±0.5	2.75±0.5	0.7±0.6	0.7±0.6	1.7±0.6	2.4±1.1	1.7±0.5	1.0±1.0	0.023
Caspase 5	0.25±0.5	2.25±0.5	1.3±0.6	0.7±0.6	1.0±1.0	1.7±0.6	1.2±0.5	1.0±1.0	0.018
Caspase 7	0.25±0.5	2.25±0.5	1.3±1.1	1.0±0.0	1.0±1.0	1.0±1.7	0.7±0.9	1.0±1.0	0.032
Vimentin	3.0±0	1.5±0.6	2.0±1.0	3.0±0	2.0±1.7	2.3±1.1	2.0±1.1	1.7±0.6	0.021
Neuron specific enolase	3.0±0	0.5±0.6	2.3±0.6	3.0±0	0.7±1.1	0.7±1.1	1.2±0.9	1.3±0.6	0.009
Neurofilament protein	3.0±0	1.0±0.8	2.0±1.0	3.0±0	2.0±1.0	1.0±0.0	1.7±1.5	2.3±0.6	0.017
Glial fibrillary acidic protein	3.0±0	1.5±1.0	2.7±0.6	3.0±0	1.0±1.0	2.0±1.0	2.2±0.9	2.3±0.6	0.062
Myelin basic protein	3.0±0	1.5±1.0	2.7±0.6	3.0±0	2.0±1.0	2.0±1.0	2.2±0.9	2.7±0.6	0.062

*URXS 1HJDWLYH FRQWUROV *URXS 3RVLWLYH FRQWUROV ZLWK LQIODPPDWLRQ PHGLDWHG IHWDOLQMXU\ *URXS /RZ GRVH LQWUD DPQLRWLF SHQWR[LI\OOLQH IHWDOLQMXU\ *URXS +LJK GRVH ZLWKRXW IHWDOLQMXU\ *URXS +LJK GRVH LQWUD DPQLRWLF SHQWR[LI\OOLQH ZLWKRXW IHWDOLQMXU\ weak staining; 2, moderate staining; and 3, diffuse staining

ZKHUHDV KLJK GRVH JURXS O HG JURRGSHF UDHDQGV HGRYKISP HQWHLFQU HDQVGHG S X
16(S IRU ERWK FRPSDUHG WR E RMLKF GR VFRVQ WURQHV [JLQRFXUSH D VH LQ ,/
Therefore, high-dose oral PTX seemed more effective than IFN- VWDLQLQJ S D Q G S UHVS
ORZ GRVH RUDO 37; DJDLQVW IHWDOLQHV RQWMLQH [SKRHV HUGH VFXRQWVU B O VR indicated some anti-inflammatory effect of IA PTX on the also associated with decreased pulmonary COX1 expressions preterm fetal brain, although PTX might lead to increased white S 1R VLJQLILFDQW GLIIHUUHQFH V
PDWWHU DSRSWRVLV DQG QHXURQD parameters when group 5 or 6 were compared with group 2 WKH amniotic fluid.

)HWDO 3XOPRQDU\ ,PPXQRKLVWRFKHPWKFDQW)QGLQJ V
Table 4 shows the immunostaining intensities of the fetal F R Q W U R O V G H P R Q V W U D W L Q J W K D W pulmonary parenchyma. As expected, inflammatory and effects on fetal lungs after IA administration.

apoptotic parameters were increased, whereas surfactant overall, high-dose oral PTX was the most effective treatment ZHUU GHFUHDVHG LQ WKH PRGHO mddity against inflammation-driven protein fetal pulmonary RUDO 37; JURXS DOOHYLDWHG ,LQMSXU\ ZLWK UHSWXUQ WR EDVHOLQH H IFN- S ,)1` S FDVSDVH S FDVSDVH

S DQG &2; S H[SUHVVRQVFRPSDUHG WR SRVLWLYH FRQWUROV JURXS +LJK the current study, we tested the therapeutic efficacy of oral more effective, as shown by amelioration of all lung parameters and IA PTX administrations against inflammation-mediated WR EDVHOLQH JURXS FRQWURO O B Y B D Q W !D O D R Q G D I Q Q B P S Q M X M R Q Q W and significantly decreased inflammation and apoptosis 37; ZDV JLYHQ SURSK\ODFWLFDOO\ L

S IRU DOO H[FHSW &2; VWDLQLQJMHSWFLRQZLWKHQADM, \$H\\$7; ZDV DG VXUIDFWDQW SURWHLQ OHYHOV S with entoxD. Different doses labeled as low- and high- IA PTX was generally associated with improved fetal pulmonary function. Two different treatments were evaluated for both the oral and IA ways inflammation; however, lacked any positive effects on apoptosis. RI DGPQLVLVWUDWLRLQ 2YHUDOOGDW and surfactant synthesis. Both low- and high-dose IA PTX N J PDWHUQDO ZHLJKW GDLO\ XVH RI

7 D E O H & R P S D U L V R Q V R I I H W D O S X O P R Q D U \ S D U H Q F K \ P D O L P P X Q R V W D L Q L Q J L Q W kids	Group 1	Group 2	Group 3	*URXS	*URXS	Group 6	*URXS	*URXS	S Y D
Interleukin-1	0.25±0.5	3.0±0	0.7±0.6	0.7±0.6	1.3±0.6	0.7±1.1	0.7±0.5	0.7±1.1	0.022
Interleukin-4	0.25±0.5	2.75±0.5	0.7±1.1	0.3±0.6	1.0±1.0	1.0±1.0	1.5±1.0	1.3±1.1	0.030
Interleukin-6	0.5±0.6	2.5±0.6	1.0±1.0	0.7±0.6	0.7±0.6	0.7±1.1	1.0±1.1	0.3±0.6	0.040
Interferon-alpha	0.25±0.5	3.0±0	1.3±0.6	0.7±0.6	1.0±0.0	1.3±1.1	1.7±1.3	0.7±0.6	0.013
Interferon-beta	0.25±0.5	2.75±0.5	2.0±1.0	0.3±0.6	2.0±1.0	2.0±1.7	1.0±0.8	0.3±0.6	0.017
Tumor necrosis factor-alpha	0.25±0.5	2.75±0.5	0.7±0.6	0.7±0.6	1.3±0.6	2.0±1.0	1.5±1.3	2.0±0.0	0.023
Cyclooxygenase-1	0.25±0.5	2.75±0.5	1.0±0.0	0.3±0.6	2.0±1.0	1.0±0.0	1.2±1.2	0.7±0.6	0.014
Cyclooxygenase-2	0.75±0.5	2.5±1.0	0.7±1.1	1.0±0.0	1.3±1.5	0.7±1.1	1.2±1.5	1.0±1.0	0.095
Caspase 3	0.25±0.5	2.5±0.6	0.7±0.6	0.3±0.6	1.0±1.0	1.7±1.5	0.5±0.6	1.0±1.0	0.024
Caspase 5	0.25±0.5	2.25±0.5	0.3±0.6	0.7±0.6	1.0±1.0	1.3±1.1	0.7±0.9	1.0±1.0	0.024
Caspase 7	0.25±0.5	2.5±1.0	1.0±0.0	0.3±0.6	1.3±0.6	2.0±0.0	1.2±0.9	1.7±0.6	0.040
6 X U I D F W D Q W S U R W H 2.6±0.6	0.25±0.5	1.3±0.6	2.3±0.6	1.7±1.1	0.7±0.6	1.2±1.2	2.3±0.6	0.016	
6 X U I D F W D Q W S U R W H 2.6±0.6	0.5±0.6	1.0±1.0	2.7±0.6	0.7±1.1	1.0±1.7	1.5±1.3	2.0±1.0	0.023	
6 X U I D F W D Q W S U R W H 2.75±0.5	0.25±0.5	1.0±1.0	3.0±0	0.3±0.6	0.7±1.1	1.2±1.2	2.3±0.6	0.012	
6 X U I D F W D Q W S U R W H 0.9±0'	0.75±0.9	1.0±1.7	3.0±0	1.3±1.1	1.0±1.0	2.0±1.4	2.3±1.2	0.026	
Pro-surfactant protein B	3.0±0	0.5±0.6	1.0±1.0	3.0±0	1.0±1.7	0.7±0.6	2.0±0.8	2.7±0.6	0.009

*URXS 1HJDWLYH FRQWUROV *URXS 3RVLWLYH FRQWUROV ZLWK LQIODPPDWLRQ PHGLDWHG IHWDOLQMLQMXU\ *URXS /RZ GRVH LQWUD DPQLRWLF SHQWR[L]\OOLQH IHWDOLQMXU\ *URXS +LJK GRVHZLWKRXW IHWDOLQMXU\ *URXS +LJK GRVH LQWUD DPQLRWLF SHQWR[L]\OOLQH ZLWKRXW IHWDOLQMXU\ weak staining; 2, moderate staining; and 3, diffuse staining

endotoxin insult as the most effective protective therapeutic active forms, IA drug delivery may have inadequate anti-R S W L R Q D J D L Q V W L Q I O D P P D W L R Q Inflammation and HWDQWDP action. Furthermore, PTX when given into the amniotic fluid had some potentialit can be speculated that the maternal liver and possibly the to decrease the IA inflammation, some adverse effects suchplacenta "detoxify" the parent compound into more active increased apoptosis in the placenta and fetal brain secondand less fetotoxic compounds. Evidence in favor of such an to stimulation of an immune or toxic reaction is a concern thateffect can be adverse fetal reactions we encountered in our may restrict use of IA PTX for preterm fetal neuroprotection. design, including increased apoptosis in fetal brain following There are some potential explanations why oral PTX was moA PTX administrations in pregnancies without intrauterine H I I H F W L Y H L Q R X U G H V L J Q 6 L Q F H WkathnRptD On SubRwYR frx PTX DadminisRk kOsF W L in nature with repeated daily doses, the neuroprotectivegroups for preterm delivery should be the preferred way of effects of PTX might have become more apparent before theadministration for fetal neuroprotection. inflammatory insult. This may imply that PTX is generally Experimental data on use of PTX for inflammation-induced active as a preventive therapy, when given relatively early iadverse effects in the placenta are scarce. In a tissue culture the inflammation-driven preterm birth model with limited model that used second trimester human placentas treated action following delayed administration. Repeated doses of PTX with endotoxin and PTX, placental expression and production instead of a single-dose may be required for relevant actionR I L Q I O D P P D W R U \ PDUNHUV VXFK DV , A D V Z H O O + R Z H Y H U P D W H U Q D O D Q GshoD FedkewDw as kind of administration for PTX test wLfv\ R I PTX may also play a role. Oral PTX administered maternally results are in agreement with in vivo data from our experiments, P H W D E R O L] H G L Q W R D W O H D V W Q TIOING THE MAXIMUM INFLAMMATION ACTIONS OF RTX IN THE PLACENTA W K H liver, and the main active metabolite called lisofylline has bee6 R P H S U H Y L R X V D Q L P D O V W X G L H V shown to have anti-inflammatory and antifibrotic activity. the placental and fetal effects of maternal PTX in the endotoxin- Moreover, the anti-inflammatory actions of both PTX andinduced intrauterine inflammation models. PTX was reported lisofylline were attributed to 8-oxo derivatives rather than theto mitigate endotoxin-induced up-regulation of placental parent forms 6 L Q F H D G P L Q L V W U D W L R Q herhe3oxygeGdseHif wCgnart qMERTXWkHalso shown D P Q L R W L F IO X LG Z L O O Q R W H Q D E Otl deRceWehBryP ResptorR Oeta] DmrtalRyQ ardl fetal;

pregnant mice + R Z H Y H U W K H V H S R V L WhalMdf thl daily B00 mg Ztts dt ar QtaVenous infusion, and partially replicated in a rabbit model. In pregnant rabbits given the rest 400 mg as oral tablet. Considering the dose scheme in intrauterine endotoxin, animals that received PTX 20 mg/kg/day our study that corresponds to higher oral doses than that of in 3 divided doses had similar preterm delivery rates, despite D X W H U E D F~~the necess~~Y and feasibility of additional prolonged time until fetal death compared to controls On daily intravenous administrations are questionable. Therefore, the other hand, in experimentally induced equine placentitis future clinical studies evaluating fetal neuroprotective effects of using intracervical inoculation of *Streptococcus equi*, 17 mg prophylactic antenatal PTX therapy can focus on relatively low kg daily maternal dose of PTX given orally from the onset of P J G D L O \ R U D O G R V H V R I 37 ; Z clinical signs to delivery was associated with improved viability administrations, which necessities admission to the hospital.

of foals and negative fetal bacterial culture. Depending on these results in association with our current data, oral maternal PTX treatment given for a longer period, particularly before There were certain limitations of the current experimental study. Although various tissue parameters for inflammation, apoptosis SOD F H Q W D O D Q G I H W D O L Q M X U \ F R P T H Q Y H V V H P Y P R U H H H H F W L Y H W R alleviate subsequent intrauterine inflammation.

In the English literature, we were able to identify only one additional methods such as genetic expressions and Western experimental study that specifically evaluated the fetal neuroprotective effects of antenatally administered PTX¹. and clinical evidence in favor of safety of oral PTX use during This study by Dilek et al. used intraperitoneal endotoxin in the third-trimester of pregnancy, our design did not include WR LQGXFH IHWDO LQMXY\ LQ BJUHQJDQWQDWBVQDQGQDGRAYH² standalone oral PTX experimental groups. There was also no NJ RI PDWHUQDOO\ LQMHFWHG 37 RUDRSQDFWHFRP JHBRXSYHBRZHYDHU DG G associated with decreased apoptosis and MBP immunostaining³. groups into the present design would be unethical. C-reactive in periventricular white matter of the pups. The results imply protein and white blood cell count and differential in fetal that PTX is a potential neuroprotective agent against fetal white blood samples were not measured, as interleukins and TNF-

that PTX is a potential neuroprotective agent against fetal term delivery. Blood samples were not measured, as interleukins and TNF- α from a phylogenetically diverse animal were considered more specific for fetal inflammatory response. The current design was also unable to reveal data on temporal changes of the studied parameters by our validated model. In summary, previous experimental data show that prophylactic preterm birth was induced 5 days after IA endotoxin, a time maternal PTX treatment may decrease placental and fetal period supposed to be most suitable for evaluation of fetal but probably do not prevent preterm delivery. Although we time points, including postpartum alterations, since newborn did not specifically address the timing of preterm delivery in our experiments, our results generally elaborate these findings. The present experimental model cannot and support use of maternal PTX as a fetal neuroprotective agent, particularly for pregnancies at risk for preterm delivery. Moreover, we showed the efficacy of oral daily doses at 60 mg caused spontaneous preterm birth, since preterm delivery was

Moreover, we showed the efficacy of oral daily doses at 30 mg/day of betamethasone administered iatrogenically to retrieve fetal and placental samples. We could identify only one clinical study on the use of antenatal corticosteroids. Finally, CP is multifactorial condition that can occur during the intraoperative period, during or after delivery. The current data do not explicitly reveal information on preterm birth between 23-34 weeks of gestation. Women between 23-34 weeks of gestation related to CP and/or related complications and are restricted to women with CP who have been delivered before term. The current data do not explicitly reveal information on preterm birth between 23-34 weeks of gestation related to CP and/or related complications and are restricted to women with CP who have been delivered before term.

^dConclusion

magnesium sulfate for neuroprotection. The cerebroplacental ratio at week 3 of treatment was found to be significantly higher in the treatment arm. Moreover, composite neonatal outcome preterm delivery in a prophylactic fashion alleviates fetal delivery was similar. Our results are principally in line with the safety profile of PTX during the third trimester of pregnancy, findings from this pilot clinical study. We did not specifically clinical studies evaluating its antenatal use in imminent preterm our results similarly imply that PTX given for at least 2 weeks has delivered against Q M X U \ D U H Z D U U D Q W H G

(WKL FV

(WKL FV & RPPLWWHH \$SSURYDO 7KH V\W X G Y L S U R W R F R O Z D V V X E M H F W
WR DQLPDO HWKLFV FRPPLWWHH DSSURYDO E\ 1 p PHWK 3LQWPU 6 Q K L E L W R
8QLYHUVLW\ \$QLPDO ([SHULPHQWDWLRO / RFD O / WKL FV & RPPLWWHH
DSSURYDO GDWH DQG QR
, QIRUPHG & RQVHQW Experimental study.

\$XWKRUVKLS & RQWULEXWLRQV

& RQFH SW 0 6 \$. g g 0 + ' . \$ 2007;62:2703. 'HVLJQ

0 6 \$. ' . 'DWD & ROOHFWLRQ RU 0 6 P H Q . g + D O X J U 0 . D

g g 0 + ' . \$ \$ 2 g \$ Q D O \ V L V R U H W D P U S Q I P W D W L R Q P H G L D W H G I H W D O

g g 0 + 2 g / L W H U D W X U H 6 H D U F K 0 6 \$. j 2 g U W L Q J

0 6 g g \$ Q W D O \ D O x 0 2] P H Q 2 + D O X J U 0 6 H]LN

& RQIOLFW RI , QWHUHVW No conflict of interest was declared by the authors.

)LQDQFLDO 'LVFORVXUH The present study was supported by SYNXFHZLFK / + 0DUVHOOD 5 0D[2

I X Q G V I U R P W K H 6 F L H Q W L I L F D Q G 7 H F C K Q P A n a c o k i n e t i c s o f p e n t o x i f y l l i n e u s e f u l o f

RI 7XUNH\ UHVHDUFK SURMHFW QR Preliminary data were presented as abstracts at the 2013

Congress on Ultrasound in Obstetrics and Gynecology, 6-9

2 F W R E H U 6 \ G Q H \ \$ X W W D C o n g r e s s D Q G B W W K A

R Q 8 O W U D V R X Q G L Q 2 E V W H W U L F V * \ Q H F O R J

% D U F H O R Q D 6 S D L Q

ovine experimental endotoxemia model. Inflammopharmacology

2016;24:59-64

on the pre-eclamptic-like symptoms in ewes. Eur J Obstet Gynecol Reprod Biol 2001;99:25-32.

: D W D Q D E H 7 0 D W V X G D 7 + D Q L W D 7 2 N X V

. H W D O , Q G X F W L R Q R I Q H F U R W L] L Q J I X

of intravenous granulocyte-colony stimulating factor and intra-

amniotic endotoxin in premature fetal sheep. Pediatr Res

\$ 2007;62:2703. 'HVLJQ

g g colony stimulating factor and high-dose intraamniotic endotoxin in

the caprine model. Turk J Obstet Gynecol 2019;16:41-9.

\$ Q W D O \ D O x 0 2] P H Q 2 + D O X J U 0 6 H]LN

following single high-dose intra-amniotic betamethasone treatment

in preterm goat kids. J Turk Ger Gynecol Assoc 2012;13:242-6.

)LQDQFLDO 'LVFORVXUH The present study was supported by SYNXFHZLFK / + 0DUVHOOD 5 0D[2

I X Q G V I U R P W K H 6 F L H Q W L I L F D Q G 7 H F C K Q P A n a c o k i n e t i c s o f p e n t o x i f y l l i n e u s e f u l o f

metabolite after oral and intravenous administration of pentoxifylline

to healthy adult horses. Am J Vet Res 2006;67:1621-7.

0 D U V H O O D 5 1 L F N O L Q &) 0 X Q V R Q - : 5 R E

of pentoxifylline in dogs after oral and intravenous administration.

Am J Vet Res 2000;61:631-7.

Am J Vet Res 2000;61:631-7.

of fetal pulmonary aspiration of intra-amniotic administered

surfactant in animal experiment. J Perinat Med 2004;32:354-8.

% H V W % 0 % X U Q V - & 'H 9 L Q F H Q] R - 3 K H C

Y T , + b v a l Pediatric Pharmacology Research Unit Network.

Pharmacokinetic and tolerability assessment of a pediatric oral

formulation of pentoxifylline in Kawasaki disease. Curr Ther Res Clin Exp 2003;64:96-115.

1 L F N O D V V R Q 0 % M | U N P D Q 6 5 R W K %

1 R W H U H R V H Q W E W L Y H P H W D E R Q L V P R I S H Q V

humans. Chirality 2002;14:643-52.

: y M F L N 3 D V] F H R B . : Q X N G] L N D E ' . R F] X U N L H Z

3 6 D Q D N 0 H W D O 3 H Q W B [H] Q O Q L Q H D Q G

attenuate transforming growth factor-1-induced asthmatic

bronchial fibroblast-to-myofibroblast transition. Acta Biochim Pol

2016;63:437-42.

22. Bhat VB, Madayastha KM. Antioxidant and radical scavenging

properties of 8-oxo derivatives of xanthine drugs pentoxifylline and

lisofylline. Biochem Biophys Res Commun 2001;288:1212-7.

6 S H H W 6 (0 R / L Q , 0 X U Q H \ \$ F R X : , V O D P 6

inhibits lipopolysaccharide-induced inflammatory mediators in

human second trimester placenta explants. Placenta 2017;58:60-6.

(I I H F W V R I 5 D G L [V F X W H O O D U L D H D Q G 5

Q H F U R W L] L Q J H Q W H U R F O L W L V L Q Q H R Q D

D P D W 2006;36:418-428.

K D Q J & 0 D J Q H V L X P R / : D Q J + ; X ' ; / L S

sulfate for neuroprotection in the setting of chorioamnionitis. J

/ 3 6 X S U H J X O D W H V W K H H [S U H V V L R Q R I

Matern Fetal Neonatal Med 2018;31:1156-60.

placenta. Placenta 2007;28:951-7.

+ D U U L V (6 F K X O] N H 6 0 3 D W R O H 6 . 3 H Q W R Q J L I T O Q K H : < L Q O D S U H W H R Q J ; & = K D L ; +

neonates: a systematic review. Paediatr Drugs 2010;12:301-11.

(I I H F W V R I 5 D G L [V F X W H O O D U L D H D Q G 5

3 D P P L 0 + D T X H . 1 3 H Q W R [L I \ O O L Q H I R U L W G X I P H V G D Q R U R V L R Q S D Q Q \ W R Q F X W H U L Q H ,

Q H F U R W L] L Q J H Q W H U R F O L W L V L Q Q H R Q D

D P D W 2006;36:418-428.

K D Q J & 0 D J Q H V L X P R / : D Q J + ; X ' ; / L S

studies. Ital J Pediatr 2019;45:108.

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

U H W D U G D W L R Q L Q P L F H 7 R [L F R O / H W W

%DLOH\ & 6 ODFSKHUVRQ 0/ 3R]RU 0\\$KLWHR RG WWRHQJ DQ MXU\ LQ D UDW PRGHO
%HQVRQ 6 *LJXHUUH 6 HW DO 7UHDWP Matern Fetal Neonatal Med 2018;26:1865-71 KRSULP
VXOIDPHWK[R[D]ROH SHQWR[LI\OOLQH DQ/G DOWHDFK 5 5\WOHZVNLD [3DMZCRZN F]
induced equine placentitis. Theriogenology 2010;74:402-12.
Br ERURZLF] HW DO (IHFHW RI SHQWR
'LOHN 0 .XPUDO \$ 2N\D\ (2]EDO 6 7XJRXQFRPXIXQD)UDQGRPL]HG SURVSHFWLYI
Protective effects of pentoxifylline on lipopolysaccharide-induced preterm labour, on the foetal-placental circulation and neonatal Pharmacol Toxicol 2012;110:342-6.

The relationship between isolated pes equinovarus and aneuploidies and perinatal outcomes: Results of a tertiary center

b]ROH SHV HNLQRYDUXV LOH DQ|SORL
VRQXoODU 7HUVL\HU WHN PHUNH] VR

© 0HW H © X6F•X H\PDQ & DQVXQ 'HPLU

Çukurova University Faculty of Medicine, Department of Obstetrics and Gynecology, Adana, Turkey

\$EVWUDFW

2EMHFVLYH & RQJHQLWDO SHV HTXLQRYDUXV 3(9 LV WKH PRVW FRPPRQ FRQJHQLWDO 0.2-0.3%. It can be diagnosed from the 12 week of pregnancy. Non-isolated cases tend to be syndromic and complex. We aimed to evaluate the results of perinatally diagnosed isolated PEV.

0DWHLUDOV DQG 0HWKRGV This was a retrospective cohort study conducted between March 2015-March 2020. Women who presented with isolated pes equinovarus (PEV) were included. Karyotype analysis was discussed for patients with PEV. Pregnancy termination was recommended for those with chromosomal/life-threatening anomalies. The diagnosis was confirmed by postnatal examination'autopsy. Postnatal diagnosis was accepted as false-positive in those with no PEV.

Results: 2QH KXQGUHG WKLW\ HLJKW SDWLHQWV ZHUh IRXQG WR KDYH 3(9 RI ZK WKH ILUVW WULPHVWHU ZDV VLJQLILFDQWO\ KLJKHU FRPSDUHG ZLWK WKH VHFRQG WUL LQ SDWLHQWV LQ WKH LVRODWLG JURXS 7HUPLQDWLRQ ZDV SHUIRUPHG WR DQRPDOLHV ZHUh GHWHFWHG LQ SDWLHQWV DQG WHUPLQDWLRQ ZDV UHFRPPH DQRPDOLHV LQFRPSDWLEOH ZLWK OLIH ,Q WKH SRVWQDWDO HYDOXDWLRQ WKH VXUJL & RQFOXVLRQ When PEV is diagnosed, detailed fetal anomaly screening must be performed, patients should be informed about the chromosomal anomalies. ULVN +LJK IDOVH SRVVLWLYH UDWHV LQ WKH ILUVW WULPHVWHU VKRXOG EH NHSW LQ PL It should be remembered that some neuromuscular/skeletal system anomalies may occur for the first time in the postnatal period in isolated cases.

.H\ZRGV Clubfoot, Down syndrome, diagnostic imaging, karyotyping

Öz

\$PDo .RQMHQQLWDO SHV HNLQRYDUXV 3(9 D\DIYxQ HQ VxN J|U•OHQ NRQMHQLWDO GHIR VxNOxNOD J|U•O•U *HEHOLYLQ KDIWDVxQGDQ LWLEDUHQ WHÜKLV HWPHN P•PN•QG dDOxüPDPx]GD SHULQDWDO G|QHPGH WHÜKLV HGLOHQ L]ROH 3(9 ROJXODUxQxQ VRQXoO *HUHo YH <|QWHPOHU dDOxüPDPx] 0DUW 0DUW WDULKOUL DUDVxQGD \•U•W•OH EDÜYXUDQ YH\D KHUKDQJL ü•SKHOL IHWDO DQRPDOL QHGHQL\OH VHYN HGLOHQ NDGxQO DQRPDOLOHU DoxVxQGDQ NRQWURO HGLOGL 3(9 VDSWDQDQ KDVWDODUOD NDU\RWLS D JHEHOLN WHUPLQDV\RQX |QHULQGL 7DQx SRVWQDWDO PXD\HQH YH\D RWRSLV LOH GRÜL %XOJXODU <•] RWX] VHNL] KDVWDGD 3(9 VDSWDQGx .xUN ELUL L]ROH LGL b]RO NxDVODQGxüxQGD DQODPOx GHUHFHGH \•NVHNWL VxUDVx\OD YH S b]RO KDVWD\D WUL]RPL QHGHQL\OH WHUPLQDV\RQ X\JXODQGx 1RQ L]ROH JUXSWD KDVWD\D \DüDPOD EDüGDüPD\DQ DQRPDOLOHU QHGHQL\OH JHEHOLN WHUPLQDV\R WHGDYL RUDQx VxUDVx LOH YH LGL YH DUDGDNL IDUN LVWDWLNVHO RODUDN DQO

PRECIS: We aimed to evaluate the perinatal and neonatal results of pregnant women who were found to have isolated PEV during the first and second trimester ultrasonographic screening in our clinic.

\$GGUHV V IRU &RUUHVSROQHQ\FH6XBX\WPD \$GUHVL

dXNXURYD 8QLYHUVLW\)DFXOW\ RI 0HGLFLQH 'HSDUWPHQW RI 2EVWHWULFV DQG *|QHFRORJ\ \$GDQD 7XUNH\

Phone: +90 505 617 65 38 (PDLO metesucu@yahoo.com 25 & , ' , orcid.org/0000-0002-6889-7147

5HFHLYHG *HOLÜ 7DULKL 29.11.2020 \$FFHSWHG .DEXO 7DULKL 30.11.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

6RQXo 3(9 WHÜKLVL NRQGXÿXQGD HÜOLN HGHQ DQRPDOLOHU LoLQ D\UxQWxOx ELU IH KDNNxQGD ELOJLOHQGLULOPHOLGLU 7DQx LoLQ LON WULPHVWHUGHNL \NVHN \DQOxü S %D]x Q|URP•VN•OHU YH LVNH OHW VLVWHPL DQRPDOLOHULQLQ L]ROH ROJXODUGD LON N \$QDKWDU .HOLPHOHU dDUSxN D\DN 'RZQ VHQGURPX WDQxVDO J|U•QW•OHPH NDU\RWL

Introduction

Congenital pes equinov D U X V 3(9 R U FOXEIRRWLVLV D FROJHOLWD foot or both feet, inward tilting of the heel, and adduction of the forefoot . It is seen with a frequency of 2-3 per 1000 live births and is the most common congenital deformity of the foot can be unilateral or bilateral, and its incidence in male fetuses is 2 times higher.

Although the diagnosis of congenital PEV is usually made from W K H V H F R Q G W U L P H V W H U Z L W K X O W L D V R Q R J U D S K V during the prenatal period increased the risk of congenital

Congenital PEV can be diagnosed more frequently through the development of ultrasound technology and the increase in the skills of physicians over time.

6\Q G U R P L F F D V H V W H Q G W R E H P R U H F R P S O H D Q C W K H U D P I R L R Q with other congenital malformations and/or chromosomal and genetic anomalies is common. It has been associated with some aneuploidies, deletion syndromes, sex chromosome abnormalities, neuromuscular disorders, microdeletion and duplications. Despite advances in molecular gene studies course and accompanying anomalies

D P D M R U F D X V D W L Y H J H Q H K D V Q R i M t H i S t u d y w e G a i n e d M o l e c u l a r D e o p e n e d O f f e n s e d O features of even familial cases show heterogeneity

Positional PEV is mostly associated with intrauterine factors limiting fetal movements, such as oligohydramnios, twin pregnancy and uterine anomalies. Early amniocentesis is one of the iatrogenic reasons that may lead to this

accompanying anomalies or it can be seen as isolated. Idiopathic PEV is usually isolated and generally have a good prognosis.

their relationship with chromosomal anomalies is limited, and familial cases have been reported. The fact that it has a higher prevalence in some populations and that it is more common among the male sex suggests that it is the result of a polygenic predisposition.

Environmental and genetic factors are thought to play a role in the etiology. It has been shown that maternal smoking, L Q F U H D V H G E R G \ P D V V L Q G H [% 0 , reuptake inhibitor use in the first trimester increases the risk of Congenital PEV , W Z D V U H S R U W H G W K D W / D during the prenatal period increased the risk of congenital PEV .

Conservative treatment is the primary method recommended do not respond to conservative treatment or who are late for treatment. Untreated patients may experience fibulation, motion, deformity, and pain in the long term. Conservative physiotherapy, and serial manipulations . The surgical method may vary depending on the severity of the clinical course and accompanying anomalies


D P D M R U F D X V D W L Y H J H Q H K D V Q R i M t H i S t u d y w e G a i n e d M o l e c u l a r D e o p e n e d O f f e n s e d O and orthopedic results of pregnant women who were found to have isolated PEV during the first and second-trimester

ultrasonographic screening in our clinic.

Materials and Methods

This study was a retrospective cohort study conducted in the Department of Obstetrics and Gynecology, between March 2015 and March 2020. Patients who presented to our clinic for routine first-trimester and second-trimester fetal anomaly screening and patients referred to our clinic due to any suspected fetal anomaly or positive screening test were included in this study. Among the patients admitted in the first trimester, those between 12 and 14 weeks were included in the study. All

S D W L H Q W V Z H U H V X E M H F W H G W R D G F K H F N H G I R U W K H S U H V H Q F H R I 3(9 of all patients were performed by four researchers experienced L Q I H W D O D Q R P D O \ V F U H H Q L Q J X V L Q J S U R E H Z L W K D 9 R O X V R Q (* (0 H G L F D O device, and information of all patients was recorded on the 0 L F U R V R I W 9 L H Z S R L Q W * (0 H G L F D O system. Information of the patients and accompanying anomalies were obtained retrospectively from patient files and 0 L F U R V R I W 9 L H Z S R L Q W * (0 H G L F D O 6 \ comprised a heterogeneous patient group including high and



L J X U H PEV ultrasonography image

PEV:Pes equinovarus

low-risk patients. Approval for the study was obtained from

WKH (WKLKV & RPPLWWHH RI dXNXURYD 8QLYHUVLW\ OHGLFDO)DFXOW\

were confirmed by karyotype analysis in peripheral blood.


L Q W K H X Q L O D W H U D O J U R X S D Q G
7 U L V R P \ Z D V G H W H F W H G L Q R Q H J S D R W X I S H Q W K H D Q G I I H U H Q E I Q Z R Q M H V W D W L V W
patient.

When the frequency of chromosomal anomalies was evaluated according to unilaterality or bilaterality, it was found as 5.88%

Trisomy 21 was detected in 51 patients in the entire study group

@ , Q I LY H R I I H W X V H V Z

K D G 3 (9 \$ I W H U W K H H O L P L Q D W L R



) L J X U H Clinical course of PEV cases diagnosed in the prenatal period

PEV: Pes equinovarus

7 D E O H Distribution of postnatal false positivity rate of PEV due to laterality in antenatally diagnosed isolated and non-isolated groups

8 Q L O D W H % D O D W H U R O V D O
, V R O D W H G Q

Non-isolated
Q

P-value*

*chi-square test was used, PEV: Pes equinovarus

7 D E O H Postnatal false positivity distribution according to the gestational week at the time of antenatal diagnosis in the isolated and non-isolated groups

) L U V W	Second	S Y D C
	7 U L P H V	W H U P H V W H U	
, V R O D W H G	Q		

1 R Q L V R O D W H G Q

7 R W D O Q

*chi-square test was used

21 in the entire group, the PEV rate was calculated as 1.58%

7 K H U D W H R I W U L V R P \ L + R Z H Y H U W K H U D W H R I

Z L W K R X W 3 (9 Z D V I R X Q G D V

6.6-fold increase in the risk for trisomy 21 in patients with PEV.

7 K L U W \ R Q H S D W L H Q W V L Q W K H conservative treatment. Conservative treatment was performed

R Q S D W L H Q W V L Q W K H Q R Q L M i l t e r a l D W H G J U R X S W K H G L I I H o l 3 4 Q F H Z D V V W D W L V W L F D O O \ V L J Q L I L F D Q W B i l a t e r a l 7 K H F R Q V H U Y D W L Y H W A U 3 D W P H Q

rate was statistically significantly higher in the isolated group

S 6 X U J L F D O W U H D W P H Q W Z D V did not respond to conservative treatment or who were late fo

W U H D W P H Q W & R U U H F W L Y H F D V W L Q used in conservative treatment. In terms of surgery, the mos

preferred methods were achillotomy and posteromedial release surgery.

Discussion

First-trimester and second-trimester fetal anomaly screening are recommended to all pregnant women during antenatal follow-up. Although PEV incidence is stated as 0.2-0.3% in the literature, the results in our study were far from these values,

as some of the patients were referred. Although the diagnosis

of PEV is usually made in the second trimester, Keret et al. showed that it was possible to make a diagnosis from the 12

Z H H N L Q W K H I L U V W W U L P H V W H U + R T H Y H U W K H G L D J Q R V L V P D G H L Q

the first trimester has some drawbacks. Bogers et al. showed that there was a temporary PEV position during the norma

development of the lower extremity in the first trimester and this development continued until the 13week. Diagnoses made without waiting for this physiologic positional change

will cause an increase in false positivity. In our study, the rate

The false-positive rate was statistically significantly higher in the isolated group compared to the non-isolated group.

S D W L H Q W V L Q W K H I L U V W W U L P H V W H U Y V S , Q W K H L V R O D W H G J U R X S Z D V I R X Q G D V U H D F K L Q J L

In the literature, this rate varies between 0% and 40% for isolated cases. Our findings were similar to the literature.

+ R Z H Y H U L Q W K H L V R O D W H G J U R X S

diagnosed in the first trimester draws attention, which can be explained by the fact that the patients in the isolated group were milder and by the physiologic position change of the foot in the first trimester. Due to high false-positive rates, isolated cases,

7 D E O H Clinical features of PEV patients diagnosed in the prenat period

	Isolated Q	1 R Q L V R O D S W H G Q
Age	25.32±4.25	26.12±4.72
BMI		0.396

Conception method

Natural	0.406
, 9 , & 6 , (7	0.305
Other ART	0.105

Gestational week at the time of	
7 K E V L Q G L F D W H V D	

G L D J Q R V L V Z H H N I P Y S U H V S P O G H G W R / D W H U D O L W \	
-----------------------------------------------------------------------------	--

Fetal Karyotyping	
Normal	
Trisomy 21	0.82
Trisomy 18	0.79
Trisomy 13	0.73
6 H [F K U R P R V R P D O anomalies	-

Pregnancy result	
Pregnancy termination	
Delivery	
Vaginal birth	0.31
Caesarean	0.42

Birth week	
Birth weight	3230

Birth weight	3230
Girl	0.23
Boy	0.24

Neonatal intensive care need	
------------------------------	--

*chi-square test was used, PEV: Pes equinovarus, BMI: Body mass index	
-----------------------------------------------------------------------	--

especially those diagnosed in the first trimester, should be advanced maternal age or positive screening test should not be followed up with serial examinations to confirm the diagnosis avoided . PEV was detected in five of 51 patients with trisomy In this study, the median gestational week at the time of diagnosis L Q R X U V W X G \ S R S X O D W L R Q of PEV was determined as 21.5 and 19.1 for the isolated and of trisomy 21 in patients with PEV 6.6 times. Offerdal et non-isolated groups, respectively. This can be explained by the detected aneuploidy at the rate of 13% in patients with fact that the disease is more complex and severe in the presence of PEV and showed that there was a strong relationship between of accompanying anomalies and therefore can be diagnosed PEV and chromosomal anomalies, and they recommended earlier + D U W J HrepboW D median gestational karyotyping for all patients including isolated cases. Tegnanader week at the time of diagnosis as 23 weeks. and Eik-Nes reached similar results.

Postnatal examinations allow the detection of accompanying According to the findings of Bakalis et al. the prognosis was I L Q G L Q J V W K D W F R X O G Q R W E H I R X Q eselaAnd the frequently H Q Dromosomat hbtareS was higher in the non-isolated group, chromosomal anomalies were found in the bilateral group, similar to our study. In the study of Viaris in two patients who did not undergo amniocentesis during the et al. , no difference was found between the two groups.

D Q W H Q D W D O S H U L R G W U L V R P \ Despite the high incidence of PEV, only a few causative genes S D W L H Q W , Q W K H L V R O D W H G J U R X S known RPI/DXG (MANO2B49)DGFBD3(RIMD40732), VTBX4Q G chromosomal anomalies were found in the postnatal period and RBM10 genes have been found to be associated with isolated / D X V R Q HatedDt that neurologic, developmental, and PEV . Recommending chromosomal microarray studies additional structural anomalies could be detected in postnatal addition to conventional karyotyping to patients with PEV follow-up in isolated cases. In their studies, it was observed will help to better understand the factors causing the disease that 10% of isolated cases turned into complex cases after because multigenetic factors play a role in the etiology minimum of 1-year follow-up. Di Mascio et al. reported that Conservative treatment is the primary method recommended in anomalies related to the skeletal system and neuromuscular W K H W U H D W P H Q W R I 3 (9 6 X U J H U \ L V U system were detected at a rate of 7% in the postnatal follow-up do not respond to conservative treatment. There is no treatment of patients diagnosed as having isolated PEV in the prenatal in the prenatal period. The accepted method in conservative period. Offerdal et al. made a minimum of 2-years follow-up W U H D W P H Q W L V 3 R Q V H W L F D V W L Q J and found that 15% of the cases turned into complex cases Z D V S H U I R U P H G R Q W Z R S D W L H Q W V 6 K L S S D Q G %fudQnElturts in their study. Our S D W L H Q W V L Q W K H Q R Q L V R O study has limitations in this regard because we have not yet Z D V V W D W L V W L F D O O \ V L J Q L I L F D Q W followed-up all patients for at least one year. screening performed to detect accompanying anomalies will 2 X U V H [G L V W U L E X W L R Q E R \ J L U O help us understand whether the cases are isolated and predict which was consistent with the literature. In our study, the the postnatal prognosis.

percentage of non-isolated PEV was 73%. Although this rate varies between 48% and 51% in some community studies, rates up to 80% have been reported in tertiary centers such as our The limitations of this study are that it had a retrospective clinic where high-risk patients are treated . design, only patients diagnosed during the intrauterine period

In our study, although chromosome anomalies were detected could be reached, and the rate of PEV detection could not be with a rate of 5.8% in the isolated group, the rate was 16.3% specified due to the exclusion of patients diagnosed for the first in the non-isolated group. Many authors believe that karyotype time in the postnatal period.

is necessary in the presence of anomalies accompanying PEV Another limitation is that only conventional karyotyping however, there are ongoing discussions for isolated cases could be performed in patients, chromosomal microarray was The most common chromosomal anomalies associated with PEV R W S H U I R U P H G 6 W X G L H V L Q Y R O Y L Q D U H W U L V R P L H V D Q G , W L V S Revalations pre ned to better understand the etiology of the trisomy 13 and 18 using ultrasonography due to accompanying disease.

D Q R P D O L H V + R Z H Y H U V H [F K U R P R V R P H D Q R P D O L H V D Q G W U L V R P \ Conclusion

21 sometimes display very limited or no findings. For this

reason, especially in isolated PEV cases, karyotyping comes The diagnosis of PEV can be made in the late first and second the fore due to the risk of trisomy 21. In the study of Viaris trimesters. In the first trimester, the rate of false positivity et al. , the rate of chromosomal anomalies in the isolateds higher, and the diagnosis should be confirmed with J U R X S Z D V / D X rpeboW tiv inadence serial examinations. When PEV is diagnosed, detailed fetal of chromosomal anomalies as 2.3% in the isolated group anomaly screening should be performed for anomalies that Recommending karyotype to isolated cases in the presence may accompany, and patients should be informed about the

increased incidence of chromosomal anomalies, and karyotype and chromosomal microarray analysis should be recommended. Chromosomal microarray can identify clinically significant below the resolution of conventional chromosome analysis. The risk of this chromosomal and structural anomaly further increases in the presence of accompanying additional findings. It should be kept in mind that some neuromuscular and skeletal system anomalies may occur for the first time in the postnatal period in isolated cases.

(W K L F V

(W K L F V & R P P L W W H H \$ S S U R Y D O Approval for the study was obtained from all patients.

\$ X W K R U V K L S & R Q W U L E X W L R Q V

6 X U J L F D O D Q G 0 H G L F D O 3 U D F W L F H V 6 K L 6 S & 7 % & R Q F F H U S M D I % 0 5 6 7 K H V L J Q L I L F D ' H V L J Q 0 6 ' D W D & R O O H F W L R Q R U R U , Q W H U S U H W D W L R Q 6 & ' / L W H U D 1998;118:6002

6 & ' & R Q I O L F W R I , Q W H U H V W No conflict of interest was declared by the authors.

) L Q D Q F L D O ' L V F O R V X U H Authors have no financial interests about the research.

References

1. / R F K P L O O H U & - R K Q V W R Q ' 6 F R W W \$ epidemiology study of idiopathic talipes equinovarus. Am J Med Genet 1998;79:90-6.
2. 6 K D U R Q : H L Q H U 0 6 X N H Q L N + D O H Y \ 5 % L U R Q 6 K H Q W D O 7 0 D U N R Y L W F K 2 ' L D and outcomes of pregnancies with clubfoot detected by prenatal sonography. Prenat Diagn 2017;37:754-63.
3. \$ O G H U P D Q %: 7 D N D K D V K L (5 / H O L H U 0 W D O L S H V H T X L Q R Y D U X V L Q : D V K L Q J W R Q 1991;2:289-92.
4. . H U H W ' (] U D (/ R N L H F) + D \ H N 6 6 H J H Y of prenatal ultrasonography in confirmed club foot. J Bone Joint 6 X U J % U % D V L W 6 . K R V K K D O . , * H Q H W L F V R I F O by prenatal monography. Eur J Med 2018;61:107-13.
5. future perspectives. Eur J Med Genet 2018;61:107-13.
6. 6 D Q] D U H O O R , 1 D Q Q L 0) D O G L Q L & 7 K H Isolated clubfoot diagnosed prenatally. Is it really indicated? Pediatr Orthop B 2017;26:143-51.
7. 3 D Y R Q H 9 & K L V D U L (9 H V F L R \$ / X F H Q W I R R G I R Z V D ' 7 U D H Q V W D 8 P V T K D H G 0 * U D K D P - etiology of idiopathic congenital talipes equinovarus: a systematic review and meta-analysis. Arch Dis Child 2016;101:101-6.
8. : H P D N R U \$ & D V V R Q . * D U Q H (% D N N H U first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Eur J Epidemiol 2015;30:1187-98.
9. < D] G \ 0 0 0 L W F K H O O \$ \$ / R X L N & : H U O serotonergic reuptake inhibitors during pregnancy and the risk of clubfoot. Epidemiology 2014;25:859-65.
10. ' R O N + - H Q W L Q N - / R D Q H 0 0 R U U L V - G H lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008;71:714-22.
11. * B Q H V D O R % V H V [L P R Q 1 \$ \$ O X P D B O H \$ % D Ponseti method in the management of clubfoot under 2 years of age. J Bone Joint Surg Am 2008;90:103-10.
12. 6 K D E W D L / 6 S H F K W 6 & + H U] H Q E H U J - (Ponseti method for clubfoot. World J Orthop 2014;5:585-90.
13.) H U U H L U D *) 6 W p I D Q L . & + D M H ' 3 1 R J X H L L Q F K L O G U H Q Z L W K F O X E I R R W D I W H U Z D O P H W D Q D O \ V L V R I R E V H U Y D W L R Q D O V W X G L % R J H U V + 5 L I R X Q D 0 6 & R K H Q 2 Y H U E H I : L O O H P V H Q 6 3 Y D Q G H U 6 S H N 3- H W D O development of the fetal foot position using three-dimensional ultrasound in virtual reality. J Obstet Gynaecol Res 2019;45:280-8.
14. 2 I F H U G D O . - H E H Q V 1 % O D D V + * (L N 1 H V detection of talipes equinovarus in a non-selected population of 49314 deliveries in Norway. Ultrasound Obstet Gynecol 2007;30:838-44.
15. 4. 5 10 D R D Q Q 7 + H D K M 0 70 * H Q H W F - 5 : H U O H U 0 for clubfoot: what factors predict prenatal detection? Prenat Diagn 2014;34:389-93.
16. 7 L H S D H A H L R ') b o X F P D Q \$ K D O L O \$ 5 L] J R * 0 D al. Outcome of isolated fetal talipes: A systematic review and meta-analysis. Arch Dis Child 2012;97:104-8.
17. D Q D O \ V L V \$ F W D 2 E V W H W * \ Q H F R O 6 F D Q G + D U W J H ' 5 * D H U W Q H U 6 : H L F K H U W - 3 U H outcome of congenital talipes equinovarus in 106 fetuses. Arch Dis Child 2012;97:104-8.
18. 6 W D M O 1 / D X V R Q 6 \$ O Y D U H] & 3 D W H O 0 6 / D Q J O R D Y H Y diagnosed isolated clubfoot. Ultrasound Obstet Gynecol 2010;35:708-14.
19. 0 D P P H Q / % H Q V R Q & % 2 X W F R P H R I I H W X V by prenatal monography. Eur J Med 2004;23:497-500.
20. 24. Malone FD, Marino T, Bianchi DW, Johnston K, D'Alton ME. Isolated clubfoot diagnosed prenatally. Is it really indicated? Obstet Gynecol 2000;95:437-40.
21. 25. Creveuil C, et al. Prenatal diagnosis of clubfoot: Chromosomal abnormalities associated with fetal defects and outcome in a tertiary center. Ultrasound Obstet Gynecol 2010;44:100-5.
22. 26. N, Creveuil C, et al. Prenatal diagnosis of clubfoot: Chromosomal abnormalities associated with fetal defects and outcome in a tertiary center. Ultrasound Obstet Gynecol 2010;44:100-5.
23. 27. 7 H J Q D Q G H U ((L N 1 H V 6 + 7 K H H [D P L Q H U has a significant impact on the detection rate of congenital heart

- defects at the second-trimester fetal examination. Ultrasound Obstet Gynecol 2006;28:8-14.
29. Menke DB, Guenther C, Kingsley DM. Dual hindlimb control HOOPHQWV LQ WKH 7E[JHQH DQG UHJLRQ (VWHU \$5 :H\PRXWK .6 % XUW \$:LVH & \$ vertebral limbs. Development 2008;135:2543-53.
HW DO \$O WHUHG WUDQVPLVVLRQ RI +2;< DQG +D S+KSHARWL F& D1-3 V LG HQ WLH\; =KDQJ a potential common pathway for clubfoot. Am J Med Genet A missense mutations in the filamin B gene are associated with isolated 2009;149a:2745-52.
F R Q J H Q L W D O W D O L S H V H T X L Q R Y D U X V + X

\$EVWUDFW

2EMHFVLYH 7R FUHDWH D QHZ DQG VLPSOH PRGHO IRU SUHGLFWLQJ WKH OLNHOLKRRG time of admission.
 0DWHULDVOV DQG 0HWKRGV \$ SURVSHFWLYH REVHUYDWLRQDO VWXGI ZDV SHUIRUPHG DV 'HFHPEHU LQ SUHJQDQW ZRPHQ DWWHQGLQJ WKH ODERXU URRP ZLWK RQH SUHYLRLX FHVDUHDQ 72/\$& 7KH VDPSOH VLJH ZDV \$ 9%\$& VFRUH ZDV FDOFXODWHG IRU HDFK at the time of admission such as maternal age, gestational age, Bishop's score, body mass index, indication for primary cesarean section, and clinical H V W L P D W H G I H W D O Z H L J K W 7 K H U H V X O W V R I W K H 9 % \$ & V F R U H V Z H U H F R U U H O D W H G Z L V t-test was used for comparison among the groups. Descriptive and regression analysis was performed for the study variables.
 Results: 2 X W R I 72/\$& F D V H V K D G V X F F H V V I X O 9 % \$ & D Q G W K H U H P D L Q G H U K D G I

Öz

\$PDo %X oDOxüPD EDüYXUXGD RODQ GHylÜNHQOHUL NXOODQDUDN VH]DU\HQ VRQUDVx ROXüWXUPDN LoLQ \DSxOPxüWxU
 *HUhO YH <|QWHPOHU +DU\DQD·GDNL •o•QF• EDVDPDN VDýOxN PHUNH]LQGH D\OxN EL GDKD |QFH ELU NH] VH]DU\HQ LOH GRýXP \DSDQ YH '*HEHOHUGH 6H]DU\HQ 6RQUDVx 'Rý J|]OHPVHO oDOxüPD \DSxOGx YH |UQHNOHP E•••NO•ý• LGL +HU KDVWD LoLQ 669' VNRL VH]DU\HQ HQGLNDV\RXQ YH NOLQLN RODUDN WDKPLQ HGLOHQ IHWDO DýxUOxN JLEL KD KHVDSODQGx 669' VNRUXQXQ VRQXoODUx EDüDUxOx YH\ID EDüDUxVx] 669' üHNOLQGH 6WXGHQW·V W WHVWL NXOODQxOGx dDOxüPD GHylÜNHQOHUL LoLQ WDQxPOD\xFx DQDOL %XOJXODU <•] HOOL 72/\$& NULWHUOHULQH X\DQ JHEHQLQ ·LQGH EDüDUxOx 669' YH VDKLS ROPD RODVxOxýx LoLQ LoLQ YH ! LoLQ LGL 7DKPLQ PRGHOL D LOD HýUL DOWxQGDNL DODQ LOH L\l SHUIRUPDQV J|VWHUPLÜWLU 6RQXo %X oDOxüPD |QHULOHQ 669' WDKPLQ PRGHOLQLQ 72/\$& VRQXFQX WDKPLQ HWPH GRýXP üHNOL NRQVXXQGD GDQxüPDQOxN \DSPDN LoLQ NXOODQxODELOHFHylQL J|VWHUP VDKLS GLýHU EX W•U PRGHO OHU OH LOJLOL GDKD ID]OD oDOxüPD \DSxOPDVx JHUHNPHNW \$QDKWDU .HOLPHOHU 6H]DU\HQ VRQUDVx YDMLQDO GRýXP WDKPLQ PRGHO

PRECIS: A new prediction model of vaginal birth after cesarean containing factors available at the time of admission was tested and it was found to be a good tool.

\$GGUHV V IRU &RUUHVSRQGHQFH\<|D\N\W\B\B\\$&GRJFH\&URI

%KDJDW 3KRRO 6LQJK *RYHUQPHQW 0HGLFDO &ROOHJH IRU :RPHQ .KDQSXUNDODQ 6RQHSDW +DU\DQD ,QGLD

Phone: +91 839 883 61 81 (PDLO drpinki_18@yahoo.com 25 & , ' , ' orcid.org/0000-0002-9252-6864

5HFHLYHG *HOLÜ 7DULKL 03.06.2020 \$FFHSWHG .DEXO 7DULKL 18.10.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

The effective and safe use of cesarean delivery has been a focus and concern for last the three decades. It was the result of W KH 1 DW L R Q D O , Q V W L W X W H V R I + H D O W K & R Q V H Q X X Y & R Q I H U H Q F H on Cesarean Childbirth held in response to the three-fold L Q F U H D V H L Q W KH U D W H R I F H V D U H D Q E O X V L R Q 6 E Q U L Q H W B D S U H J Q D Q F \ Y H W R L Q W K D W Y D J L Q D O E L U W K R Q H S U R U H 6 & 6 Z L W K Q R Q U H F X U U H Q V came into being. As a result, the VBAC rate rose from 19.9% in 1990 to 28.3% in about a decade and the cesarean delivery rate decreased from 22.7% to 20.7%. D W H U Z L W K L Q F U H D V H L Q F J H L W H U H D U V R U !

incidence of uterine rupture, VBAC had a setback and went into disrepute, once again leading to an increase in the cesarean rates. This has led to significant research in determining the best permutations and combinations of the factors to achieve the optimum outcome of a previous cesarean delivery. There are numerous factors such as maternal age, body mass index % 0 , J H V W D W L R Q D O D J H V S R Q W D of significant factors used in previous models given by Troyer conception period, estimated fetal weight, Bishop's score, type and Parisi et al., Flamm and Geiger, Grobman et al. , of previous cesarean scar, and indication for primary cesarean delivery, which can influence the decision to undergo a trial included six variables, four of which, namely maternal age in R I O D E R X U D I W H U F H V D U H D Q 7 2 / \$ & years, gestational age in weeks, indication for primary cesarean, 9 % \$ & H P H U J H Q F \ U H S H D W F H V D U H D Q D BMI were also included in Grobman's model.given of Y D J L Q D O G H O L Y H U \ cervical dilation, we used Bishop's score, which was the main Rates of maternal complications are highest among women who attempt vaginal birth and fail, intermediate among women who have planned cesarean delivery, and lowest among women who attempt vaginal birth and succeedVBAC success rates also and most studied individual factors instead of prediction vary between institutions and service providers. Thus, it is worthmodels, which is why statistically significant factors previously remarking that as of now, there is no reliable and demonstrablestudied in Indian studies as well as supported by the American algorithm or nomogram that correctly identifies or accuratelyCollege of Obstetrics and Gynecology and the Royal College of predicts the success of VBAC + H Q F H P D Q D J H P H O D M e t r i c s l G n a l d o l y guidelines were included. Each of previous lower segment cesarean section continues to be variable used in the prediction model was assigned a score of 0, obstetric dilemma.

Therefore, an accurate and reliable prediction model must be designed and validated to predict a successful outcome, but literature is scarce from India that could assess the ante-partum failure to progress . A score of 2 was chosen for breech and intrapartum determinants for predicting successful VBACand fetal distress because, according to the literature, this + H Q F H W K L V V W X T G e a i \ D m t h e S t u d y Q a s h G group had a statistically significant favourable VBAC outcomes create a new model for predicting the likelihood of VBAC using L Q 7 2 / \$ & V G L X P G D H V W O \ R W K H U I D F W R U variables available at the time of admission.

7 K H R E M H F W L Y H R I W K H V W X G \ Z D V S D R W L W H Q W W W K K H S H H V R U R D Q E H U R I W K H O prediction model for success of VBAC delivery.

Materials and Methods

This prospective observational study was conducted at a WH U W L D U \ F D U H F H Q W U H R Y H U D S H U D R W H R U Q D P R Q W K F Q - D Q Q U D U \ D ! W R ' H F H P E H pregnant women attending the labour room with one previous cesarean section. This hospital 3. Indication for primary caesarean-section: U H I H U U D O F H Q W H U I R U W K U H H P D M R D U G R Q W S U L R J M H R V + D I U Q D E B U S W I D B W H D Q G India with annual live birth rates ranging from 4,500 to 5,000, E , Q W U D X W H U L Q H J U R Z W K U H V W U L F average overall cesarean rate of 20-25% of total deliveries, and Q W H S D U W X P K D H P R U U K D J H a repeat cesarean rate of 30-35% of total cesareans. At 5% alpha E U H H F K S U H V H Q W D W L R Q R U I H W D O H U U R U S R Z H U D Q G F R Q I L G H Q F H % Q W K H R S Y D I R L & H D W K H V D E P S O H F

V L] H F D O F X O D W H G X V L Q J 0 D V W H U (W K L F D O F R P P L W W H H D S S U R Y D O R I W K Q X P E H U % 3 6 * 0 & : 5 & , (& D Q G L Q I R consent was given by each patient who fulfilled the following L Q F O X V L R Q D Q G H [F O X V L R Q F U L W H U L D L Q F U H D V H L Q W K H U D W H R I F H V D U H D Q E O X V L R Q 6 E Q U L Q H W B D S U H J Q D Q F \ Y H R Q H S U R U H 6 & 6 Z L W K Q R Q U H F X U U H Q V K L V W R U \ P D W H U Q D O D J H \ H D U V K L F Q X V L R Q F J H L W H U H D U V R U ! \ H D U V fetal death, lethal fetal anomalies, non-reassuring fetal heart rate on admission, cephalopelvic disproportion, malpresentation, history of antepartum haemorrhage or adherent placenta in the current pregnancy, history of uterine surgery other than cesarean section.

The following system was designed using the relative weights of significant factors used in previous models given by Troyer and Parisi et al., Flamm and Geiger, Grobman et al. , Wen et al. D Q G 0 H W . In the proposed model, we included six variables, four of which, namely maternal age in R I O D E R X U D I W H U F H V D U H D Q 7 2 / \$ & years, gestational age in weeks, indication for primary cesarean, 9 % \$ & H P H U J H Q F \ U H S H D W F H V D U H D Q D BMI were also included in Grobman's model.given of cervical dilation, we used Bishop's score, which was the main Rates of maternal complications are highest among women who attempt vaginal birth and fail, intermediate among women who have planned cesarean delivery, and lowest among women who attempt vaginal birth and succeedVBAC success rates also and most studied individual factors instead of prediction vary between institutions and service providers. Thus, it is worthmodels, which is why statistically significant factors previously remarking that as of now, there is no reliable and demonstrablestudied in Indian studies as well as supported by the American algorithm or nomogram that correctly identifies or accuratelyCollege of Obstetrics and Gynecology and the Royal College of predicts the success of VBAC + H Q F H P D Q D J H P H O D M e t r i c s l G n a l d o l y guidelines were included. Each of previous lower segment cesarean section continues to be variable used in the prediction model was assigned a score of 0, obstetric dilemma.

R U 6 F R U H V Z H U H G H F L G H G E D V H G

Therefore, an accurate and reliable prediction model must be designed and validated to predict a successful outcome, but literature is scarce from India that could assess the ante-partum failure to progress . A score of 2 was chosen for breech and intrapartum determinants for predicting successful VBACand fetal distress because, according to the literature, this + H Q F H W K L V V W X T G e a i \ D m t h e S t u d y Q a s h G group had a statistically significant favourable VBAC outcomes create a new model for predicting the likelihood of VBAC using L Q 7 2 / \$ & V G L X P G D H V W O \ R W K H U I D F W R U variables available at the time of admission.

accordingly. A pilot study of this model was performed on 50

7 K H R E M H F W L Y H R I W K H V W X G \ Z D V S D R W L W H Q W W W K K H S H H V R U R D Q E H U R I W K H O made, and later it was performed on 150 more patients.

VBAC scoring system used in the proposed prediction model:

W H U W L D U \ F D U H F H Q W U H R Y H U D S H U D R W H R U Q D P R Q W K F Q - D Q Q U D U \ D ! W R ' H F H P E H pregnant women attending the labour room with one previous cesarean section. This hospital 3. Indication for primary caesarean-section: U H I H U U D O F H Q W H U I R U W K U H H P D M R D U G R Q W S U L R J M H R V + D I U Q D E B U S W I D B W H D Q G India with annual live birth rates ranging from 4,500 to 5,000, E , Q W U D X W H U L Q H J U R Z W K U H V W U L F average overall cesarean rate of 20-25% of total deliveries, and Q W H S D U W X P K D H P R U U K D J H a repeat cesarean rate of 30-35% of total cesareans. At 5% alpha E U H H F K S U H V H Q W D W L R Q R U I H W D O H U U R U S R Z H U D Q G F R Q I L G H Q F H % Q W K H R S Y D I R L & H D W K H V D E P S O H F

5. BMI in kg/m² on admission:

D E F

6. Clinically estimated fetal weight in grams according to Johnson's formula:

Johnson's formula:

VBAC scores were calculated for each patient fulfilling the FULWHULD WR XQGHUJR 72/\$& DW W result obtained was correlated with the outcome i.e. failed VBAC or successful VBAC.

6WDWIVWLEDO \$QDOWLV

for statistical analysis. Descriptive statistics were used for the demographic features such as age, parity, gestational age, BMI, Bishop's score, and the indication for primary cesarean birth. Multivariate logistic regression analysis using the enter method was performed to calculate the model to determine their association with successful VBAC. A 95% CI was calculated.

Results

2XW RI 72/\$& FDVHV KDG VXFFH
UHPDLQGHU KDG IDLOHG 9%\$& HP
VHFWLRLQ 7DEOH GHSLFWV WKH LQG

prediction model, their frequency distribution, and their means with standard deviation. Table 2 shows the indications of cesarean section in the failed VBAC group. The most common indication was fetal distress followed by scar tenderness and

respectively. Out of eight cases of scar tenderness, three had

We developed a total score of 0-12. The final cumulative VBAC

more ranged from 2 to 11 in the present study. It was 10 or more in 5.30%, 7 to 9 in 47.3%, 4 to 6 in 40.10%, and 3 or less

DirQ7G30% of the cases in VAS can be seen in graph V, the odds are very low probability of having a successful VBAC for VBAC score 0-3.

predicted VBAV percentages were calculated using binary logistic regression analysis and were

When the multivariate regression family of Hofzaal-Van Praag models is used,

depicted in Table 3. Odds that variables like gestational age and Bishops score had the odds of 2.047 and 3.082

7DEOH	'HPRJUDSKLF FKDUDFWHULVWLKV RI ZRPHQ XQGHUJRLQJ WULDO RI ODERXU	
'HPRJUDSKLFV FKDUDFWHULVWLKV)DLOHG 9%\$&	6QFFHVVIXO 9%\$& Q 1
1XPEHU RI ZRPHQ XQGHUZHQB 9%\$&		
0DWHUQDO DJH \UV	25.93±3.51	25.82±3.70
25-30		0.92
!		
% 0 , NJP	25.08±3.62	23.19±2.63
25-30		0.04
!		
* HVWDWLQRQDO DJH ZHHNV	38.12±1.36	38.96±1.24
39-40		0.16
!		
Indication of primary cesarean		
132 / RWKHUV		
,8*5 ROLJRK\GUDPQLRV \$3+		
breech, fetal distress		
&OLQLFDOO\ HVWLPDWG IHWDO ZHLJ 8389.54±470.45V	3402±470.5	
2500-3500		0.61
!		
Bishop's score	3.60±0.82	6.34±2.35
0-3		
4-5		
6-10		
'DWD DUH H[SUHVVHG DV SHUFHQWDJHV ZLWK IUHTXHQFLHV LQ WKH SDUHQWKHVHV DQG PHDQ " VWDQGDUC ODERXU ,8*5 ,QWUDXWHULQH JURZWK UHVWULFWLRQ \$3+ \$QWHSDUWXP KDHPRUUKDJDH		

respectively, for having a successful VBAC with significant p-values in both, and with each 1 unit increase in BMI the odds R I K D Y L Q J D V X F F H V V I X O 9 % \$ & U H G X F I other three factors i.e. age, indication for previous cesarean, and H V W L P D W H G I H W D O Z H L J K W - R K Q V R Q . V associated with successful VBAC.

As shown in Table 4, we studied five additional variables out of the model variables, namely spontaneous onset of labour, parity, interdelivery interval in months, previous history of successful VBAC, and previous history of normal vaginal delivery. These variables were chosen because they were also included in the previous models by Grobman and Flamm, Geiger and Wen et al. . Out of these five, two i.e. spontaneous onset of labour and parity were significantly associated with successful VBAC with odds of 2.58 and 5.138, respectively; the remaining three had no significant effect.

6 H Y H Q W H H Q S D W L H Q W V R X W R
7 2 / \$ & K D G F R P S O L F D W L R Q V V X F K D V Q
D G P L V V L R Q V Q I D L O H G D Q G V X F F H V V I X O

* U D S K Predicted compared with observed vaginal birth after F H V D U H D Q V H F W L R Q 9 % \$ & 6 X F F H V V I X O

) L J X U H ROC curve for the scoring system showing area under W K H F X U Y H \$ 8 &

ROC: Receiver operating characteristic curve

Zs H ; Å § Ö X ?Å¢5p š œ ¬ Å

E R W K D Q G E O D G G H U L Q M X U \ Q I & Q W K H W R D L O H G R P % \$ & H G R Z L S W K D Q D G L O H G D W R W D O R I F D V H V R I 3 3 + D O O D W R Q R F 3 3 + D Q I G R X W K H Q F W D Q F W X F R H V X F X Q I V VBAC group and six in the failed VBAC group. There were no cases of uterine rupture and ICU admissions in the present study. The VBAC score of the failed VBAC group was 5.03 ± 1.82 and that study.

) L J X U H V K R Z V W K H 5 2 & F X U Y H Z L W K D Q S \$ 8 & H T X R Q D W R W K R U V F R Q F O X G H G &, W R D I D L U M X G J P H Q W R I V X F F H V V I X O Y D J L

Discussion

The ACOG 2010 quoted the success rate of VBAC as 60-80% VBAC success rates also vary between institutions and service providers. The success rate of VBAC in the present study was

78%, similar to the quoted percentage. The mean age of the women in the present study was 25.84 \pm 4.20 years and there was no significant difference in the ages of the women in the two groups i.e. successful VBAC and failed VBAC groups, similar delivery since the last cesarean, and indication for primary cesarean of the arrest of dilation or descent. All variables were

mean age in the current study was lower as compared with those that could be determined at the first antenatal visit with study by Xing et al. because 76.6% of the women were from rural areas where young marriage and childbirth is common. This model was improved in 2009 by adding certain other factors the mean age in the successful VBAC and failed VBAC groups, most recent BMI within 2 weeks of delivery, gestational age was higher and there was a significant difference between the delivery, gestational diabetes mellitus, preeclampsia, cervical W Z R J U R X S V D Q G S examination findings at admission, and the undertaking of

Troyer and Parisi in 1992 studied 264 women with one labour induction. The result was expressed as the percentage of

previous cesarean section and developed a model with four factors, namely previous dysfunctional labour, non-reassuring fetal heart tracing at admission, no previous vaginal delivery and labour induction. Each variable was given one point which were available at the time of admission because our

the total score ranged from 0-4. The patients with the lowest hospital is a referral hospital and most of the time our patients

V F R U H L H K D G W K H K L J K H V W 9 D % \$ & X Q V F F K H V Q X O D V H L Q D W K H S U H V H

compared with those with higher scores. This model has

The AUC of the ROC curve of Grobman's 2007 model was not been studied extensively and needs further research and that of the new model was 0.779, and these values validation. The indication of primary cesarean section i.e. known as the MFMU calculator and is freely available on the

V W X G \ P H Q W L R Q H G K H U H D V 1 3 2 / Internet. The AUC of the ROC curve of our model is 0.77,

J H U R V F R U H V L P L O D U W R W K D W R I * U R E P D Q V

There is a popular model known as the Flamm scoring system which was developed in 1997 in California. The research was performed well.

performed on 5022 pregnant women including four variables. In 2018, Wen et al. conducted a retrospective cohort study known at the time of admission i.e. age of the patient, vaginal delivery before and after the cesarean section, a non-recurrent indication of primary caesarean, cervical dilatation and cervical effacement. The result was given as a score of 0-10 and compared the two. The considered potential score had a different percentage of success i.e. 0-2 corresponded to 49.1%, 3-7 corresponded to 59.9%, 66.7%, 77%, 88.65%, and two new variables, maternal height and estimated fetal weight. Their overall VBAC success rate was 83.3%. The AUC study, we used two of the above factors in the VBAC predictor model i.e. patient age, but instead of cervical dilation, we used the Bishop's score.

Patel et al. conducted a prospective observational study on 150 women with one previous cesarean section using the Flamm scoring system. The Grobman's model was well accepted in the Chinese population, and supplemented with maternal

height and estimated fetal weight needed to be further studied current and subsequent pregnancies. Parity, spontaneous onset in the Chinese population.

There was no case of uterine rupture in the present study whereas the incidence was 0.90% in the study by Patel et al. A recent meta-analysis thickness antenatally in women with a previous caesarean delivery could be used to predict the occurrence of a uterine VBAC. Further prospective observational studies are needed uterine rupture.

The present study included a very important variable i.e. Bishop's score that has not been incorporated in any of the popular models by Flamm and Geiger and Grobman et al., who included only the individual components of Bishop's score⁹ and Xing et al. included Bishop's score in their model, despite their study also used the Δ value as the main factor in developing a score to which a value of 2 to 4 was assigned. The authors report no conflict of interest.

BMI, primary cesarean delivery because of nonrecurrence of the research variables that may be incorporated in the present model and a further study can be planned. There are insufficient studies about VBAC prediction models and most studied only individual variables. Other variables studied in other prediction models are weight gain in pregnancy, preeclampsia, gestational diabetes, insurance, and race. There is a need for the development of a standard prediction model and further studies of this model and many more such models with different permutations and combinations of various variables are required to help predict

WKH VXFFFVV RI 72/\$ & ZLWK KLJK DFF

6WXG / LPLWDWLRQ V

7KH VPDOO VDP SOH VLJH LV WKH OLPURWLDQH The study was approved by the institutional ethics committee and was performed in accordance with the ethical standards described in an appropriate version of the 1975 Declaration of Helsinki. Among the authors and this study was not funded by any RUDQL DWLRQ

Conclusion

The present study tests a new VBAC prediction model and shows that it is a good tool for predicting VBAC and hence can be used to counsel women regarding the mode of delivery in

of labour, admission Bishop's score, gestational age, and BMI

were the factors with a statistically significant association with the comparison of two different types of scoring systems, each system with different variables in a given population/ 8 6

thickness antenatally in women with a previous caesarean delivery could be used to predict the occurrence of a uterine

VBAC . Further prospective observational studies are needed

XVLQJ D VWDQGDUG PHWKRG RI LQWUDSDUWXP/86 WKLFNQHVW PHDVXUHPHQW WR SUHGLFW WKH RXWERPH RI 72/\$ & DQG ULVN RI

uterine rupture.

3HHU UHYLHZ Externally peer-reviewed.

\$XWKRUVKLS & RQWULEXWL RQV

6XUJLFDQ DQG 0HGLFDO 3UDFWLFHV

and Xing et al. included Bishop's score in their model, despite

LW EHLQJ D VXE MHFWLYH YDULDEOHRULWQWPHRSUHWBPHZD V3KLJK&L3KWH&

their study also 0HW] HUsedit@ value as the main

DGGHG IRU DQRWKHU IRXU YDULDEO&RQIOLFWRUVQWHUHVW

BMI, primary cesarean delivery because of nonrecurrence

LQGFLFDWLRQ PDWHUQDO DJH \HDUVWR JHW WKH ILQDO 9%\$ & VFRUH

, Q WKH SUHVHQW VWXG\ LW KDV DQ DGMVXVHG RGGV UDWLR RI DQG

KDV D YHU\ VWURQJ DVVRFLDWLRQ ZLWK VXXFHVVIXO 9%\$ & S

6SRQWDQHRXV RQVHW RI ODERXU DQG &HYDUDQ&KLOGEUWK1HU&RQVHOVXV

variables that may be incorporated in the present model and

a further study can be planned. There are insufficient studies

about VBAC prediction models and most studied only individual

variables. Other variables studied in other prediction models are

insurance, and race. There is a need for the development of

a standard prediction model and further studies of this model

and many more such models with different permutations and

combinations of various variables are required to help predict

WKH VXFFFVV RI 72/\$ & ZLWK KLJK DFF

6WXG / LPLWDWLRQ V

7KH VPDOO VDP SOH VLJH LV WKH OLPURWLDQH

The study was approved by the institutional ethics committee

and was performed in accordance with the ethical standards

described in an appropriate version of the 1975 Declaration

RI + HOVLQNL DV UHYLVHG LQ 7KHUH LV QREQLQHFWRULQHVW

among the authors and this study was not funded by any

RUDQL DWLRQ

Conclusion

The present study tests a new VBAC prediction model and

shows that it is a good tool for predicting VBAC and hence can

be used to counsel women regarding the mode of delivery in

the Chinese population.

of labour, admission Bishop's score, gestational age, and BMI

were the factors with a statistically significant association with

the comparison of two different types of scoring systems, each

system with different variables in a given population/ 8 6

thickness antenatally in women with a previous caesarean delivery could be used to predict the occurrence of a uterine

VBAC . Further prospective observational studies are needed

XVLQJ D VWDQGDUG PHWKRG RI LQWUDSDUWXP/86 WKLFNQHVW PHDVXUHPHQW WR SUHGLFW WKH RXWERPH RI 72/\$ & DQG ULVN RI

uterine rupture.

3HHU UHYLHZ Externally peer-reviewed.

\$XWKRUVKLS & RQWULEXWL RQV

6XUJLFDQ DQG 0HGLFDO 3UDFWLFHV

and Xing et al. included Bishop's score in their model, despite

LW EHLQJ D VXE MHFWLYH YDULDEOHRULWQWPHRSUHWBPHZD V3KLJK&L3KWH&

their study also 0HW] HUsedit@ value as the main

DGGHG IRU DQRWKHU IRXU YDULDEO&RQIOLFWRUVQWHUHVW

BMI, primary cesarean delivery because of nonrecurrence

LQGFLFDWLRQ PDWHUQDO DJH \HDUVWR JHW WKH ILQDO 9%\$ & VFRUH

, Q WKH SUHVHQW VWXG\ LW KDV DQ DGMVXVHG RGGV UDWLR RI DQG

KDV D YHU\ VWURQJ DVVRFLDWLRQ ZLWK VXXFHVVIXO 9%\$ & S

6SRQWDQHRXV RQVHW RI ODERXU DQG &HYDUDQ&KLOGEUWK1HU&RQVHOVXV

variables that may be incorporated in the present model and

a further study can be planned. There are insufficient studies

about VBAC prediction models and most studied only individual

variables. Other variables studied in other prediction models are

insurance, and race. There is a need for the development of

a standard prediction model and further studies of this model

and many more such models with different permutations and

combinations of various variables are required to help predict

WKH VXFFFVV RI 72/\$ & ZLWK KLJK DFF

6WXG / LPLWDWLRQ V

7KH VPDOO VDP SOH VLJH LV WKH OLPURWLDQH

The study was approved by the institutional ethics committee

and was performed in accordance with the ethical standards

described in an appropriate version of the 1975 Declaration

RI + HOVLQNL DV UHYLVHG LQ 7KHUH LV QREQLQHFWRULQHVW

among the authors and this study was not funded by any

RUDQL DWLRQ

Conclusion

The present study tests a new VBAC prediction model and

shows that it is a good tool for predicting VBAC and hence can

be used to counsel women regarding the mode of delivery in

the Chinese population.

of labour, admission Bishop's score, gestational age, and BMI

were the factors with a statistically significant association with

the comparison of two different types of scoring systems, each

system with different variables in a given population/ 8 6

thickness antenatally in women with a previous caesarean delivery could be used to predict the occurrence of a uterine

VBAC . Further prospective observational studies are needed

XVLQJ D VWDQGDUG PHWKRG RI LQWUDSDUWXP/86 WKLFNQHVW PHDVXUHPHQW WR SUHGLFW WKH RXWERPH RI 72/\$ & DQG ULVN RI

uterine rupture.

3HHU UHYLHZ Externally peer-reviewed.

\$XWKRUVKLS & RQWULEXWL RQV

6XUJLFDQ DQG 0HGLFDO 3UDFWLFHV

and Xing et al. included Bishop's score in their model, despite

LW EHLQJ D VXE MHFWLYH YDULDEOHRULWQWPHRSUHWBPHZD V3KLJK&L3KWH&

their study also 0HW] HUsedit@ value as the main

DGGHG IRU DQRWKHU IRXU YDULDEO&RQIOLFWRUVQWHUHVW

BMI, primary cesarean delivery because of nonrecurrence

LQGFLFDWLRQ PDWHUQDO DJH \HDUVWR JHW WKH ILQDO 9%\$ & VFRUH

, Q WKH SUHVHQW VWXG\ LW KDV DQ DGMVXVHG RGGV UDWLR RI DQG

KDV D YHU\ VWURQJ DVVRFLDWLRQ ZLWK VXXFHVVIXO 9%\$ & S

6SRQWDQHRXV RQVHW RI ODERXU DQG &HYDUDQ&KLOGEUWK1HU&RQVHOVXV

variables that may be incorporated in the present model and

a further study can be planned. There are insufficient studies

about VBAC prediction models and most studied only individual

variables. Other variables studied in other prediction models are

insurance, and race. There is a need for the development of

a standard prediction model and further studies of this model

and many more such models with different permutations and

combinations of various variables are required to help predict

WKH VXFFFVV RI 72/\$ & ZLWK KLJK DFF

6WXG / LPLWDWLRQ V

7KH VPDOO VDP SOH VLJH LV WKH OLPURWLDQH

The study was approved by the institutional ethics committee

and was performed in accordance with the ethical standards

described in an appropriate version of the 1975 Declaration

RI + HOVLQNL DV UHYLVHG LQ 7KHUH LV QREQLQHFWRULQHVW

among the authors and this study was not funded by any

RUDQL DWLRQ

Conclusion

The present study tests a new VBAC prediction model and

shows that it is a good tool for predicting VBAC and hence can

be used to counsel women regarding the mode of delivery in

the Chinese population.

of labour, admission Bishop's score, gestational age, and BMI

were the factors with a statistically significant association with

the comparison of two different types of scoring systems, each

system with different variables in a given population/ 8 6

thickness antenatally in women with a previous caesarean delivery could be used to predict the occurrence of a uterine

VBAC . Further prospective observational studies are needed

XVLQJ D VWDQGDUG PHWKRG RI LQWUDSDUWXP/86 WKLFNQHVW PHDVXUHPHQW WR SUHGLFW WKH RXWERPH RI 72/\$ & DQG ULVN RI

uterine rupture.

3HHU UHYLHZ Externally peer-reviewed.

\$XWKRUVKLS & RQWULEXWL RQV

6XUJLFDQ DQG 0HGLFDO 3UDFWLFHV

and Xing et al. included Bishop's score in their model, despite

LW EHLQJ D VXE MHFWLYH YDULDEOHRULWQWPHRSUHWBPHZD V3KLJK&L3KWH&

their study also 0HW] HUsedit@ value as the main

DGGHG IRU DQRWKHU IRXU YDULDEO&RQIOLFWRUVQWHUHVW

BMI, primary cesarean delivery because of nonrecurrence

LQGFLFDWLRQ PDWHUQDO DJH \HDUVWR JHW WKH ILQDO 9%\$ & VFRUH

, Q WKH SUHVHQW VWXG\ LW KDV DQ DGMVXVHG RGGV UDWLR RI DQG

KDV D YHU\ VWURQJ DVVRFLDWLRQ ZLWK VXXFHVVIXO 9%\$ & S

6SRQWDQHRXV RQVHW RI ODERXU DQG &HYDUDQ&KLOGEUWK1HU&RQVHOVXV

variables that may be incorporated in the present model and

a further study can be planned. There are insufficient studies

about VBAC prediction models and most studied only individual

variables. Other variables studied in other prediction models are

insurance, and race. There is a need for the development of

a standard prediction model and further studies of this model

and many more such models with different permutations and

combinations of various variables are required to help predict

WKH VXFFFVV RI 72/\$ & ZLWK KLJK DFF

6WXG / LPLWDWLRQ V

7KH VPDOO VDP SOH VLJH LV WKH OLPURWLDQH

The study was approved by the institutional ethics committee

and was performed in accordance with the ethical standards

described in an appropriate version of the 1975 Declaration

RI + HOVLQNL DV UHYLVHG LQ 7KHUH LV QREQLQHFWRULQHVW

among the authors and this study was not funded by any

RUDQL DWLRQ

Conclusion

The present study tests a new VBAC prediction model and

shows that it is a good tool for predicting VBAC and hence can

be used to counsel women regarding the mode of delivery in

the Chinese population.

of labour, admission Bishop's score, gestational age, and BMI

were the factors with a statistically significant association with

the comparison of two different types of scoring systems, each

system with different variables in a given population/ 8 6

thickness antenatally in women with a previous caesarean delivery could be used to predict the occurrence of a uterine

VBAC . Further prospective observational studies are needed

XVLQJ D VWDQGDUG PHWKRG RI LQWUDSDUWXP/86 WKLFNQHVW PHDVXUHPHQW WR SUHGLFW WKH RXWERPH RI 72/\$ & DQG ULVN RI

uterine rupture.

3HHU UHYLHZ Externally peer-reviewed.

\$XWKRUVKLS & RQWULEXWL RQV

6XUJLFDQ DQG 0HGLFDO 3UDFWLFHV

and Xing et al. included Bishop's score in their model, despite

LW EHLQJ D VXE MHFWLYH YDULDEOHRULWQWPHRSUHWBPHZD V3KLJK&L3KWH&

their study also 0HW] HUsedit@ value as the main

DGGHG IRU DQRWKHU IRXU YDULDEO&RQIOLFWRUVQWHUHVW

BMI, primary cesarean delivery because of nonrecurrence

LQGFLFDWLRQ PDWHUQDO DJH \HDUVWR JHW WKH ILQDO 9%\$ & VFRUH

, Q WKH SUHVHQW VWXG\ LW KDV DQ DGMVXVHG RGGV UDWLR RI DQG

KDV D YHU\ VWURQJ DVVRFLDWLRQ ZLWK VXXFHVVIXO 9%\$ & S

6SRQWDQHRXV RQVHW RI ODERXU DQG &HYDUDQ&KLOGEUWK1HU&RQVHOVXV

variables that may be incorporated in the present model and

a further study can be planned. There are insufficient studies

about VBAC prediction models and most studied only individual

variables. Other variables studied in other prediction models are

insurance, and race. There is a need for the development of

a standard prediction model and further studies of this model

and many more such models with different permutations and

combinations of various variables are required to help predict

WKH VXFFFVV RI 72/\$ & ZLWK KLJK DFF

6WXG / LPLWDWLRQ V

7KH VPDOO VDP SOH VLJH LV WKH OLPURWLDQH

The study was approved by the institutional ethics committee

and was performed

11. Royal College of Obstetricians and Gynaecologists. Birth After ;LQJ <3 4L ;< :DQJ ;= <DQJ)= 'HYHORS
 3UHYLRXV & DHVDUHDQ %LUWK *UHHQ W **Score System to predict risk of uterine rupture after cesarean birth after RCOG; 2015.**
 3DWHO 50 . DQVDUD 90 3DWHO 6. \$QDQB^N11 , PISHDFWP RI, &/\\$08PHHU % & GH *UDDI
 scoring on cesarean section rate in previous one lower segment (6RQRJUDSKLF PHDVXUHPHQW RI ORZHU
 cesarean section patient. Int J Reprod Contracept Obstet Gynecol to predict uterine rupture during a trial of labor in women with
 2016;5:3820-3. previous cesarean section: a meta-analysis. Ultrasound Obstet Gynecol 2015;42:R32-9. IRU VXFFHVIVXO
 'RVKL +8 -DLQ 5. 9DJLUDQL \$ 3URJQRVObstet Gynecol 2015;42:R32-9. IRU VXFFHVIVXO
 vaginal birth after cesarean section- Analysis of 162 cases. J Obstet Gynecol India 2010;60:498-502.
 %ULOO < :LQGULP 5 9DJLQDO ELUWK DIWHU FHVDUHDQ VHFWLRQ UHYLHZ RI
 antenatal predictors of success. J Obstet Gynaecol Can 2003;25:275-
 86.

Impact of the expanded examination of fetal heart to the prenatal diagnosis of congenital heart diseases

* HQLÜOHWLOPLÜ IHWDO NDUGL\DN GH
KDVWDÖXNODU×Q×Q SUHQDWDO WDQ×

© 3HOLQ 1. © üJHHQUL K 9HÖLGS D XDRHÖ X³HDV NLQPHW !x© VWDQXWHQ 8oDU

1(VNLÜHKLU 2VPDQJD]L 8QLYHUVLW\)DFXOW\ RI 0HGLFLQH 'HSDUWPHQW RI 3HGLDW

2(VNLÜHKLU 2VPDQJD]L 8QLYHUVLW\)DFXOW\ RI 0HGLFLQH 'HSDUWPHQW RI 2EVWHW

3(VNLÜHKLU 6WDWH +RVSLWDO &OLQLF RI 3HGLDWULF &DUGLRORJ\ (VNLÜHKLU 7XU

\$EVWUDFW

2EMHFWL YH In the present study, for which reasons fetal cardiac evaluation was requested from our pediatric cardiology clinic, the effects of FDUGLDF HYDOXDWLRLQ LQ REVWHWULF XOWUDVRQRJUDSK\ 86* RQ WKH GHWHFWLRQ RI &+ DFFRUGLQJ WR SUHJQDQF\ ULVN SURILOHV ZHUH UHWURVSHFWLYHO\ DQDO\]HG 0DWHULDODV DQG 0HWKRGV Fetal echocardiography reports which containing the nineteen-month period were retrospectively examined. IHWDO HFKRFDUGLRJUDSK\ IRU DOO SUHJQDQW ZRPHQ ZKR ZHUH UHIHUHG WR SHGLDW FDWHJRUL]HG LQWR WZR JURXSV EDVHG RQ WKH ULVN RI &+ /RZ ULVN DQG KLJK ULVN as complex, moderate, and mild according to perinatal mortality risk.

Results: 2I WKH SUHJQDQFLHV ZHUH WZLQ DQG IHWDO FDUGLDF HYDOXDWLRLQ ZDV SH ULVN JURXS DQG SUHJQDQFLHV LQ WKH ORZ ULVN JURXS 7KH PRVW FRPPRQ ULVXDO]H WKH IHWDO KHDUW ZKLOH VVSHFWHG IHWDO FDUGLDF DEQRUPDOLW\ FDUGLDF DEQRUPDOLWLHV ZDV DPRQJ KLJK ULVN SUHJQDQFLHV DQG DPR ZDV VLPSOH FDUGLDF DEQRUPDOLWLHV IROORZHG E\ FRPSOH[OHVLRQV 7KH PR RI FDVHV ZKLOH WKH PRVW FRPPRQ FRPSOH[FDUGLDF DEQRUPDOLW\ ZDV SXOF obstetricians and pediatric cardiologist in terms of the diagnosis of the congenital cardiac malformations.

&RQFOXVLRQ 5RXWLQH HYDOXDWLRLQ RI WKH IHWDO KHDUW E\ PHDQV RI REVWHWULF 86 for diagnosing congenital cardiac malformations to a large extent during the intrauterine period.

.H\ZRGV Congenital heart disease, fetal echocardiography, high risk pregnancy, low risk pregnancy, prenatal diagnosis

Öz

\$PDo %X oDOxüPDGD SHGLDWULN NDUGL\RORML NOLQLýLPL]GHQ IHWDO NDUGL\DN GHÿH UXWLQ IHWDO NDUGL\DN GHÿHUOHQGLUPHQLQ NRQMHQLWDO NDOS KDVWDÖXNODU×Q×Q JHEHOLN ULVN SURILOLQH J|UH GDÿxOxPx UHWURVSHNWLI RODUDN LQFHOOHQPLÜWLU *HUHo YH <|QWHPOHU 2Q GRNX] D\OxN G\QHPH DLW IHWDO HNRNDUGL\RJUDIL UDSRUOD\UxQWxOx REVWHWULN 86* WDUDPDVx VRQUDVxQGD SHGLDWULN NDUGL\RORML NOLQLý J|UH G•ü•N YH \•NVHN ULVNOL RODUDN LNL JUXED D\UxOGx 7HVSLL HGLOHQ NRQMHQLW KDILI GHUHFH ROPDN •]HUUH VxQxIODQGxUxOGx %XOJXODU 7RSODP JHEHQLQ WDQHVL LNL] JHEHOLN ROXS EHEHÿH IHWDO NDULVN JUXEXQGD LVH JHEHOLN PHYFXWWX)HWDO HNRNDUGL\RJUDIL GHÿHUOH ROXS IHWDO NDUGL\DN DQRUPDOOLN ü•SKHVL LNLQFL HQ VxN QHGHQGL G•ü•N ULVNOL JHEHOHUGH LGL (Q \•NVHN RUDQGD VDSWDQDQ PDOIRUPDV\RQ WLS LNLQFL VxUDGD\Gx (Q VxN VDSWDQDQ NDUGL\DN DQRPDOL YHQWULN•OHU VHSWD

PRECIS: 7KH H[SDQGHG H[DPLQDWLRQ RI WKH IHWDO KHDUW E\ PHDQV RI REVWHWULF

\$GGUHVV IRU &RUUHVSQGHQE@ <PDJ&HBD\$&QWH3ULLI

(VNLÜHKLU 2VPDQJD]L 8QLYHUVLW\)DFXOW\ RI 0HGLFLQH 'HSDUWPHQW RI 3HGLDWULF &DUGLRORJ\ (VNLÜHKLU

Phone: +90 222 239 29 79 (PDLO pelinkosger@gmail.com 25 & , , orcid.org/0000-0002-3926-9002

5HFHLYHG *HOLÜ 7DULKL 24.03.2020 \$FFHSWHG .DEXO 7DULKL 27.06.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

S X O P R Q H U D W U H] L \ G L . . + . Q L Q W D Q x Q P D V x D o x V x Q G D Q R E V W H W U L V \ H Q Y H S H G L D V
 6 R Q X o) H W D O N D O E L Q G J U W E R ü O X N Y H Q W U L N • O O H U L Q o x N x P \ R O O D U x Y H o o G D P D U
 N R Q M H Q L W D O N D U G L \ D N P D O I R U P D V \ R Q O D U x Q L Q W U D X W H U L Q G | Q H P G H E • \ o N R U D Q G D W
 \$ Q D K W D U . H O L P H O H U . R Q M H Q L W D O N D O S K D V W D O x N O D U x I H W D O H N R N D U G L \ R J U D I L \ o

Introduction

& R Q J H Q L W D O K H D U W G L V H D V H & + . L V W K H P R Y W F R P P R Q
 congenital abnormality, and it is six times more common than chromosomal abnormalities and four times more common than neural tube defect 7 K H L Q F L G H Q F H R I & + . L V
 F D V H V S H U O L Y H E L U W K V I R U I X O O W H U P E L U W K V D Q G
 W K L V U D W H L V D S S U R [L P D W H O \ W L P H V P R U H T R O S U H W H U P
 births \$ S S U R [L P D W H O \ R I & + . V L Q F O X G H F U L W L F D O
 malformations, which must be intervened directly after birth 8 Q I R U W X Q D W H O \ R I W K H V H
 E L U W K D Q G R U M X V W E H I R U H E L U W K 8 6 * U H S R U W V R I H D F K F D V H Z H U H U H W
 malformations are diagnosed after the infant is discharged from the hospital, and the mortality risk increases because of the delay. The identification of severe cardiac abnormalities during the intrauterine period enables the use of approaches that lead to significant decreases in perinatal morbidity and mortality, such as performing the delivery at a center where cardiac surgery can be performed, providing the required medical support in the newborn intensive care unit until transfer to the relevant center, and/or if needed, promptly performing transcatheter palliative interventions. Therefore, fetal cardiac evaluation has become an echocardiography evaluation requests have increased due to

22nd weeks of pregnancy in the Department of Perinatology at our university. In this scan, four chambers of the heart, three vessel and trachea, left and right ventricular outflows, and the patients were referred to the Department of Pediatric Cardiology unit form perinatology division of our university hospital either suspected cardiac abnormalities, accompanying diseases that increase risk of fetal cardiac malformations, parental congenital heart malformation or suboptimal evaluation during routine anomaly scan. To identify all reasons for fetal echocardiography requests, detailed obstetric data of pregnant women were retrieved. Comorbid medical use, and characteristics of previous pregnancies were recorded. Pre-gestational and gestational medical data of pregnant women were retrieved. Comorbid medical and/or if needed, promptly performing transcatheter palliative interventions. Therefore, fetal cardiac evaluation has become an echocardiography evaluation requests have increased due to

The current approach in many clinics in Turkey involves ventriculoatrial shunts, great vessels outflow tracts, ductal and performing fetal cardiac evaluations within defined indications. Aortic arches, and rhythm were evaluated. If all views could owing to long examination times and inadequate number of not be clearly evaluated or if a suspicious finding is detected pediatric cardiologists and cardiovascular surgery experts. On the first evaluation, repeated evaluations may be required. hospital is a tertiary center and includes the only perinatology clinic that provides services to recorded. Fetal echocardiographic evaluation was scheduled large region, which consists of our city and neighboring according to the gestational week of the pregnancy, the referral cities. In the present study, for which reasons fetal cardiac diagnosis of the fetus, and the availability of our out-patient evaluation was requested from our pediatric cardiology clinic. Each case was informed about applying for postnatal W K H H I I H F W V R I U R X W L Q H I H W D O F D a d d i a d a f u a t i o n E v e n x f D o p t h R o g y l w a s r e f e r e d i n t h e f e l a F 8 R Q W K H G H W H F W L R Q R I & + ' V D Q G W e k a h u a G o l V o n t b l e P r o d a l o R p e r f o r m i n g a s w i a h D a v u l b i d r s Q H G L D J Q R V L V R I & + ' V D F F R U G L Q J W R a s u d a l a d y D a p o s s i b l e l p o s t n a t a l B h o l c a d d i b y o g h y l e v a l u a t i o n s U H W U R V S H F W L Y H O \ D Q D O \] H G

Materials and Methods

In this retrospective study, the total number of anomaly examined. Prenatal and postnatal echocardiography data of V F D Q V L Q W K H S H U L Q D W R O R J \ X Q L 261 G a x e s , f o r w h i c h p o s t n a t a l d a t a c o u l d b e r e t r e a v e d D e t e c t e d congenital cardiac structural malformations were All patients in the study underwent routine fetal anatomic classified as complex, moderate, and mild according to perinatal V F D Q Q L Q J D F F R U G L Q J W R W K H , Q W H P U R Q D M D L O R Q M D C U L M D M D C P R Q D M D D R X Q Q in Obstetrics and Gynecology guidelines between the 18 in this classification, and malformations with low mortality risk

7 D E O Classification of prenatally diagnosed congenital heart defects	
Complex; atresia or severe hypoplasia of valve or chamber	+ H W H U R W D [\ R U D W U L D O ventricle, hypoplastic left heart, pulmonary atresia, tricuspid atresia, aortic atresia, mitral atresia, and Ebstein's anomaly, complete atrioventricular septal defect, truncus arteriosus, congenitally corrected transposition of the great arteries, double outlet left or right ventricle
Moderate; congenital heart disease requiring operation or intervention, but not included in the complex group	Transposition of the great vessels, tetralogy of Fallot, coarctation of the aorta, aortopulmonary window, critical aortic or pulmonary stenosis, partial atrioventricular septal defect, total anomalous pulmonary venous connection, large ventricular septal defect
Minor; no intervention	6 P D O O Y H Q W U L F X O D U V H septal defect and less severe aortic or pulmonary stenosis
Others	Dysrhythmias, cardiomyopathies, secondary dextrocardia/levocardia and restrictive ductus

were evaluated in the others category. This study was approved by the
E\ WKH (VNLÜHKLU 2VPDQJD]L 8QLYH^{at}
Committee.

Results

echocardiography examination was performed was 26.4 ± 4.4 weeks. Of the 736 pregnancies, 22 were twin pregnancies, and fetal cardiac evaluation was performed in 758 fetuses. Twelve patients underwent examination for a second time. In total,

37.9% of the examinations were performed before the 20 week of pregnancy, while 62.1% were performed after the 20 week of pregnancy. Number of fetuses with congenital structural anomalies: F D U G L D F P D O I R U P D W L R Q Z D V I H W X V H V Z L W K D U U K \ W K P L D Z D V The reasons for fetal echocardiography requests were classified as follows: D F F R U G L Q J W R & + ' U L V N S U R I L O H W \$ V V R F L D W L R Q U H F R P P H T Q D e p i l a t i o n R Q & + ' D F E R U G L Q J W R U L V N I D F W R U V

pregnancies in the low-risk group. The most common cause for fetal cardiac evaluation request was inability to adequately cardiac malformation was detected as the most frequent among pregnant women referred to the pediatric cardiology due to echocardiography and classified according to mortality risk according to pregnancy risk groups was presented in Table 3. Number of fetuses detected with cardiac abnormalities was low-risk pregnancies. The prevalence of cardiac abnormalities The most common type of malformation was simple cardiac ventricular septal defect. The most common fetal arrhythmia was ventricular septal defect. The most common complex cardiac abnormality was pulmonary atresia with suspected fetal cardiac arrhythmia, two had complete atrioventricular block, two fetuses had blocked premature atrial contractions, and two fetuses had supraventricular tachycardia. The other nine fetuses had premature atrial and ventricular contractions, which recovered during the late weeks of pregnancies.

records could be referred to echocardiography examinations performed at birth, autopsy reports determined whether sibling D had a similar presentation as his brother or sister up until his passing. D V 21 W K H L Q I D Q W V She then had a follow-up test, the results were compared, there were 24 test. G L V F R U G D Q W G L D J Q R V H V 2 Q H P D

Results for which fetal echocardiography was requested because of the presence of a sibling with heart disease and which did not have fetal cardiac abnormalities, total anomalous pulmonary

Discussion

7 D E OTThe distribution of the fetal echocardiography request reasons and the congenital cardiac malformation rates according to pregnancy risk profile*

, Q G L F D W L R Q V Z L W K K L J K H U U L V N S U R I L O H

7 R W D O Q & + ' Q

Gestational diabetes

Pregestational diabetes

Collagen tissue disease maternal D X W R D Q W L E R G L H V

& + ' L Q W K H I L U V W G H J U H H U H O D W L Y H V R I W K H I H W X V P R W K H U I D W K H U V L E O L Q J

Fetal cardiac abnormality suspected on obstetrical ultrasound

Fetal extracardiac abnormality suspected on obstetrical ultrasound

Fetal tachycardia or bradycardia, or frequent or persistent irregular heart rhythm

) H W D O L Q F U H D V H G 1 7 ! • P P

Monochorionic twinning

Fetal hydrops or effusions

Polyhydramnios

7 R W D O

, Q G L F D W L R Q V Z L W K O R Z H U U L V N S U R I L O H

0 D W H U Q D O P H G L F D W L R Q V D Q W L F R Q Y X O V D Q W V 1 6 \$, ' 6 L Q I L U V W V H F R Q G W U L P H V V

Fetal abnormality of the umbilical cord or placenta

Abnormal first or second trimester screening tests

Oligohydramnios

/ D W H P D W H U Q D O D J H

6 X E R S W L P D O H Y D O X D W L R Q

7 R W D O

& + ' & R Q J H Q L W D O K H D U W G L V H D V H 1 6 \$, ' 6 1 R Q V W H U R L G D O D Q W L L Q I O D P P D W R U \ G U X J 1 7 1 X F K D O W U D Q

in all pregnant women. Thus, basic fetal cardiac evaluation has echocardiography request, inadequate evaluation of the fetal E H F R P H D S D U W R I W K H 8 6 * L Q U R X W K Q I B U R M E V Z M D H W W W I K I H P I R R Q V L W W R F U R L P Q P J R Q + U V H D V F can be detected during the intrauterine period at a rate of 4.5%-1 D P L O \ K L V W R U \ R I & + ' D Q B O P O D L W W H K W Q D 8.1% with the evaluation of the fetal heart in four chamber view which were reported to be the top two most common reasons and at 43.8%-85.5% with the additional examination of the right for fetal echocardiography requests in the previous studies, and left ventricular outflow tracts. Therefore, the prevalence of were 3.4% and 7.8%, respectively in the present study.

L Q W U D X W H U L Q H G L D J Q R V L V R I & + ' Y I n D t b l d p h e s e r D S t u d y , L s i G i l a Q t d C M a R e t W M k t e c S d t R M a t R F R O performed by the centers for fetal cardiac evaluation In abnormal cardiac finding during obstetric follow-up was more the present study consisting of an eighteen-month period, fetal F R P P R Q W K D Q I D P L O \ K L V W R U \ R I & + ' D congenital cardiac malformation prevalence was 13.7%. Fetal the reasons for fetal echocardiography requests. Compatibility congenital cardiac malformation prevalence was reported to be between the findings of the pediatric cardiologist and the 5.6% from another tertiary center in Turkey At our center, obstetrician in the cases referred to fetal echocardiography evaluation of the fetal heart in four chamber view is a routine part Z L W K V X V S H F W H G & + ' E \ W K H R E V W H W R I W K H R E V W H W U L F 8 6 * 0 R U H R Y H U the H e x p e n d e d G t h e H t m o r I r f t D e b C r i e D S t u d y Y D e C r a t e D o t W L P including right and left ventricular outflow tracts and three consistency was 40.1% between obstetricians and pediatric vessels and trachea view is routinely performed in each pregnancy cardiologist in terms of the diagnosis of the congenital cardiac woman by skilled perinatologists between the 18th and 22nd weeks P D O I R U P D W L R reported G l u t a n t i a malformation of pregnancy. Furthermore, since the fetal echocardiography was detected during fetal echocardiography in 45 of 275 was performed in selected pregnancies who were identified as S U H J Q D Q W Z R P H Q U H I H U U H G Z L W I risky in antenatal screening in our tertiary reference center, the Meyer-Wittkopf et al. demonstrated that cardiac abnormality reported prevalence may be higher than expected. Z D V G H W H F W H G L Q R X W R I

In the present study, while suspected fetal cardiac abnormality referred to fetal echocardiography with suspected fetal cardiac Z D V W K H V H F R Q G P R V W F R P P R Q abnormality and the diagnosis was fully compatible in 62% of

7 DE OH Intrauterine detected congenital heart diseases and distribution according to pregnancy risk groups*

Results of fetal echocardiography	+ L JK	UL VNZ	UL VNR	WD Q
HFKRF DUGL RJUD	\$UKR XS	QUR XS	Q	
& RPSOH[
3\$ ZLWK , 96 96'	\$ 96'	0		
6LQJOH YHQWULFXOH		0		
+ / + 6	6	0		
DORV	3	1		
Ebstein's anomaly	2	0		
Idiopathic diffuse calcification	1	0		
6KRQH FRPSOH[2		0		
/HW DWULDO LV2RPHULVOP				
\$ 96'	2	0		
7RWDO	29	1		
0RGHUH				
TOF	7	2		
CoA	5	1		
d-TGA	4	0		
7RWDO	16	3		
6LPSOH				
96'	14	4		
Possible CoA	4	3		
36	0	3		
\$ 6	8	2		
\$ 6'	2	3		
7RWDO	28	15		
Other				
Tricuspid regurgitation	1	0		
/39 & 6	3	0		
Intracardiac Mass	2	0		
Double aortic arch	1	0		
Dextrocardia	1	0		
Dysrhythmias	14	1		
7RWDO	22	1		
& R\$ & RDUFWDWLQ RI DRUWD \$6 \$RUW VWHQRVLV YHQWULFXODU VHSWDO GHIFW '259 'RXEOH RXWQHULQK WYHQWULFOH OHW KHDUW VQGURPH ,96 ,QWDFW YHQWULFXODU VHSWXP 39 & 6 /HW SHQVLPWDQW YHQD FDYD VXSHULRU 3\$ 3XOPRQDU DWUHVLD 36 3XOPRQD F R PWRQVLV 7*\$ U7H DQVRQ/LWR RQ W HJT XHW WLQ J YHVVHOV 72) 7HWUDORJ RI)DOORW 96' 9HQWULFXODU VHSWDO GHIFW 'TR24YHJU1AWDO FDUGLDF PDOIRUPDWL				

*The prevalence of cardiac abnormalities in each category was higher in high-risk patients.

these patients. Obstetricians' increasing experience in evaluating

the intrauterine period.

When pregnant women that underwent fetal echocardiography were classified according to risk levels in terms of fetal car-

7DE OH Comparison of pregnancy risk groups in terms of fetal echocardiography results

)HWDO FDUGLDF ULVN /JURUXISVN	JURX
DQRPDO\ Q	
& RPSOH[
0RGHUH	
6LPSOH	
Other	

*chi-square test

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

malformation; 46.3% were in the high-risk group, and 53.6% was detected most commonly in the high-risk group with a rate of 23.5%. In the low-risk group, determination of congenital heart abnormality rate was 5%, and it was significantly higher among high-risk pregnancies. This was associated with the detection of cardiac malformation in 40.1% of pregnancies referred to fetal echocardiography due to suspected fetal cardiac

intrauterine period as well. In the present study, consistent with the literature, the most common cardiac malformation in cardiac malformations were reported to be the most common J U R X S R I & + ' R Z H Y H U Z H I R X Q G F R P P R Q F R P S O H [& + ' Z D V 3 \$ 6 L Q F H W K H S U H J Q D Q F L H V G L D J Q R V H G Z L W K F R P S O H [W \ S H F R Q J H Q L W D O cardiac malformations were referred to the surgical center during the prenatal or postnatal period, and the others. diagnosed as moderate type lesions gave birth in our hospital, postnatal results of all of these pregnancies were retrieved. echocardiography results could be retrieved, were diagnosed with fetal cardiac abnormality by an obstetrician or pediatric cardiologist. The incompatibility between prenatal and postnatal echocardiography in these 261 cases were mostly due to simple lesions. It was found that the diagnoses did not change in complex lesions which were detected by a pediatric cardiologist, but one case with a normal fetal echocardiography was diagnosed with total anomalous pulmonary venous return abnormality during the postnatal period. Pulmonary venous fetal echocardiography, and are frequently diagnosed after birth. Meyer-Wittkopf et al. also reported that a total anomalous pulmonary venous return abnormality diagnosed in the postnatal period could not be detected in the fetal echocardiography.

6 W X G \ / L P L W D W L R Q V

Although each evaluated pregnant woman was informed about the importance of postnatal echocardiography, a significant amount of postnatal echocardiographic evaluation, in which a statistical analysis for sensitivity and specificity could not be performed in order to make a confirmation or comparison.

Conclusion

, Q P D Q \ F H Q W H U V U H J D U G O H V V R I & + perform fetal echocardiography by a pediatric cardiologist to all pregnant women. Therefore, routine evaluation of the fetal heart E \ P H D Q V R I R E V W H W U L F 8 6 * L Q F O X tracts' and three vessel views, would allow for diagnosing congenital cardiac malformations to a large extent during the intrauterine period.

diseases in high and low risk pregnancies. Anadolu Kardiol Derg 2011;11:125-30.

) U L H G E H U J O . 6 L O Y H U P D Q 1+ & K D Q J L Q 6 J K D Q P D F 6 D W D R Q V I T D U X U H W D D Z D U 1 & 5 R O H echocardiography in a University Center population. Prenat Diagn 2004;24:781-6.

& K D 6 . L P *% . Z R Q % 6 % D H (- 1 R K &, , trends in indications of fetal echocardiography and postnatal outcomes in fetuses diagnosed as congenital heart disease. Korean Circ J 2012;42:839-44.

6 L P S V R Q // , Q G L F D W L R Q V I R U I H W D O H F K R F D U G L R Q U B S K G H R P D V W H U W L D U \ & K D U D I H G G L Q H) + D F K H P \$. L E E L 1 \$ E X care obstetric sonography practice. J Clin Ultrasound 2004;32:123-8.

0 H \ H U : L W W N R S I 0 & R R S H U 6 6 K R O O H U G L D J Q R R M U L H O B W E R Q J H Q W W D Q K H D U W G L V H fetal cardiac diagnosis by obstetric and pediatric cardiologist F K D O O H Q G H V - 6 D X G L + H D U W \$ V V R F sonographers and comparison with postnatal findings. Ultrasound Obstet Gynecol 2001;17:392-7.

AT, et al. Prenatal detection of congenital heart diseases: One-year survey performing a screening protocol in a single reference center Z, et al. The first fetal echocardiography experience for prenatal

• < D V L Q ' X O U \$ O S H U . D U 6 D Q R I P \$ \ ü H ' X D X 1 X I U M M W O N D Q O % R P B Q h Q V D O
• * | N K D Q % R \ U D]

8 Q L Y H U V L W \ R I + H D O W K 6 F L H Q F H V 7 X U N H \ (W O L N =• E H \ G H + D Q x P : R P H Q . V + H D O W K
Turkey

PRECIS: Transdiaphragmatic thoracotomy, colon resection, ileostomy and development of any extra-pulmonary complication were identified as independent predictors of pulmonary morbidity.

\$ G G U H V V I R U & R U U H V S R Q G H Q F H < D] x ü P D \$ G U H V L < D V L Q ' X U P X ü 0 '

8 Q L Y H U V L W \ R I + H D O W K 6 F L H Q F H V 7 X U N H \ (W O L N =• E H \ G H + D Q x P : R P H Q . V + H D O W K 7 U D L Q L Q J D Q G 5 H V H D U F K + R

Phone: +90 312 567 40 00 (PDLO dr_yasindurmus@hotmail.com 25 & , ' , ' orcid.org/0000-0002-5404-0118

5 H F H L Y H G * H O L ü 7 D U L K L 05.05.2020 \$ F F H S W H G . D E X O 7 D U L K L 18.07.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

6RQXo 7UDQVGL\DIUDP WRUDNRWRPL GL\DIUDP FHUUDKLVL JHoLUHQ KDVWDODUGD SXO
WUDVGL\DIUDP WRUDNRWRPLOHUGHQ NDoxQPDN YH WDP NDW GL\DIUDP UH]HNVL\RQODU
SXOPRQHU PRUELGLWH RUDQxQxQ D]DOWxOPDVxQD YH SRVWRSHUDWL EDNxP PDVUDIOD
\$QDKWDU .HOLPHOHU 'L\DIUDJP FHUUDKL VLWRUHG•NWLI RYHU NDQVHUL PRUELGLWH

Introduction

of initial treatment for advanced epithelial ovarian cancer¹. It is estimated that nearly 40% of patients with advanced ovarian cancer have gross disease located on the diaphragm.² Patients with advanced ovarian cancer and diaphragm involvement who had undergone diaphragm surgery had better survival rates than those who had not.³ Thus, a significant proportion of patients with advanced ovarian cancers require diaphragm surgery to achieve optimal cytoreduction and therefore better survival rates. Complete cytoreduction is also associated with improved overall survival in advanced uterine corpus cancers⁴ and patients with metastatic diaphragm disease require diaphragm surgery .⁵

Previous studies reported that diaphragm surgery was associated with pulmonary morbidity, and they reported higher rates of pleural effusion, higher rates of pneumothorax and longer hospital stay after diaphragm surgery. Furthermore, several studies showed higher rates of pulmonary morbidity after diaphragm full-thickness resections compared with diaphragm peritoneal stripping, but others did not show a significant difference. Previous studies were not able to assess other types of pulmonary morbidity such as pneumonitis and atelectasis due to the small number of cases. Thus, pulmonary morbidity related to diaphragm surgery needs further evaluation with a larger number of cases. We performed the present study to improve knowledge about pulmonary morbidity related to diaphragm surgery, and we also assessed other potential surgical factors that may contribute to pulmonary morbidity.

Materials and Methods

All patients who had undergone diaphragm surgery as a part of cytoreductive surgery procedures performed for advanced or recurrent ovarian and uterine corpus cancers between January 1, 2001 and June 1, 2018 were reviewed retrospectively. Data

, 2007, and June 1, 2013, were reviewed retrospectively. Data were obtained from hospital medical records. Patients who had an ablative intervention to the diaphragm were excluded from the study. We included only cases involving surgical resections of the diaphragm peritoneum with or without diaphragm muscle and overlying parietal pleura. Patients with preoperative pleural effusions and intraoperative chest tube replacements would lead to unreliable evaluation of the postoperative pulmonary complications so they were excluded.

Diaphragm debulking surgery to excise all visible metastatic tumoral deposits on the diaphragm surface was performed. SULPDULO\ E\ H[FLVLRQ RI WKH GLDp
VWULSSLQJ 7KH H[WHQW RI WKH C was classified as "total hemi-diaphragm peritoneal stripping".

"partial hemi-diaphragm peritoneal stripping", or "focal implant resection." Excision of the whole hemi-diaphragm peritoneum starting from the anterior costal margin was identified as "total K H P L G L D S K U D J P S H U L W R Q H D O V W U L S L P S O D Q W V " F P L Q G L D P H W H U Z D V L resection". All the other peritoneal excisions that were not compatible with the above definitions were classified as "partial hemi-diaphragm peritoneal stripping".

starting a right hemi-diaphragm total peritoneal stripping or partial hemi-diaphragm stripping or a focal implant resection procedure depending on the location of the tumor. Tumor involvement on the left hemi-diaphragm is more easily resected. Diaphragm surgery may be complicated by transdiaphragmatic thoracotomy. In our study, we classified the cause of transdiaphragmatic thoracotomy as either "willful partial hemi-diaphragm full-thickness resection" or "accidental transdiaphragmatic thoracotomy". If the surgical report indicated a histologically confirmed tumor implant invading the diaphragm muscle with or without parietal pleura, we identified the cause of the transdiaphragmatic thoracotomy as "willful partial hemi-diaphragm full-thickness resection". If not, we identified the cause as "accidental transdiaphragmatic thoracotomy".

Diaphragm repair was done by continuous suturing of the diaphragm. The anesthetist was performing a forced inspiration with the help of the ventilator and the surgical team was applying a negative pressure to the thorax cavity with the help of a thin aspiration

All patients received preoperative antibiotics and anticoagulant prophylaxis. No prophylactic antibiotics were used. S R V W R S H U D W L Y H O \ (Q R [D S D U L Q H was administered 2 hours before the surgery and then repeated daily for 30 days after the surgery if the body mass index of the child S D W L H Q W Z²DeMoxapar Ne 6000 IU was administered by LI W K H E R G \ P D V V L Q G A H [patients] were N J assessed with a chest radiography on the first postoperative day

Chest radiography was repeated on the following days if any signs were noted or the physical examination. Chest radiography was repeated if there was any change in the patient's condition. "Admission to the postoperative general care room or the

median time from surgery to the first chemotherapy cycle was 7 weeks. The overall survival rate at 1 year was 60%. Three patients died within the 30-day period after surgery, and the mortality rate was 1.3%. One patient died because of aspiration pneumonitis and 2 died as a result of septic complications.

In our study, accidental transdiaphragmatic thoracotomy S Q H X P R W K R U D [S D W L H Q W V G R F F X U U H G L Q S D W L H Q W V : L O S D X W L S Q W W L D O I X G I O Y W Q R B S N H C H D W H O excision of the hemi-diaphragm was performed in 33 patients developed pulmonary embolism. We divided the study

regard to pulmonary morbidity. There was a higher rate of chemotherapy, and rate of postoperative admission to intensive pulmonary complications when the surgical notes reported care for patients with or without pulmonary complications and the presence of transdiaphragmatic thoracotomy. Twenty-one patients developed a pulmonary complication. Thirty-seven patients significantly developed a pulmonary complication. Thirty-seven patients longer hospital stay, longer time interval to chemotherapy,

Z K R G L G Q R W K D Y H D W U D Q V and D i s c l e d D o s t o P u l m o n a r y M e d i c i n e D a t e r w e r e f r e q u e n t l y . developed a pulmonary complication postoperatively. The differences in mean hospital stay and mean time interval G L I I H U H Q F H Z D V V W D W L V W L F D O O \ t v L o c h o n t h e r a p y b e t w e e n t h e g r o u p s w i t h o u t w i t h o u t According to our data, patients who developed pulmonary/transdiaphragmatic thoracotomy were insignificant. But the complications and patients who did not develop pulmonary rate of admission to postoperative intensive care of patients complications showed insignificant difference with regardwith transdiaphragmatic thoracotomy was significantly higher to age. The mean age of patients who developed pulmonary than that of patients without transdiaphragmatic thoracotomy complications was 57.4 ± 7.9 . The mean age of patients who did not develop pulmonary complications was 60.9 ± 9.7 . The

GLIIHUhQFH EHWZHQB WZR JURXSV ZDV LQJ Discussion

Patients who underwent small-bowel resection, colon resection, pelvic peritonectomy, appendectomy, tumor resection from liver Glisson's capsule, tumor resection from the omentum and Morrison's pouch, tumor resection from colon serosa, ileostomy, colostomy concurrently or sequentially, had significantly higher rates of pulmonary complications. The patients with metastatic diaphragm disease require diaphragm mean intraoperative blood loss of the patients who developed surgery. When diaphragm surgery is performed, it may cause pulmonary complications was significantly higher than that of pulmonary complications and additional morbidity. In this patients who did not develop any pulmonary complications study, 25% of patients developed a pulmonary complication.

Patients who did not develop any pulmonary complication, 20.7% of patients developed a pulmonary complication and complication had significantly higher rate of pulmonary 20.7% developed pleural effusions postoperatively; 2.6% FRPSOLF DWLRQV FRPSDUHG ZLWK WKRQH VWDQFH UHODWLRQ. QTRW studies reported pleural Patients who developed an intestinal anastomosis leak haemifusion rates after diaphragm surgery of between 2% and 59%, VLJQLILFDPQWO\ KLJKHU UDWH RI SXORRQDQH DQG DQHOLVWLRQ ERS ODFVFRP 10% BRQ 5%. S

The factors associated with pulmonary morbidity are patients who had undergone diaphragm peritonectomy or transdiaphragmatic pleurectomy. We found that transdiaphragmatic pleurectomy was predictive of postoperative pulmonary complications in a logistic regression model. We found that transdiaphragmatic pleurectomy was predictive of postoperative pulmonary complications in a logistic regression model.

7 D E O H Factors associated with pulmonary morbidity

Factors	'HYHORSPHQW RI SXOPRQDU\ FRP		p
	Yes	No	
Transdiaphragmatic thoracotomy	< HV No		0.004
Unilateral versus bilateral diaphragm stripping	Unilateral Bilateral		0.109
Total versus partial or focal diaphragm stripping	Total Partial/focal		0.069
Transdiaphragmatic thoracotomy	Accidental Partial full-thickness resection		0.089
+ L V W R S D W K R O R J\	Ovarian-tubal-peritoneal invasive epithelial cancer Others		0.518
Primary site	Ovary-tuba-peritoneum Uterine corpus		0.786
Cytoreduction	Primary •		0.422
3 U H R S H U D W L Y H & D	° , 8 P / PHDQ " 6 '	1328.70±1465.32	1151.96±1353.90
Intraoperative ascites	< HV No		0.356
\$ V F L W H V Y R O X P H P / PHDQ " 6 '		2447.62±2127.35	2760.26±2599.02
6 X S U D K H S D W L F G U D L Q	° , H V No		0.422
' X U D W L R Q R I W K H V X S U D K H S D W L F G U D L Q	6.04V	PHDQ 4"6.62.4	0.111
2 S H U D W L R Q W L P H P L Q X W H V PHDQ " 6 '	340.7±76.9	335.6±68.8	0.796
, Q W U D R S H U D W L Y H E O R R G O R V V P / PHDQ 1"132.6±1213.4	672.7±751.5	0.045	
6 P D O O E R Z H O U H V H F W L R Q	° , H V No		0.002
Colon resection	< HV No		
Pelvic peritonectomy	< HV No		0.001
Appendectomy	< HV No		0.018
Tumor resection from liver Glisson's capsule	< HV No		0.038
Tumor resection from omentum minus	< HV No		0.039

7 DE OH FR QWLQ XHG

Tumor resection from Morrison's pouch	< H V No	0.015
Tumor resection from colon serosa	< H V No	0.036
Ileostomy	< H V No	
Colostomy	< H V No	
Any extra-pulmonary complication	< H V No	
Intestinal anastomosis leakage	< H V No	0.006

\$OO FRQFXUUHQW VXUJLFDO SURFHGXUHV DQG H[WUD SXOPRQDU\ FRPSOLF DWLRQV ZHUH DQDO\]HG RQO\
 a)2QH ERUGHUOLQH PXFLQRXV WXPRU DQG V\QFKURQL]HG FDQFHUV ZHUH H[FOXGHG IURP WKH DQDO\VLV
 b)LYH V\QFKURQL]HG FDQFHUV ZHUH H[FOXGHG IURP WKH DQDO\VLV
 c)2QO\ RYDULDQ WXEDO SHULWRQHDO HSLWKHOLD O FDQFHUV VXEMHFHWG WR SULPDU\ F\WRUHGXFWRQ VXU

7 DE OH Independent predictors of pulmonary morbidity

, QGHSHQGHQW SUHGLFWRUV RI SXOPRQDU\	P <small>RE</small> G <small>E</small> L <small>U</small> D <small>W</small> R <small>Q</small> I <small>L</small> G <small>H</small> Q <small>F</small> H	pQWHUY
7UDQVGLDSKUDJPDWLF WKRUDFRWRP\	266UIRUP20-692YHUVXV	QRM6SHUIRUPH
& RORQ UHVHFWRQ SHUIRUPHG YHUVXV 5/21QRW S.14U1.13UPHG		
, OH RVWRP\ SHUIRUPHG YHUVXV QRW S.1011RUPH.24-250.0		0.019
\$Q\ H[WUD SXOPRQDU\ FRPSOLF DWLRQ 2.35RVLW 1.13H.88 HUVXV QHQJ23WLYH		

7 DE OH Comparison of pulmonary complications in patients with and without transdiaphragmatic thoracotomy

3XOPRQDU\ FRPSOLF DWLRQ	1R WUDQVGLDSKUDJPDWG EDSKUDJPDWLF WKRUDFRWRP\ JURXRSQ	
Any kind of pulmonary complication	< H V No	0.004
Pleural effusion	< H V No	0.042
Pleural effusion, did not necessitate drainage	< H V No	0.812
Pleural effusion, necessitated drainage	< H V No	0.006
Pneumothorax	< H V No	0.002
Pneumonitis	< H V No	0.01
Atelectasis	< H V No	0.032
Pulmonary embolism	< H V No	!

7 D E O H Mean length of hospital stay, mean time from surgery to chemotherapy, and rate of postoperative intensive care

	/HQJWK RI KRVSLWDQWHUYDO IURP VVXUJH3RVWRSHUDWL YH LQ VWD\ GD\V pPHDQ FKHPRWKHUDS\ pGD\VFDUH XQLW Q p " 6' PHDQ " 6'	Yes	No
--	----------------------------------------------------------------------------------------------------------------------------	-----	----

Pulmonary complication

< H V	17.56±10.95	20.48±11.14	0.023
No	10.61±7.42	16.63±9.56	

Transdiaphragmatic thoracotomy

< H V	13.33±8.85	18.83±10.96	0.344	0.001
No	12.05±8.95	17.17±9.81		

6' 6 WD Q G D U G G H Y L D W L R Q

patients had undergone diaphragm resection or had diaphragm present study is the largest case series evaluating pulmonary SH U I R U D W L R Q (O H Y H Q R I S D W L H Q W V related G d Y i l o R g n H G r y S V l e O v e n A b l e D O effusions. Although 73% of patients who underwent diaphragm show that patients with transdiaphragmatic thoracotomy resection and had perforations developed ipsilateral effusions developed pulmonary morbidity, pleural effusions, pleural statistical analysis did not show a significantly increased rate of effusions necessitating drainage, pneumothorax, pneumonitis, of ipsilateral effusions after diaphragm resection or diaphragm and atelectasis significantly more frequently than patients who perforation. The small number of patients in the study group underwent diaphragm surgery without transdiaphragmatic and relatively high rates of pleural effusion may have led to thoracotomy. In the current study, all the diaphragm surgery the absence of statistical significance in our study, 20.7% procedures and diaphragm repairment procedures were of patients developed pleural effusions postoperatively. The performed by gynecological oncologists and we think that rates of pleural effusion in patients without transdiaphragmatic diaphragm surgery procedures can be managed by experienced thoracotomy and with transdiaphragmatic thoracotomy were gynecological oncologists. A thorax surgeon should attend the 17.8% and 30.8%, respectively. Pleural effusion was more operation when a pulmonary parenchymal resection is planned. frequent among patients with transdiaphragmatic thoracotomy and it was statistically significant.

6 R O H \ P D Q L 0 D M p a r e d 64 cases with diaphragmatic involvement.

peritoneectomy and 36 cases with pleurectomy with regard to Eisenhauer et al. reported that ipsilateral pleural effusion pulmonary morbidity. The rates of pulmonary morbidity in the was not associated with an increased length of hospital stay. peritoneectomy group and the pleurectomy group were 9.3% Benedetti Panici et al. D Q D O \] H G S D W L H Q W V and 19%, respectively, and there was no significant difference ovarian cancer. They performed diaphragm peritonectomy in 25

S 7 K H \ Z H U H D E O H W R V K R Z K L J K H U U D W H V R I S X O P R Q D U \ morbidty after pleurectomy compared with peritonectomy, but patients and diaphragm resections in 43 patients and reported they were unable to show a statistically significant difference that diaphragmatic resection was associated with significantly due to the limited number of cases < H H W M p a r e d 124 O R Q J H U S R V W R S H U D W L Y H K R V S L W D O V V patients with diaphragmatic peritonectomy and 26 cases with S \$ F F R U G L Q J W R R X U G D W D G H Y H full-thickness diaphragmatic resection with regard to pulmonary morbidity was associated with longer hospital stay, longer time interval to chemotherapy, and a higher rate of postoperative morbidity, and they showed that patients who underwent full-thickness diaphragmatic resection developed pleural effusion intensive care. Patients with transdiaphragmatic thoracotomy V L J Q L I L F D Q W O \ P R U H I U H T X H Q W O \ needed postoperative intensive care more frequently than patients and significantly more frequent symptomatic pleural effusion without transdiaphragmatic thoracotomy. Decreasing the rate of U H T X L U L Q J G U D L Q D J H Y Z p a r e d IV transdiaphragmatic thoracotomy among patients undergoing et al. compared 79 patients who underwent diaphragmatic stripping and 33 patients who underwent diaphragmatic resection and showed that patients with diaphragmatic resection Development of an extra-pulmonary complication, concurrent G H Y H O R S H G S O H X U D O H I I X V L R Q V L J colon resections, and ileostomy were also independent predictors Y H U V X V S of pulmonary morbidity. Among patients with concurrent In the current study, we were able to identify transdiaphragmatic colon resections and ileostomy, prolonged intravenous support thoracotomy as an independent predictor of pulmonary and electrolyte imbalance may have contributed to higher rates morbidity after diaphragm surgery. To our knowledge, the of pleural effusions and pulmonary morbidity.

6 W X G \ / L P L W D W L R Q V

The retrospective design of the study and the absence of a patient group with advanced gynecological cancer that did not undergo diaphragm surgery are limitations of the current study. The high number of patients in the study, the competence in evaluating pulmonary complications separately, and identifying independent factors associated with pulmonary morbidity by our knowledge, the present study is the largest case series evaluating pulmonary morbidity related to diaphragm surgery.

Conclusion

In conclusion, diaphragm surgery helps to enhance complete cytoreduction rates and therefore improves survival in advanced epithelial ovarian cancers and uterine corpus cancers.

Transdiaphragmatic thoracotomy is an independent predictor of pulmonary morbidity among patients who undergo diaphragm surgery. Avoiding accidental transdiaphragmatic thoracotomies with maximal attention may help decrease pulmonary morbidity rates and postoperative care costs. Potential benefits of preventing entry into the thorax cavity while performing full-thickness diaphragm resections should further be investigated.

(W K L F V

(W K L F V & R P P L W W H H \$ S S U R Y D O All procedures performed in this study were in accordance with the ethical standards of declaration and its later amendments or comparable ethical standards. Institutional Review Board approval was received for

W K L V V W X G \ D S S U R Y D O G D W H D Q G Q X (

(, Q I R U P H G & R Q V H Q W 6 L J Q H G L Q I R U P H publication of disease related information was obtained from each patient.

3 H H U U H Y L H Z Externally and internally peer-reviewed.

\$ X W K R U V K L S & R Q W U L E X W L R Q V

& R Q F H S W < ' ' H V L J Q < ' ' D W D & R O O H E W L R Q U

< ' 6 \$ ' d \$ Q D O \ V L V R U , Q W H U S U H W D M T R Q < ' \$.

\$. 1 % * % 7 7 : U L W L Q J \$. 1 % 6 R O H A P D Q L T 0 D M G +) H U U D U L) 0 D Q H N 6

& R Q I O L F W R I , Q W H U H V W The authors report no conflict of interest.

) L Q D Q F L D O ' L V F O R V X U H Authors have no financial interests about the research.

References

- % U L V W R Z 5(7 R P D F U X] 5 6 \$ U P V W U R Q J in patients undergoing initial debulking surgery for ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
- & K L ' 6 (L V H Q K D X H U (/ / D Q J - + X K - + D et al. What is the optimal goal of primary cytoreductive surgery

I R U E X O N \ V W D J H , , , & H S L W K H O L D O R Y D U Oncol 2006;103:559-64.

Papadia A, Morotti M. Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature. Arch Gynecol Obstet 2013;287:733-41.

Benedetti Panici P, Di Donato V, Fischetti M, Casorelli A, Perniola G, Musella A, et al. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: analysis and management of complications in upper abdominal surgery. Gynecol Oncol 2015;137:406-11.

\$ O H W W L * ' R Z G \ 6 & 3 R G U D W] . & & O L E \ of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 2006;100:283-7.

\$ O D J N L R] L G L V , * U R V V P D Q \$ 7 D Q J 1 = : H * H W D O 6 X U Y L Y D O L P S D F W R I F \ W R U H G X advanced stage cancer of the uterine corpus: a retrospective cohort

V W X G \ , Q W - 6 X U J W H R Q P D I S X Q Q R (Q D U H \ B R B S Q k F D W b R Q V III and -IV endometrial cancer: a single oncology centre review of 104 cases. J Obstet Gynaecol 2016;36:81-6.

Fanfani F, Fagotti A, Gallotta V, Ercoli A, Pacelli F, Costantini B, et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol 2010;116:497-501.

(L V H Q K D X H U (/ ' . \$ Q J H O L F D 0 , \$ E X 5 X V W X T X H Y H R R , X V L Q J V W D S O H G H Y L F H V WR, Barakat RR, et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced Mullerian cancer. Gynecol Oncol 2006;103:871-7.

' H Y R O G H U . \$ P D Q W) 1 H Y H Q 3 Y D Q * R U I. Role of diaphragmatic surgery in 69 patients with ovarian

cancer. Int J Gynecol Cancer 2008;18:363-8.

& K H U H D X (5 R X] L H U 5 * R X \ 6) H U U R Q * al. Morbidity of diaphragmatic surgery for advanced ovarian cancer.

U H W U R V S H F W L Y H V W X G \ R I F D V H V (X U % D V K L U 6 * H U D U G L 0 \$ * L X Q W R O L 5 / 0 6 X U J L F D O W H F K Q L T X H R I G L D S K U D J P IX

X R E diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer. Gynecol Oncol

2010;119:255-8 = D S D U G L H O , 3 H L U H W W L 0 = D Q D J Q R O R 9

F, et al. Diaphragmatic surgery during primary cytoreduction for

advanced ovarian cancer: peritoneal stripping versus diaphragmatic

resection. Int J Gynecol Cancer 2011;21:1698-703.

< H 6 + H 7 / L D Q J 6 & K H Q ; : X ; < D Q J + surgery and related complications in primary cytoreduction for advanced ovarian, tubal, and peritoneal carcinoma. BMC Cancer

< ' 6 \$ ' d \$ Q D O \ V L V R U , Q W H U S U H W D M T R Q < ' \$. (G L W L Q J & D R I G H H Q resection with pleurectomy during Visceral-Peritoneal Debunking

9 3 L Q F R Q V H F X W L Y H S D W L H Q W V Z L W K a surgical-histological analysis. Gynecol Oncol 2016;140:430-5.

* R X \ 6 & K H U H D X (& X V W R G L R \$ 6 8] D Q & H W D O 6 X U J L F D O S U R F H G X U H V D Q G P R U E

in patients undergoing initial debulking surgery for

' R Z G \ 6 & / R H Z H Q 5 7 \$ O H W W L *) H L W R] of outcomes and morbidity following diaphragmatic peritonectomy

Gynecol Oncol 2008;109:303-7.

Hemorrhagic corpus luteum: Clinical management update

+HPRUDMLN NRUSXV OXWHXP .OLQLN

⑩ 0 \ N K D L O R 9 ⑪ K D G \$ Y Q H V G R E Y R ⑫ S a c a M G u k t l a p a n e ⑬ \$ Q G U H D 7 L Q H O O L

¹Dnipropetrovsk Medical Academy of Health Ministry of Ukraine, Dnipropetrovsk, Ukraine

²Santa Maria Hospital, Gym Care and Research, Clinic of Obstetrics and Gynaecology, Bari, Italy.

³Veris Delli Ponti Hospital, Clinic of Obstetrics and Gynecology, Scorrano, Lecce, Italy

⁴Veris Delli Ponti Hospital, Chief of Clinic of Obstetrics and Gynecology, Scorrano, Lecce, Italy.

\$EVWUDFW

+HPRUUKDJLF FRUSXV OXWHXP +&/ LV DQ RYDULDQ F\vw IRUPHG DIWHU RYXODWLRLQ D
+&/ UXSWXUH KDSSHQV D KHPRSHULWRQHXP UHVXOWV &OLQLFDO V\PSWRPV DUH PDLQC
is extensive and standard management is not defined. The authors elaborated a comparison of the differential diagnosis and therapeutic modalities from
ODSDURVFRSLF DSSURDFK WR QRQVXUJLFDO PHGLFDO RSWLRQV EHFDXVH KHPRUUKDJH
WKH GHYHORSPHQW RI +&/ WU\LQJ WR JLYH KRPRJHQHLW\ WR OLWHUDWXUH GDWD 7KH
LQWR PDQ\ WRSLFV 7KH ZDLW DQG VHH DWWLWXGH DYRLGV XQQHFHVVDU\ ODSDURVFRS
WUDQVIXVLRQV DQG DQWLELRWLF SURSK\OD[LV 6XUJLFDO WKHUDS\ RSHUDWLYH PDQ
ovarian wedge-shaped excision or oophorectomy. Prevention: the possibility to preserve fertility is essential, mainly in patients with bleeding disorders
XQGHUJRLQJ DQWLFRDJXODQW WKHUDS\ WKHUHIRUH WKH\ QHHG HVWUR SURJHVWLQLF
UHYLHZ ZLOO DLG SK\VLFLDQV LQ PDNLQJ DQ HDUO\ GLDJQRVLV RI +&/ WR DYRLG XQQH
. H\ZRUGV Corpus luteum, ovarian cyst, ectopic pregnancy, laparoscopy

Öz

+HPRUDMLN NRUSXV OXWHXP +./ \XPXUWODPDGDQ VRQU D ROXÜDQ YH NRUSXV OXWHJ
NLVWLGLU +./ U•SW•U• PH\GDQD JHOG LÝLQGH KHP RSHULWRQHXP ROXÜXU .OLQLN VHP:
EDöOxGxU \$\xUxFx WDQxVxQGD ELU oRN GXUXP YDUGxU YH WDQxPODQPxü VWDQGDUW
VHoHQHNOHUH o•QN• +./ GHQ ND\QDNODQDQ NDQDPD JHQHOOLNOH NHQGL NHQGLQL VxG
ELU NDUüxODüWxUPDVxQx \DSPDNWDODU <D>DUODU OLWHUDW•U YHULOHULQH KRPRMHD
OLWHUDW•U YHULOHULQL DQDOL] HWWLOHU YH WxEEL \DNODüxPx ELUoRN DOW JUXED D
LQI•]\RQX WUDQVI•]\RQODU YH DQWLEL\RWL N SURILODNVL N XOODQDUDN JHUVNVL] O
\XPXUWDOxüxQ NDPD üHNOLQGHNL HNVL]\RQX YH\DRRIHUVNWRPL üHNOLQGH ROPDOxGx
WHGDYL DODQ KDVWDODUGD |QHPOLGLU EX QHGHQOH \XPXUWODPD\x |QOHPHN YH EDÜM
LKWL\Do YDUGxU %X GHUOHPH KHNLP OHUH +./ QLQ HUNHQ WHÜKLVLQL NR\PDGD JHUVN
\$QDKWDU .HOLPHOHU .RUSXV OXWHXP \XPXUWDOxN NLVWL HNWRSLN JHEHOLN ODSDU

Introduction

Ovulation is a physiologic monthly event and may be rarely associated with hemoperitoneum, leading the patient to shock and subsequent death. It can occur at all stages of a woman's reproductive life. The onset of bleeding is often triggered by exercise, coitus, trauma, or dental procedures. Clinical symptoms are mainly due to the loss of blood. The differential diagnosis includes ectopic pregnancy, ovarian torsion, and endometrioma.

\$GGUHVV IRU &RUUHVSQRQGHQFH <D>xüPD \$GUHVL 0\NKDLOR 9 0HGYHGLHY 0'
'QLSURSHWURYVN 0HGLFDO \$FDGHP\ RI +HDOWK 0LQLVWU\ RI 8NUDLQH 'QLSURSHWURYVN 8NUDLQ
Phone: +380677378117 (PDLO medvedev.mv@gmail.com 25&,' , orcid.org/0000-0002-0443-0572
5HEHI YHG *HOI ü 7DUIKL 19.04.2020 \$FEHWSWHG DEXO 7DUIKL 18.10.2020

diagnosis is extensive and includes ectopic pregnancy, adnexal torsion, ovarian cysts, endometriosis, pelvic inflammatory disease, and other gynecological conditions. The differential diagnosis is broad and can include non-gynecological conditions such as appendicitis, diverticulitis, and other abdominal emergencies. It is important to consider the patient's history, physical examination findings, and laboratory results to make an accurate diagnosis.

A significant correlation between coitus and rupture of the Aggarwal et al. UHSRUWHG D GH[WUR SUHSRQ & / ZDV GHV EUL F HG F VshSwindalzDmattHWR ID O SDWLHQWV

The study of Tang et al reported a right prevalence of 81.25%, and proposed that the right preponderance was the result of a different venous architecture causing higher venous pressure in of spontaneous miscarriage

elaborated a comparison of differential diagnosis and therapeutic modalities from the laparoscopic approach to nonsurgical medical options. According to some authors, the presence of the rectosigmoid colon protects the left ovary from trauma, especially during

, Q W K L V L Q Y H V W L J D W L R Q Z H U H Y L H Z H G D O H S D W D L P S O L F D W H G Z L W K + & sexual intercourse. Pain in the right iliac fossa may mimic acute appendicitis, development, such as age, race, heritage, reproductive factors, sex hormone, obesity, diet, smoking, physical activity, stress, and the same symptoms related to the left quadrant might be talc use, and environmental and other factors. To perform the underestimated in many patients, and this may contribute to clinical research, the authors consulted the following scientific W K H L Q F U H D V H G U L J K W S U H Y D O H Q F H P

GDWDEDVHV 3XE0HG WKH Fulphuetab reported a greater ovulatory activity by the right RYDULQPHFLWKDWLWKH OHIW RYDU\ GXUL LQGH[7KH &KLQD - RXUQDQO\ HXQHQZJHLW'R'DW\DEPDVHG \$ QWLFRDJX &KLQHVH 6FLHQWLILF - RXUQDOV\ XQO\ 7HLW'DWDDEDVH &KLQHVH %LRPHGLFDO /LWHUDWXUH DWDDEDVH DOG WKH :\$1) \$1* GDWDEDVH Patients with bleeding disorders have a greater risk of extensive hemoperitoneum than patients with normal coagulation

The following key terms were used to access the records luteum, corpus luteum rupture, bleeding, cyst, pregnancy, hemorrhagic corpus luteum, corpus luteum rupture. The available; otherwise, literature that was the most relevant to the topic was used at the authors' discretion. Peer-reviewed articles function, and the former often require surgery to stop the bleeding.

Many cases of hemoperitoneum have been reported in patients with von Willebrand disease type 1, 2A, 3 patients with afibrinogenemia, thrombasthenia, patients with hemophilia A, hemophilia B, deficiency of factor X and factor XIII, and in patients receiving anticoagulant therapy for antiphospholipid antibody syndrome.

topic was used at the authors' discretion. Peer-reviewed articles included for the aims of this work. Additional articles were identified from the references of retrieved papers. The aim of this extensive review was to provide information about the clinical and surgical data implicated with the development of ovarian enlargement and hemorrhagic effusion detected, anticoagulant therapy should be stopped. In women with known bleeding disorders or receiving + & / D Q G L W V W U H D W P H Q W P R G D O L W L H V W W N H O U W F E V R U W H G E V U D H O H Y D Q F H Z H U H & / F \ V to literature data.

in the presence of lower quadrant abdominal pain
Complete coagulation screening is essential for the early identification of patients with bleeding disorders; anamnesis, physical examination, laboratory tests, and imaging studies can provide important information.

the granulosa layer is penetrated by blood vessels that fill hormone analogs.

& O L Q L F D O \$ V S H F W V

5 X S W X U H R I &/ P D \ E H D V \ P S W R P D W L P T R U D V A R I P D V H G Z L W K W R
sudden onset of lower abdominal pain. The pain often begins during strenuous physical activity, such as exercise or sexual intercourse, often lasting less than 24 hours.

6 \ P S W R P V V W D U W L Q D W K L U G R I S D W L Q W V W L Q W R U L Q W P D P S
preceding the acute pain, due to hemoperitoneum resulting from the rupture .

The cramps are caused by the luteal cavity distension due to the intracystic bleeding and the pain can range from a diffuse tenderness to acute abdomen when the rupture and the consequent hemoperitoneum occurs; even a small peritoneal effusion is large enough to cause real acute abdomen. Other symptoms may include nausea and vomiting caused by visceral reaction due to peritoneal irritation, vaginal bleeding, weakness, hypotension, syncope, and cardiovascular collapse. Visceral pain can also be related to emotional signs such as marked anxiety and autonomic signs such as pallor, sweating, nausea, vomiting, bradycardia or tachycardia. These signs further amplify the symptoms caused by bleeding.

Barel et al. reported abdominal pain as a prevalent and constant symptom in all patients; 10.7% also had fever, 13% had nausea and vomiting, and 4% showed urinary disorders. It is worth mentioning that it is not always clinically possible to differentiate hemorrhagic cyst and ruptured hemorrhagic cyst.

, Q P D Q \ F D V H V R I 5 &/ S D W L H Q W V U H R D W Q F K K H Q P R R Q R Q D B Q B G D L Q Q S D W W E P X O D U V
and a moderate amount of free fluid in the abdominal cavity could be a normal finding in the postovulatory period. For this article.

Diagnosis

A physical examination of the abdomen and vagina is critical in the first evaluation of the patient. Accurate diagnosis depends on the clinical presentation, the results of tests, and the index of suspicion. A negative pregnancy test is important to exclude ruptured ectopic pregnancy.

6 R P H G L D J Q R V W L F W H V W V D U H Q H I T R A N D U \ 3 U L P D U L O \ G L D J Q R V L V
U H T X L U H V D Q X O W U D V R X Q G 8 6 H T K B L Q B W L Q D Q W H K H F X Q W X D O W R O R W R I
L Q V S H F W W K H &/ D Q G W K H D E G R P L Q D O R T Q D I N T E R D I G I T A T I O N S forming a "complex mass" entering into a complete blood count, blood clotting tests, and an evaluation of inflammatory markers.

/ D E R U D W R U \ 7 H V W V

For a patient's hemostasis evaluation, the following parameters should be evaluated:

‡ 3 U R W K U R P E L Q W L P H 3 7 7 K L V L V e n s e t c o m p a t t e r n D 24.0% V h o w e u k h a m i x e d W a t t e r Q 28.8% pathway of coagulation. PT is longer in cases of factor VII, X, II, and fibrinogen deficiency, and it is essential to evaluate the hepatic synthesis of coagulation factors and vitamin K status, as well as for monitoring anticoagulant therapy.

‡ \$ F W L Y D W H G S D U W L D O W K U R P E R S C B V W W D Q O W V W H G D I S V 7 K D Y K H H D Y D D O X D W H G used to evaluate factors of the intrinsic and common pathway

of coagulation and to monitor therapy with unfractionated heparin it could be longer in cases of a shortage of one of the intrinsic pathway factors, or in the presence of antiphospholipid syndrome.

• Fibrinogen: This is reduced in case of liver diseases, CID, and massive transfusions, and is increased during inflammation. : K L W H E O R R G F H O O observed that % Devated H W : % & SH U P / Z D V U H O D W H G W R W I

presentation and its value regresses with resolution : + H P R J O R E L Q + J E D Q G K H P D W R F U L decrease progressively and proportionally to the amount of S H U L W R Q H D O H I I X V L R Q 0 R Q L W R U L Q J essential to assess the development of blood loss to evaluate the possibility for emergency surgery.

• Platelets: generally indicated to investigate the presence of possible thrombocytopenia or thrombocytopathy in patients Z L W K D Q + &/ Z L W K R X W D K L V W R U \ R anticoagulant therapy.

7 K H K X P D Q F K R U L R Q L F J R Q D G R W U R S L four weeks of amenorrhea, and in the urine from the sixth and seventh weeks of gestation age. Beta-hCG is essential to identify K & * L V G H W H F W D E O H L Q E O R R G W K U F pregnant patients and in making a differential diagnosis with extrauterine pregnancy or intrauterine gestation.

article. The sonographic appearance of a hemorrhagic ovarian cyst can pattern depending on the formation and lysis of the clot
8 V X D O O \ + &/ D S S H D U V D V D U R X Q G R diameter of 3.0-3.5 cm, with well-defined, regular and thin

Z D O O V) L J X U H primarily, the clot forms like a fine fibrin network in the central cavity; subsequently, the coagulum in the cavity forms an R U J D Q L] H G U H W L F \$ O V D H U U S V D K H V K D U X Q V H R becomes "corpus albicans," which is not always visible with


U H D V R Q Z H G L V F X V V E R W K F R Q G L W E R Q G M I Q B B H Q J W L L W Q ' V I & J / H F \ W W W \ F I N Q H W K V H R I
pattern and interdigitations forming a "complex mass" entering into the differential diagnosis from ovarian neoplasm.

) R U W K L V U H D V R Q D Q R H I G H H & W D V K H J U H although there is always one posterior acoustic enhancement that allows to distinguish it from a solid lesion

G H V F U L E L Q J I R X U G L I I H U H Q W 8 6 S D W W R I F D V H V) L J X U H Ding et al. observed 104 cases of hemorrhagic ovarian cyst, G H V F U L E L Q J I R X U G L I I H U H Q W 8 6 S D W W R I
pathway of coagulation. PT is longer in cases of factor VII, X, II, and fibrinogen deficiency, and it is essential to evaluate the S D W W H U Q 7 K H \ D O V R R E V H U Y H G D U L C R I F D V H V) L J X U H characteristics



) L J X U H Typical sonographic features of a corpus luteum cyst
with hemorrhagic content



)LJXUH 'RSSOHU IHDXUHV RI &/&
have been well defined.

Tamura et al. L Q Y H V W L J D W H G W K H F K D during the luteal phase and early pregnancy. The relatively high U H V L V W D Q F H L Q G H [5 , G X U L Q J W with progression towards the luteal phase. By the mid-luteal S K D V H W K H 5 , Z D V O R Z L Q G L F D W L There was an increase in RI and therefore a reduction in t E O R R G I O R Z R Q U H J U H V V L R Q R I W K defects, the RI was significantly higher, indicating a decrease blood flow. During pregnancy, the RI remains at the low mid-luteal phase level for the first 7-8 weeks and then increases on W K H & / U H J U H V V H V

effusion into the abdominal cavity, especially at the lower points such as the pouch of Douglas, the vesico-uterine pouch

D Q G W K H L O L D F I R V V D H + H P R U U K D
in the Morrison pouch and the paracolic lodges. The amount
of effusion can vary from minimal to massive bleeding.

Examination of endometrium reveals a secretory pattern during the luteal phase and indicates an active production of progesterone.

Although ultrasonography is superior to computed tomography

cysts on CT scans depends on the age of the clot: blood from an acute hemorrhage has a high attenuation value, whereas blood from a previous hemorrhage has an attenuation value approaching that of water. In an acute setting, CT typically demonstrates a cystic adnexal mass with areas of high attenuation in the intramural and intracystic sites. + H P R S H U L W R Q H X P P D \ D O V R E H S U clot and blood accumulating in the pelvis. The pretreatment CT scan for ruptured corpus luteal cysts can suggest the need for surgical treatment based on image findings

'LIIHUhQWLDO 'LDJQRVLV

There are several pathologies that need a differential diagnosis Z L W K + & / 7 K H S H O Y L F S D L Q L V W \ S L disorders, such as ectopic pregnancy, PID, ovarian torsion, and several non-gynecologic diseases such as appendicitis, gastroenteritis, cystitis, and other urinary tract disorders Recently, a case of ruptured hemorrhagic ovarian cyst presenting an incarcerated inguinal hernia in an adult female was reported .

7 K H 8 6 G L I I H U H Q W L D O G L D J Q R V L V E H
masses and complex malignant lesions is necessary. Bleeding
may be generally due to the rupture of an ectopic pregnancy,
an infiltrating neoplastic disease, vascular diseases and traumas.
Clinical history and anamnesis of patients are very important
for a differential diagnosis. In the event of a positive pregnancy
test, the physician must investigate other nonspecific clinical
I L Q G L Q J V R I D Q H F W R S L F S U H J Q D Q F \
cervical rigidity, tenderness, a palpable adnexal mass and uterine
V S R W W L Q J 7 K H H D U O L H V W D S S H D U D
occurs in the sixth week after the last period. Peritoneal signs
Q J H Y L Q & F O R R G J O R Z
are indicative of intraperitoneal blood collection. Usually, the
bain is alternating and spasmodic, followed by intervals free of
symptoms.

In most extrauterine pregnancies beta-hCG production is lower, the endometrium response is not stable, and spotting is common. In 70% of ectopic pregnancies, the beta-hCG levels rise more slowly, reaching a plateau and even showing a decrease in serum levels. An abnormal beta-hCG pattern is highly suggestive of an ectopic gestation or a no longer intact gestation. Besides the unconventional rise in beta-hCG levels compared with normal pregnancies, ectopic pregnancy can be

differentiated from spontaneous abortion by a slower decrease in serum titer. In a normally developing pregnancy, beta-hCG levels double every 1.5 days in the first 5 weeks of a regular gestation.

J A H V X L R Q F D Q D O V R E H R E V H U Y H G
: L W K D V H U X P E H W D K & * O H Y H O R I
F K R U L R Q L F V D F F D Q E H G H W H F W H G

presenting a double echogenic ring around a hypoechoic gestational sac called "comet sign". Conversely, in patients with

E H W D K & * R I P , 8 P / D Q G P R U H D Q
Y I V X D O L I H G E \ 7 9 . 6 Z I W K V S H E L I I E D W I

The "tubal Ring" is a classic sonographic sign of ectopic pregnancy, represented by a hyperechogenic thick wall with anechoic content; only rarely it is possible to detect the ring of fire. Observed using the color Doppler, which is caused by the hyperechoic walls of the tube, the sign is not clear enough to differentiate an ectopic pregnancy from other tubal pathologies.

"tubal ring" of ectopic pregnancy reflected the hyperechoic area observed in intrauterine pregnancies at the initial stage, formed by the fusion of the trophoblast and the decidua. In several patients with ectopic pregnancy, the "tubal ring" has higher walls and internal pus-like echoes with cellular debris. During transvaginal examinations, patients may exhibit tenderness and more often hypoechoic.

Classically, appendicitis diagnosis is based on symptoms, diagnosis of ectopic pregnancy because about 85% of all ectopic pregnancies show symptoms of acute abdomen, and severe leukocytosis. Leuteal flow is detected ipsilaterally of the ectopic pregnancy muscle contracture and a modest increase in leukocytes while searching for an ectopic pregnancy and could be called appendix edema, both typical of an inflammatory state.

the color Doppler signals of the ectopic pregnancy.

Vidakovic et al. pregnancy with the authors suspecting an ectopic pregnancy, pregnancy was found.

Torsion of the ovarian pedicle is also one of the most common complications of ovarian neformations.

It usually occurs suddenly and can also affect normal adnexa of the pedicle, like in the case of pelvic varices with the increase of vein blood pressure, can result in ovarian edema associated

With routine ultrasonographic examination during the first trimester, the discovery of an ovarian cyst has become relatively common. Most unilocular and anechoic ovarian cysts with thin borders present after the end of the first trimester. Except in case of

Cysts presenting rapid growth may break due to abnormal vascularity in some parts of the wall.

If the cyst contains blood, differential diagnosis with rupture bleeding, and rupture. Adnexal torsion is frequently associated

With ovarian stimulation, especially during the beginning of pregnancy, and the abdomen appears slightly treatable and tense. Color Doppler ultrasound shows mainly functional, rigid, opposite hypervascularity of blood flow.

present after the end of the first trimester. Except in case of complications, surgery should be avoided. The complications of these cysts are represented mainly by torsion, intracystic hemorrhage, and the abdomen becomes increasingly common in pregnant women over the past decade. Emergency surgery during the first trimester for complications become increasingly common in pregnant women over the past decade. Endometriomas are usually found especially during the second trimester, especially during the second trimester. Emergency surgery during the first trimester for complications become increasingly common in pregnant women over the past decade. Endometriomas are usually found especially during the second trimester.

The disappearance or regression of a previously observed cyst after the menstrual event, or at 4-6 weeks

The disappearance or regression of a previously observed cyst This case presents the clinical and the histologic findings of a

In cases of PID, patients show inflammation signs such as fever, severe pain, and increased WBCs and other inflammatory markers have overcome the technical difficulty of an enlarged gravid

It certainly seems that progesterone may still play an important role postoperatively in the first trimester if surgery involves the clinical symptoms, preferably at the end of the following menstrual period. K ZHHN WKH SODFHQWD takes over the role of producing progesterone to support the pregnancy.

During the observation periods, physicians may prescribe drug therapy and supportive care; this, however, does not improve the outcome of the disease. Ovarian conservative treatment should be laparoscopic if the patient's condition permits it.

\$ QWLILEULQR O\WLF

Tranexamic acid is one of the most widely used drugs in this category. Tranexamic acid is a synthetic derivative of the amino acid lysine, which exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecule. There are clear indications for anti-fibrinolytic see" option, with a continuous follow-up of clinical, laboratory treatment, but we know from a few trials that systemic tranexamic acid administered at the outset for surgery reduces In most cases, keeping patients under observation and waiting for the remission of symptoms is enough. In rare cases, surgery may be required to stop bleeding because hemodynamic management should be laparoscopic.

An article published in 1984, in which 173 surgical cases were surgical diagnosis allowed the avoidance of surgery+ R al. showed that the use of surgery was significantly higher/ LTXLG LQIXVLRQ LV FHUWDLQO\ D XV LQ WKH V FRPSDUHG ZLWK FQVHVKHIDPDQH EHEPQWZHQV WUDWHG W -DQXDU\ DQG 'HFHPEHU FOLQLFDO PDQLIHVWDWL RQV RI + & / They are used on patients' request to relieve painful symptoms, but pain does not always recede after the administration of these drugs.

: DLW DQG VHH \$WWLWXGH

With the improvement of diagnostic tools over time, physicians have increasingly opted for a wait-and-see approach. Most cases treated conservatively .

During the observation period, it is important to continuously reported by the patient.

The acute pain often subsides within the first 24 hours, and failure to improve could be a sign of worsening. Thus, during the observation period, it is recommended to perform another antibiotic prophylaxis is conducted with 86 HYDOXDWL RQ DQG UHSHDW WKH ZLWK VLJQV RI DQHPLD IDLQWLQJ D VVWKHQLD , I +JE YDOXHV DUH VWDEOH RU DUH PDLQWDLQHG DERYH TP G7 DQG LI D 86 HYDOXDWL RQ LV FRPSDWLEO

Antibiotic prophylaxis against the most common bacteria responsible for peritonitis. Prescription of antibiotics is made on an individual basis because the literature is lacking any evidence of their use in case of infection absence. The first choice and consisted mainly of a laparotomy with oophorectomy. With the advent of laparoscopy, a minimally invasive approach is preferred to laparotomy, which however remains the first-choice method in the event of cardiovascular collapse .




Figure 3. Laparoscopic view of ruptured CLC

/D S D U R V F R S \ D Q G /D S D U R W R P \

/D S D U R V F R S \ L V W K H S U H I H U U H G U H V X O W V L Q O H V V P R U E L G L W \ W K D Q

known that the laparoscopy has several advantages compared with laparotomy, which has been replaced almost completely in gynecology during the last years

The first and most important advantage of laparoscopy is the type of incision, which is minimally invasive compared with laparotomic transverse incisions.

7 K H K R V S L W D O L] D W L R Q R I W K H S D W

F R P S D U H G Z L W K O D S D U R W R P \

operative pain is significantly reduced

Complications risks are lower in laparoscopy, which however is more operator dependent.

In the event of massive hemoperitoneum, autologous blood transfusions from blood recovered from the peritoneal cavity should also be considered, even with the laparoscopic technique .

\$ O L P L W D W L R Q R I W K H O D S D U R V F R S \ F \ V W L I L W H [F H H G V W K H G L D P H W H U O D S D U R V F R S \ L V O L P L W H G W R W K H K R Z H Y H U T X L W H U D U H L Q F D V H V R I + /

During laparoscopy, three kinds of surgical options can be used:

‡ & \ V W H F W R P \ R U H Q X F O H D W L R Q R I B Y D U L D Q F \ V W V O X W H X P H F W R P \

The technique is preferable because it allows the preservation of ovarian function.

- Ovarian wedge-shaped excision.

- Oophorectomy or ovariectomy: this was the preferred technique in the past and resulted in the total loss of the ovary, often accompanied by loss of the ipsilateral fallopian tube.

: R P H Q Z L W K & R Q J H Q L W D O R U \$ F T X L U H G % O H H G U O J L V R U H G H U Y Women receiving anticoagulant therapy or with congenital disorders of the coagulation system have a higher risk of hemodynamic instability in this category of patients. There is still not enough evidence to support a surgical or expectant approach. According to some published case series, conservative treatment is the dominant trend in carefully selected patients with coagulopathies. In summary, the observational approach in hemodynamically stable patients could be the first choice option in most cases. There are no data comparing these two strategies in this patient population, but if there are no concerns about ongoing brisk bleeding or infection or malignancy, the risks of surgery are not warranted. In cases of continuing bleeding or the decision of a patient to choose active management, a laparoscopic approach should be suggested with ovary-sparing surgery, using minimal energy.

to support a surgical or expectant approach. According to some published case series, conservative treatment is the dominant trend in carefully selected patients with coagulopathies. In summary, the observational approach in hemodynamically stable patients could be the first choice option in most cases. There are no data comparing these two strategies in this patient population, but if there are no concerns about ongoing brisk bleeding or infection or malignancy, the risks of surgery are not warranted. In cases of continuing bleeding or the decision of a patient to choose active management, a laparoscopic approach should be suggested with ovary-sparing surgery, using minimal energy.

2 X W F R P H V

There are scant data regarding the outcomes of ruptured ovarian cysts. Available studies include:

- In a series of women with a ruptured ovarian cyst and hemoperitoneum, 15 of 78 were managed surgically

3 D W L H Q W V Z K R X Q G H U Z H Q W V X U J H U \ K V X U J U F D K Q R x D S U R D F K E H F D X V H Q L D V K D G W K D Q D W K R W R P P D Q D X H G F R Q W H U V D W H Q

were managed with surgery and the remainder was managed

with observation the study did not give rates of surgical complications, transfusions or recurrence

3 U H Y H Q W L R Q R I 5 H F X U U H Q F H

There are no known methods to prevent rupture of an existing ovarian cyst, except for surgical drainage or removal of the cyst.

Patients with bleeding disorders or undergoing anticoagulant therapy have a higher risk of recurrence. Regular follow-up

F D Q P L Q L P L] H W K H U L V N V 7 K H V H S D W with a higher risk of decreased ovarian function and adhesion formation, which consequently contributes to reduced fertility rates.

Thus, the possibility of preserving a future pregnancy is essential and patients need drugs such as estrogen-progestins or OCs. Patients with bleeding disorders or pregnancy complicated by ovulation. In general, current OCs resulted in the development of fewer follicular and correspondingly lutein cysts

Conclusion

This review focuses on the pathophysiology, clinical S U H V H Q W D W L R Q G L D J Q R V L V D Q G W U H

patients with bleeding disorders or pregnancy complicated by & / F \ V W V

reproductive age. Management is based upon patient characteristics, including the severity of symptoms, whether

& X U U H Q W O \ 8 6 L V

U X S W X U H G & / F \ V W V 6 X U J L F D O W U H D W P R I Q D W L R M U W K L H Q W I U Q J G V L W R L R Q V D K O H D G S L S D W R

conditions that cause acute abdomenThe most important is ectopic pregnancy.

The "tubal ring" is a classic sonographic sign of ectopic pregnancy .

Beta-hCG is essential for identifying pregnant patients and making a differential diagnosis with extrauterine pregnancy and L Q W U D X W H U L Q H J H V W D W L R Q R U & / Observation is an adequate option in hemodynamically stable patients, without severe abdominal pain and in the presence RI D VPDOO DPRXQW RI SHOYLF IOXL a large amount of fluid is observed and/or in the presence of severe abdominal pain laparoscopy should be performed on admission. Direct laparotomy is mandatory in cases of circulatory collapse.

7 K H G H F L V L R Q R Q W K H W U H D W P H Q W see" option with a continuous follow-up of clinical, laboratory S D U D P H W H U V D Q G 8 6 G H W H F W L R Q During observation periods, drug therapy and supportive care are suggested. A careful pre-surgical diagnosis can often avoid the need for surgery.

6 X U J H U \ P D \ E H U D U H O \ U H T X L U H G hemodynamic instability and deterioration of clinical status can occur.

Patients with bleeding disorders or undergoing anticoagulant therapy have a higher risk of recurrence and often undergo surgery, with a higher risk of decreased ovarian function and fertility rates .

7 K L V D U W L F O H S U R Y L G H V D Q R Y H U¹³ helping physicians to identify the clinical signs and sonographic features early, to quickly diagnose this condition, to choose the appropriate treatment for their patient, and to prevent recurrent episodes.

(W K L F V

3 H H U U H Y L H Z Externally and internally peer-reviewed. \$ X W K R U V K L S & R Q W U L E X W L R Q V

16. 6 X U J L F D O D Q G 0 H G L F D O 3 U D F W L F H V Design: A.T., Data Collection or Processing: A.T., Analysis or , Q W H U S U H W D W L R Q 0 9 0 / L W H U D W X Writing: M.V.M.

& R Q I O L F W R I , Q W H U H V W No conflict of interest the authors.

) L Q D Q F L D O ' L V F O R V X U H The authors declared received no financial support.

References

- + D O O D W W - * 6 W H H O H & + - U 6 Q \ G H U 0 hemoperitoneum: a study of 173 surgical cases. Am J Obstet Gynecol 1984;149:5-9.
- * X S W D 1 ' D G K Z D O 9 ' H N D ' - D L Q 6. 0 L hemorrhage: rare complication of congenital and acquired coagulation abnormalities. J Obstet Gynaecol 2007;33:376-80.
- \$ J J D U Z D O \$ * R H O 3 : D Q F K X 0 0 D O K R W U corpus luteum with hemoperitoneum. J Obstet Gynecol Ind 2004;54:488-90.

4. Novak ER, Woodruff JD. Gynecologic and Obstetric Pathology. 7th H G L W L R Q Y R O 3 K L O D G H O S K L D : % 6 D X 7 D Q J / & & K R +. & K D Q 6 < : R Q J 9 & ' H [W U corpus luteum rupture: a clinical study. J Reprod Med 1985;30:764-8.

+ R : . : D Q J <) : X ++ 7 V D L +' & K H Q 7 + & K corpus luteum with hemoperitoneum: case characteristics and demographic changes over time. Taiwan J Obstet Gynecol 2009;48:108-12.

) X N X G D 0) X N X G D . \$ Q G H U V H Q & < % \ V N Of C O M P R O D U C T I O N I N D A T A R I C Y C L E S c o r r e l a t e d w i t h @ g e and D F K L H Y H P H Q W R I S U H J Q D Q F \ + X P 5 H S U R G % R W W L Q L (3 D U H W L), 0 D U L ' 0 D Q Q X F F M. Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and D I L E U L Q R J H Q H P L D & D V H U H S R U W V + D H P R B H & K H Q L Q X G H Y 6 W K H H E H D W R W 0) Q G O Y L .

Recurrent haemoperitoneum in a mild von Willebrand's disease combined with a storage pool deficit. Blood Coagul Fibrinolysis 2001;12:207-9.

* K R V K . 0 R K D Q W \ ' 3 D W K D U H \$ 9 - L haemoperitoneum in a female patient with type III von Willebrand's disease responded to administration of oral contraceptive. W R S Y W W S E O H H G L Q J E H F D X V H + D H P R S K L O L D

* R P H] \$ / X F L D -) 3 H U H O D 0 \$ J X L O O D caused by haemorrhagic corpus luteum in a patient with type 3 von : L O O H E U D Q G \ V G L V H D V H + D H P R S K L O L D

* U H H U , \$ / R Z H * ' : D O N H U --) R U E H V & in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991;98:909-18.

Javis RB, Olsen ME. Type I von Willebrand's disease presenting as recurrent corpus hemorrhagicum. Obstet Gynecol 2002;99:887-8. 7 H U] L F 0 / L N L F , 3 L O L F , % L O D - . Q management of massive hematoperitoneum caused by ovulation in a patient with severe form of von Willebrand disease--a case report. Clin Exp Obstet Gynecol 2012;39:537-40.

& H W L Q N D \ D 6 (3 D E X F F X (* 2] P H Q % ' R N P hemoperitoneum due to ovulation as a clinical sign in congenital D I L E U L Q R J H Q H P L D \$ F W D 2 E V W H W * \ Q H F R C

16. Castman G, Ruggeri M, Rodeghiero F. Congenital afibrinogenemia: successful & prevention S M recurrent hemoperitoneum during R Y X O D W L R Q E \ R U D O F R Q W U D F H S W L Y H \$ R K u s s 6 A E c p n m o M A g h e n a i o u M g I n t r a - a b d o m i n a l hemorrhage due to a ruptured corpus luteum cyst in a girl whit Congenital afibrinogenemia. Eur J Pediatr 2001;160:196. C o n g e n i t a l a f i b r i n o g e n e m i a was declared by

18. O'Brien PM, DiMichele DM, Walterhouse DO. Management of an acute hemorrhagic ovarian cyst in a female patient whit hemophilia S 1 3 H G L D W U + H P D W R O 2 Q F R O

' D I R S R X O R V . * D O D J L R V * * H R U J D G D N L V * D, Plakopoulos A, et al. Two episodes of hemoperitoneum from luteal cyst rupture in a patient with congenital factor X deficiency. 5 X r e v I O b s t e t G y n e c o l 2 0 0 3 ; 5 5 : 1 0 4 - 5 . W H X P Z L W K . K D P D V K W D 0 \$ & X D G U D G R 0 - 0 X M L F) 7 D G R V. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995;332:993-7.

< D P D K D P L / < G H \$ X U D M R % ' 6 L O Y D & \$ % 6 H Y H U H K H P R U U K D J L F F R U S X V O X W H X P F D Q S W B D Q R K R S K U R D 6 S L Q X S W Q G H R S P / X S X V & D V W H O O L Q R * & X D G U D G R 0 - * R G I U H \ 7 G R. Characteristics of patients with antiphospholipid syndrome

- Z LWK P D M R U E O H H G L Q J D I W H U R U D O D Q W S L U E F R D J X O \$ D N Q K W W / W H D W I R M R Q W Q \$ Q Q D S H K P H R K U P U K Dis 2001;60:527-30.
- 3 D \ Q H - + 0 5 D F O H D D P Q S W R Q . . % D [W H U \$ - 6 W D I D Q Q L W N R O Z L F] 5 + H P R U U K D J L F F R U S X V + H P R S H U L W R Q H X P D V V R F L D W H G Z LWK ^{B a s t o n e D i s t r i c t R n Q J E m e r g M e d 2 0 1 2 ; 2 0 : 1 3 8 . W K}
- bleeding disorders: the case for conservative management and the - D W H J D R Q N D U 3 \$ < D G D Y 6 3 5 X S W X U H G U R O H R I W K H F R Q W U D F H S W L Y H S L O O + D p r e s e n t i n g l a s t a n d i n c a r c e r a t e d i n g u i n a l h e r n i a i n a n a d u l t f e m a l e: % D U H O 2 6 P R U J L F N 1 3 D Q V N \ 0 6 F K Q H L a c r o c l i n i c a l s e n s i t i v i t y o f a c o m m o n s u r g i c a l e m e r g e n c y . C a s e R e p and laboratory presentation of hemorrhagic corpus luteum. J Emerg Med 2013;2013:925694.
- * \ Q H F R O 6 X U J + X F N H -) • O O H U V 8 ([W U D X W H U L Q H 6 F K 1 H P R W R < , V K L K D U D . 6 H N L \ D 7 . R Q L V K L 2 0 0 5 ; 3 8 : 5 5 5 6 2 . 7 8 O W U D V R Q R J U D S K L F and clinical appearance of hemorrhagic ovarian cyst diagnosed by \$ O N D W R X W , + R Q H P H \ H U 8 6 W U D X V V \$ 7 W U D Q V Y D J L Q D O V F D Q - 1 L S S R Q 0 H G 6 F K et al. Clinical diagnosis and treatment of ectopic pregnancy. Obstet 7 D N D V D N L \$ 7 D P X U D + 7 D Q L J X F K L . \$ V D H F R Q 6 X U D Y N H W D Q L 7 0 D W V X R N D \$ H W D O / X W H D O E O R R G I O R Z R D Q G O X Q W H D P W H W % R Q ' L D J Q P D V U L V Q D Q G pregnancy. Am Fam Physician 2005;72:1707-14.
- Res 2009;2:1. 9 D O H Q W L Q / , P D J L Q J L Q J \ Q H F R O R J \ Gynaecol 2006;20:881-906.
- 6 Z L U H 1 0 & D V W U R \$ U D J R Q , / H Y L Q H appearances of the hemorrhagic corpus luteum cyst. Ultrasound Q 2004;20:45-58.
- D L Q . \$ 6 R Q R J U D S K L F V S H F W U X P R I K measurements jin ectopic pregnancy. Am J Obstet Gynecol 1988;158:1239-40.
- Ultrasound Med 2002;21:879-86.
30. Parson AK. Imaging the human corpus luteum. J Ultrasound Med 2001;20:811-9.
- 6 S L Q H O O L & ' L * L D F R P R 0 0 X F F L 1 0 D V V luteum cysts: an unusual problem for pediatric surgeons. J Pediatr Adolesc Gynecol 2009;22:163-7.
52. Brennan DF. Ectopic pregnancy part I: clinical and laboratory diagnosis. Acad Emerg Med 1995;2:1081-9.
32. Patel MD, Feldstein VA, Filly RA. The likelihood ratio of sonographic findings for the diagnosis of hemorrhagic ovarian cysts. J Ultrasound Med 2005;24:607-14.
- < R I I H 1 % U R Q V K W H L Q 0 % U D Q G H V - ovarian cyst detection by transvaginal sonography: the great imitator. Gynecol Endocrinol 1991;5:123-9.
- ' L Q J = = K D Q J ' < L Q J : : D Q J - 6 R Q R J U D S K L F of hemorrhagic ovarian cysts. Eur J Gynaecol Oncol 2010;31:87-9.
- * O R F N - / % O D F N P D Q - \$ % D G J H U * - significance of morphologic changes of the corpus luteum by transvaginal ultrasound in early pregnancy monitoring. Obstet Gynecol 1995;85:37-41.
- ' X U I H H 6 0) U D W H V 0 & 6 R Q R J U D S K L F F K luteum of pregnancy. J Clin Ultrasound 1999;27:55-9.
- = D O X G , . X U M D N \$ 7 K H D V V H V V P H Q W R I and non-pregnant women by transvaginal color Doppler. J Perinat Med 1990;18:215-21.
- % R Q G H \$ \$. R U Q J R O G (.) R V W H U % 5) X Q J O S : X W F R K D H V F B Q W H D H O V V R Q H J Q D Q F \ D F D DR, et al. Radiological appearances of corpus luteum cysts and their imaging mimics. Abdom Radiol 2016;41:2270-82.
- 7 D P X U D + 7 D N D V D N L \$ 7 D Q L J X F K L . 0 D V V luteum throughout the luteal phase and during early pregnancy. 6 X J L Q R 1 & K D Q J H V L Q E O R R G I O R Z L P S H G) H U W L O 6 W H U L O
- / H H 0 6 0 R R Q 0 + : R R + 6 X Q J & . - H R Q + : corpus luteal cyst: prediction of clinical outcomes with CT. Korean J Radiol 2017;18:607-14.
- / L X ; 6 R Q J / : D Q J - / L X 4 / L X < = K D Q J CT in differentiating between ruptured ovarian corpus luteal cyst and ruptured ectopic pregnancy with hemorrhage. J Ovarian Res 2018;11:5.
- % D G D Z \ 6 = (W L R O R J \ D Q G P D Q D J H P H Q W U H S U R G X F W L Y H \ H D U V - * \ Q H F R O 6 X U J appendicitis. Bangladesh Med J 2008;37:66-7.
59. Vidaković b 6 ' R M I M i b e n d e c i Z , M a r a v i M D . R u p t u r e d c o r p u s l u t e u m c y s t s i n p r e g n a n c y : a s s o c i a t i o n w i t h o v a r i a n e d e m a . J P e d i a t A d o l e s c G y n e c o l 2 0 0 6 ; 1 9 : 3 2 5 - 7 . K X P D Q F R U S X V 9 H O F D Q L \$ & R Q N O L Q 3 6 S H F K W 1 6 R Q F ovarian abscess mimicking an endometrioma and review of cystic adnexal masses. J Radiol Case Rep 2010;4:9-17.
- \$ O F i] D U - / / H y Q 0 * D O Y i Q 5 * X H U U L H U R content using mean gray value for discriminating endometrioma from other ovarian cysts in premenopausal women. Ultrasound Obstet Gynecol 2010;35:228-32.
- 6 H U J H Q W) 9 H U V S \ F N (0 D U S H D X / 0 D Q D during pregnancy. Presse Med 2003;32:1039-45.
- & K D D N F X U W H S H R E Y H U F W S / D L Q % G D X U U L Q V W D 5 & D E et al. Effects of tranexamic acid on death, vascular occlusive

events, and blood transfusion in trauma patients with significant hemodynamically stable patient with ruptured corpus
KDHPRUUKDJH & \$6+ D UDQGRPLVHG SQPFHERFRQWKRPRHSCULWRQHXP - \$F
/DQFW

&KHQ / 'LQJ - +XD . &RPSDUDWLHY DQD 2003;10:474-7
laparotomy in the management of ovarian cyst during pregnancy. J
Obstet Gynaecol Res 2014;40:763-9.

.LP -+ /HH 60 /HH -+ -R <5 0RRQ 0+ 6KLQ - HW DO 6XFFHVVIKO
conservative management of ruptured ovarian cysts with
KHP RSHULWRQHXP LQ KHDOWK\ ZRPHQ 3NRXU2JHU\ - 6/6
5D]LHO \$ 5RQ (O 5 3DQVN\ 0 \$ULHOL 6 %XSWDV\\$, *XBSWSD (6 & XUDUDWW DOD 8
management of ruptured corpus luteum. Eur J Obstet Gynecol
Reprod Biol 1993;50:77-81.

7HQJ 6: 7VHQJ -< &KDQJ &. /L &7
Comparison of laparoscopy and laparotomy in managing

hemodynamically stable patient with ruptured corpus
OXWHXP ZKLUWKRPRHSCULWRQHXP - \$F

laparotomy in the management of ovarian cyst during pregnancy. J
Obstet Gynaecol Res 2014;40:763-9.

D X W R O R J X V E O R R G W U D Q V I X V L R Q I R U
from ectopic pregnancy or ovarian bleeding laparoscopic
3NRXU2JHU\ - 6/6

%XSWDV\\$, *XBSWSD (6 & XUDUDWW DOD 8
Conservative management of corpus luteum haemorrhage
in patients on anticoagulation: a report of three cases and
review of literature. Arch Gynecol Obstet 2015;291:427-31.



Adenoid cystic carcinoma of Bartholin's gland diagnosed after lung lobectomy: Review of the literature and a case presentation

6 H J P H Q W D O D N F L ý H U O R E H N W R P L V R
% D U W K R O L Q N D Q V H U L / L W H U D W • U G H

• 6 H G D ý D K L D Q & \$ H Y H U L \ H & D Q Q D Q / X } Q D W] 2 U W D o

¹Ankara University Faculty of Medicine, Department of Gynecologic Oncology, Ankara, Turkey

²Ankara University Faculty of Medicine, Department of Pathology, Ankara, Turkey

Abstract

% D U W K R O L Q • V J O D Q G Z D V I L U V W L G H Q W L I L H G L Q K X P D Q I H P D O H L Q E \ & D V S D U % D U W K R O L Q P X F L Q R X V D F L Q L W K H G X F W L V S U H G R P L Q D Q W O \ W U D Q V L W L R Q D O H S L W K H O L X P D Q G W L V D Q X Q F R P P R Q Q H R S O D V P \$ G H Q R L G F \ V W L F F D U F L Q R P D \$ & & R I E D U W K R O L Q J O D Q G F D O O E D U W K R O L Q J O D Q G P D O L J Q D Q F L H V \$ & & R I W K H % D U W K R O L Q • V J O D Q G L V F K D U D F W 6 R G L V W D Q W P H W D V W D V L V K D V E H H Q I R X Q G L Q R Q O \ D I H Z F D V H V W R W K H O X Q J V O L Y H \ H D U V I R O O R Z X S D Q G S U H V H Q W H G Z L W K D O X Q J P H W D V W D V L V . H \ Z R U G V \$ G H Q R L G F \ V W L F F D U F L Q R P D R I W K H % D U W K R O L Q • V J O D Q G Y X O Y D U F D Q F H U

Öz

% D U W K R O L Q E H] L \ x O x Q G D & D V S D U % D U W K R O L Q W D U D I x Q G D Q N D G x Q J H Q L W D O D Q D P • V L Q] N D Q D O W U D Q V L V \ R Q H O Y H R U L I V V N X D P] H S L W H O O H N D S O x G x U 3 U L P H U E D U N D U V L Q R P L V H o R N Q D G L U J \ U • O P H N W H Y H E D U W K R O L Q N D Q V H U O H U L Q . L Q L R O X ü W X U P Y H \ D Y D ü E \ • P H S D W H U Q L Q H G H Q L \ O H U H N • U U H Q V Y H X] D N P H W D V W D] X] X Q Y D N L W D O D D] K D V W D G D U D V W O D Q P D N W D G x U % L] \ x O O x N K D V W D O x N V x] W D N L S V R Q U D V x D N F L ý H U \$ Q D K W D U . H O L P H O H U Adenoid kistik Bartholin karsinomu, vulvar kanser, Bartholin bezi karsinomu

Introduction

F D U F L Q R P D % * & F R P S U L V H V D S S U R [L 7 K H % D U W K R O L Q J O D Q G Z D V I L U V W Y X O Y D U F D U F L Q R P D V D Q G R I I H P D O H E R G \ L Q E \ & D V S T D U m a r D f u n i t i o n R o D L Q % * & K D V P D Q \ K L W H U D C a r c i n o m a , s q u a m o u s , the Bartholin gland is to secrete mucus to provide vaginal adenosquamous, transitional cell carcinoma, and adenoid and vulvar lubrication. Each Bartholin gland is approximately F \ V W L F F D U F L Q R P D V adenosquamous carcinomas and squamous 0.5 cm in size and drains mucous into a duct 2.5 cm long. F H O O F D U F L Q R P D V H D F K D F F R X Q W I R The ducts open onto the vulvar vestibule at the four adenosquamous carcinomas according to D S S U R [L P D W H C H L J K W R \ F O R F N S R V L W L R Q V R Q H D % K & V \$ & & R R I % V & H V D J U Q Q H K D U H D Q W orifice is squamous epithelium 3 U L P D U \ F D U F L Q R P D Q R I V S Q M W L H Q W V K D Y H E H H Q G H V F U Bartholin gland has different epithelial types: the body is Bartholin gland malignancies and the first documentation of mucinous acini, the duct is transitional epithelium, and the \$ & & Z D V L G H Q W L I L H G E Q V R E B L Q L M Q H U D W Bartholin gland is an uncommon neoplasm. Bartholin gland J O D Q G L V F K D U D F W H U L] H G E \ V O R Z J U R

\$ G G U H V V I R U & R U U H V S R Q G H Q F H < D \ x ü P D \$ G U H V L 6 H G D ý D K L Q \$ N H U 0 '

Ankara University Faculty of Medicine, Department of Gynecologic Oncology, Ankara, Turkey

3 K R Q H +90 544 692 65 38 (P D L O drsdedasahinaker@hotmail.com 2 5 & , ' , ' orcid.org/0000-0001-6192-5726

5 H F H L Y H G * H O L ü 7 D U L K L 12.03.2020 \$ F F H S W H G . D E X O 7 D U L K L 18.07.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

metastases can take a long period. Only in rare cases are distant metastasis seen in the lungs, liver, bone, and brain. We present a case of ACC in a woman who presented with lung metastasis after four years of follow-up.

& D V H 3 U H V H Q W D W L R Q

, Q 6 H S W H P E H U D \H D U R O G , J H D Y J G L W \ S D U L W menopausal women presented with a palpable mass and vulval pain of the left Bartholin's gland area. Under general anesthesia the left Bartholin's gland was excised with a Bartholin gland cyst prediagnosis. A pathologic examination revealed an ACC of the Bartholin gland, the tumor continued at the positive edge of surgery with negative perineural invasion. The unexpected malignant lesion was diagnosed and a scientific study was conducted for metastatic disease. Chest, abdomen, and pelvic

F R P S X W H G W R P R J U D S K \ & 7 V F D Q M B K B I Z H C Q P R H M D V W D W I disease. Then the patient underwent hemivulvectomy with left inguinofemoral lymph node dissection. After surgery, the pathology result showed a tumor on one side of the surgical margin and positive perineural invasion. The inguinofemoral lymph nodes were collected, all of which were tumor-free. The

S D W L H Q W U H F H L Y H G Q R D G M X Y D Q W patient regularly and who showed no recurrence over a 4-year period. Forty-nine months after the surgery, she had chest pain and cough symptoms. A thorax CT scan was performed which showed a right upper lung lesion in diameter of 1.2*1.1


F P) L J X U H , Q 6 H S W H P E H U left pulmonary wedge resection. The diagnosis was clarified with pathologic results. It showed a lung metastasis of ACC with no tumor in lymph nodes and margins are negative

) L J X U H \$ S D W K R O R J \ H [D P L Q D W L R Q \ V K R Z H G F R O X P Q V R I F H O O V arranged concentrically around gland-like spaces filled with

H R V L Q R S K L O L F S H U L R G L F D F L G 6 F K the examination showed the characteristic tumor proliferation in a cribriform pattern composed of nests, hence, the presence of ACC metastasis. Two years earlier, when the first ACC was diagnosed, it showed similar speciality and was clarified with immunohistochemical characteristics. Tumour cells were Z L G H O \ S R V L W L Y H Z L W K 6 0 \$ & ' D Z L W K & . D Q G F D O S R Q L Q) L J X U H free with 56 months of follow-up and stable disease.

Discussion


In 1864, Klob was the first to describe BGC. It has various types such as adenocarcinoma, squamous, adenosquamous, transitional cell carcinoma, and ACC. Ten to fifteen percent of patients have ACC, which is histologically similar to adenocarcinoma of the salivary gland. ACC of the Bartholin gland is extremely rare. Only 80 cases have been reported in the literature. Common symptoms are a painless mass, pruritus, dyspareunia, burning sensation, vulvar pain, and abnormal bleeding. Initial misdiagnosis or delayed diagnosis may occur in up to 50% of patients, with incorrect diagnoses



W K H


) L J X U H CT scan showed right upper lung lesion in diameter of 1.2*1.1 cm

V K R Z H G F R O X P Q V R I F H O O V
CT: Computed tomography



L W L R C

Tumor in peripheral lung paranchyma, HEx60 & HEx100



The tumor is composed of basaloid cells arranged in cribriform, tubular and solid growth patterns. Vulvectomy material, HEx60 & HEx100

Tumor in vulvectomy material

shares classic histologic features with ACC of the salivary gland and complete excision of pulmonary lesion was not possible. The tumor is composed of uniform, small cells arranged in E H F D X V H W K H Q X P E H U D Q G W K H V L J H F R U G V D Q G Q H V W V Z L W K D F U L E U L I A T E R P 24 S D O N T S' H A L L O W - U P Y S D E U H A D P R O G R E S S M E D I S E A S E \ V W filled with an amphophilic or eosinophilic acellular basement, Q R X U F D V H O L N A T S, < R P A I M W A D D C I V E membrane-like material. The tumor must be located in an margins in pathologic examination, r H F H L Y H G Q R D appropriate anatomic location. Most tumors have perineural invasion; she had lung metastases 49 months after surgery, invasion, which is thought to contribute to its high local and after 56 months follow-up, she has stable disease. When recurrence rate \$ & & R I W K H % D U W K R O L Q the distant metastasis was evaluated, it seemed to be related to by slow growth, local recurrence, and distant metastases by margin positivity and perineural invasion. ACC of Bartholin's intravascular spread may occur over a long period. Distant gland is a slow-growing tumor, long-term survival is excellent metastasis of ACC is not common, it is very rare in the lung, according to Copeland et al. The 5-year progress-free interval brain, liver, and bone. Alsan et al showed the most prevalent is 47% and the 5-year survival rate is 71%. They are 38% and distant metastasis of ACC site was lungs, followed by liver, and 50%, respectively, at 10 years, and 13% and 51% at 15 years. rarely bone. Our patient had a distant metastasis after 4 years According to these results, it has been suggested to use 10- to of follow-up. 15-year-survival rates rather than 5-year survival rates for ACC

Optimal surgical treatment for ACC of the Bartholin gland is not identified with guidelines. Radical vulvectomy ± inguinal lymphadenectomy and simple excision can both be performed. occurs, it is ipsilateral to the primary tumor. In our case, there was no lymph node metastasis. In the literature, the effect of

et al. showed 68.9% of patients who had a simple excision¹ lymphadenectomy on survival and prognosis is controversial.

et al. showed 68.9% of patients who had a simple excision had recurrence rate. Patients who underwent radical vulvectomy had a 42.9% recurrence rate; resection margins in the radical vulvectomy group were positive in 30% of the patients. The S R V L W L Y H P D U J L Q U D W H Z D V L Q W K H V L P S O H H I F L V L R Q J U R X S + V X et al. presented two ACCs of Bartholin gland origin with lung metastasis; the first patient had a positive margin in pathologic H [D P L Q D W L R Q D Q G U H F H L Y H G S R V W R S H U D W L Y H D G M X Y D Q W H I W H U Q D E H D P U D G L R W K H U D S \ D Q G G L V W D Q W P H W D V W D V I V O X Q D Q G W H P S K D V L] H G S R R U O X Q D Q G F R P H V L Q H S D W was found 42 months after the radiotherapy. The other patient margins even when treated with radiotherapyA prospective There is little information on the treatment of metastasis and the management depends on the location. In literature, there are no data to support chemotherapy to prevent distant metastasis. If a distant metastasis exists, chemotherapy treatment alternatives such as chlorambucil-adriamycin, methotrexate-dactinomycin, cyclophosphamide-adriamycin-cisplatin or cyclophosphamide radiotherapy may produce tumor regression. Publications have

A prospective study by Zkr et al. presented 5 cases of ACC of the Bartholin gland. Two had lung metastases. In the first case, a 54-year-old woman had ACC of Bartholin's gland is a rare vulvar malignancy with margins even when treated with radiotherapy deciding the optimal treatment. Due to the rarity of ACC of the Bartholin gland, we can obtain data from reviews and large series.

right-side radical local excision + ipsilateral inguinal lymph unpredictable biologic behavior. Physicians have to suspect C.R.C., C.L.V., H.E.W.L.B.C., D.C.M.Y.X.D.C., H.D.C.L.B.W.K.H.U.S., E.H.V., H.E.W.L.B.C., B.D.H.U.L.C.V.

Q R G H G L V V H F W L R Q D G M X Y D Q U D F In women aged over 50 years With persistent Bartholin's D Q G S H U L Q H X U D O L Q Y D V L R Q Z H U H S gland masses. There is no consensus on the treatment and twice 7 and 8 months later and underwent metastasectomy. The treatment modality must be tailored according to each Z L W K V X E V H T X H Q W F K H P R W K H U D S \ patient. F Relativip lddap excision of Drdlear S qnd wth Q ± for the first metastasis and metastasectomy only for the second one.

for the first metastasis and metastasectomy only for the second lymphadenectomy seems to be the most suitable treatment. metastasis. After 71 months' follow-up, she had stable disease. Positive surgical margins are a very important factor related to The second case was a 60-year-old woman who had left-side H F X U U H Q F H 6 X U J H U \ U D G L R W K H U D S

UDGLFDO ORFDO H[FLVLRQ DQG Q Ran DeGuzman et al. Document 16. Kellibwdu of A6C1 of the Bantibiq PDUJLQV DQG SHULQHXUDO LQYDV LgRan DeGuzman et al. has held for a long period the its RSV DgRowti HeDavloF UHFXUUHQFH DQG GLVWDO PHWDVWDVWLV QXQJ RFFXUHG LQ WKH SDWLH WKH ORFDO PHWDVWDVLV ZDV UHPRYHG JXQJ PHWDVWDVHV RFFXUHG 3HUU UHYLHZ Externally peer-reviewed.
71.18 and 189 months after surgery and complete excision of

the pulmonary lesion was not possible because of the number of X W K R U V K L S & R Q W U L E X W L R Q V D Q G V L J H R I W K H O H V L R Q V 7 K H S D W X U J Q W F D K D G Q Q R E B I Q L H D F Q V 3 L R D F W Q G H Q R) D G M X Y D Q W W K H U D S \ 5 H V H F W L R Q P D H U J L J Q V 6 D Q S S H D W L Q H X R U D D Q H F L V Q Y P Q L R R Q Z Z H U H S R V L W L Y H / R F D O S H O Y L F U H , Q X W H U S Q U F H H W D Q V G R Q L V 6 V Y P Q P H L W D H V M D D M X H U V O X Q J R F F X U U H G L Q W K H S D W L H Q W & W Q H O Q R W D R O I P , Q W W D I W W H D W L W o Z d n f i c t u l H i R e s t / X Q J P H W D V W D V H V Z H U H D W D Q G a u t h o r s P R Q W K V D I W H U V X U J H U \

) L Q D Q F L D O ' L V F O R V X U H The authors declared that they had no financial support received no financial support

References

- & K D P O L D Q ' / 7 D \ O R U + % 3 U L P D U \ F D U F L Q R P D R I % D U W K R O L Q · V J O D Q Tark J Obstet Gynecol 2020;17:310-313.
- report of 24 patients. Obstet Gynecol 1972;39:489e94.
- + H O O H U ' 6 % H D Q 6 / H V L R Q V R I W K H % D U W K R O L Q · V J O D Q Tark J Obstet Gynecol 2020;17:310-313.
- Genit Tract Dis 2014;18:351.
- 1 D W L R Q D O & D Q F H U , Q V W L W X W H & D Q F H U ' & W B Q D M R V V & D X C Y D I O Q D Q F % U G K W \$ V 9 H C V H U F D Q F H U J R Y V W D W I D F W V K W P O Y X O D Y O K M D P U O W K S F O F L H Q V V G Q Q R Q F D G E U H O & U L W 5 H 1 D V X . . D Z D Q R < 7 D N D L 1 . D V K L P D . 0 ' X Q Q 6 \$ G H Q R L G F \ V W L F F D U F L Q R P D R I Cystic Adenoma of Bartholin's Gland.DGynet 1995;74:78-80.
- RI W K H O L W H U D W X U H D Q G U H S R U W R I D 2005;69:548.W \$ F W D 2 E V W H W * \ Q H F R O 6 F D Q G 1995;74:78-80.
- & U X P & 3 0 F & O X J J D J H : * + H U U L Q J W R Q & 6 H Y L H Z R I W K H O L W H U D W U H * \ Q H F R O 2 Q P E J. Tumours of the Vulva: Epithelial tumors. In: Kurman RJ, & D U F D Q J L X 0 / + H U U L Q J W R Q & 6 < R X Q J + V X 5+ 6 7 H G L W R U V & D Q J 5 & / X 2 & + H < 0 & K H Q < 7 & O D V V L I L F D W L R Q R I 7 X P R X U V R I) H P D O H 5 H S U R G X F W L Y H 2 U J D Q V . / R Q International Agency for Research on Cancer; 2014.p.237-8.
- / y S H] 9 D U H O D (2 O L Y D (0 F , Q W \ U H -)) X O O H U \$) 3 U L P D U \ W U H D W P H Q W of Bar-tholin's gland carcinoma with radiation and chemoradiation: a report on ten consecutive cases. Int J Gynecol Cancer 2007;17:661-7.
- . O R E - 0 3 D W K R O R J L V F K H \$ Q D W R P L H G H & R S H Q D Q F K H Q 6 O H K H U J * H U V K H Q V R Q ' 0 Wein, 1864.
- \$ O V D Q &, 9 L Q K + X Q J 9 (U H Q) \$ E D F L R Gynecol 1986;87:145-2 LG F \ V W L F carcinomas of the Bartholin's gland: case report and systematic review of the literature. Eur J Gynaecol Oncol 2011;32:567-72.
- 6 P L W K / & / D Q H 1 5 D Q N N R Z 5 0 & \ O L Q G U 6 F D U F L Q R P D \$ P - 6 X U J of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. Int J Clin Exp Pathol 2015;8:5688-94.
- & 6 H V N O - & \$ G H Q R L G F \ V W L F F D U F L Q R P D R I % D U W K R O L Q · V J O D Q Tark J Obstet Gynecol 2020;17:310-313.

Severe ovarian hyperstimulation syndrome and gonadotropin-releasing hormone agonist trigger in patients with hypogonadotropic hypogonadism: A report of two cases

+ L S R J R Q D G R W U R S L N K L S R J R Q D G L] P K
 K L S H U V W L P • O D V \ R Q V H Q G U R P X Y H J R
 D J R Q L V W L \ O H W U L J J H U p N L R O J X V X

• \$ O L 6 D P L 1 • U K Q G D 2 * (G) H D W P D 3 • x θ H b Q H S 8 P D \ • 5 E \ • ' H Y H H U

¹Novafertil IVF Center, Clinict of Obstetrics and Gynecology, Konya Turkey

²% D K o H ü H K L U 8 Q L Y H U V L W \) D F X O W \ R I 0 H G L F L Q H ' H S D U W P H Q W R I 2 E V W H W U L F V D Q

³Necmettin Erbakan University Faculty of Medicine, Department of Obstetrics and Gynecology, Konya, Turkey

4. R o 8 Q L Y H U V L W \) D F X O W \ R I 0 H G L F L Q H p V W D Q E X O 7 X U N H \

5% W N x . R o P D Q 8 Q L Y H U V L W \) D F X O W \ R I 0 H G L F L Q H ' H S D U W P H Q W R I 2 E V W H W U L F V D Q

\$ E V W U D F W

2 Y D U L D Q + \ S H U V W L P X O D W L R Q V \ Q G U R P H 2+66 LV D U D U H F R Q G L W L R Q L Q S D W L H Q W V Z K \ S R J R Q D G L V P D U H U H S R U W H G D U D U H F D V H R I V H Y H U H 2+66 D Q G D F D V H R I S U H Y H Q respectively. The first case was a 31-year-old patient. In vitro İ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hypogonadotropic hypogonadism.

. H \ Z R U G V \$ 57 I U H H] H D O O * Q 5+ D J R Q L V W W U L J J H U K \ S R J R Q D G R W U R S L F K \ S R J R Q D G L V

Öz

2 Y H U + L S H U V W L P • O D V \ R Q V H Q G U R P X 2+66 K L S R J R Q D G R W U R S L N K L S R J R Q D G L] P K D V W D O K R U P R Q * Q 5+ D J R Q L V W W U L J J H U L \ O H 2+66 H Q J H O O H Q P L ü K L S R J R Q D G R W U R S L N K L S R J R N H r i v t o İ H U W L O L] D V \ R Q , 9) W H G D Y L V L X \ J X O D Q P x ü D Q F D N R O J X G D R Y H U K L S H U V W L P • O G R N X] X Q F X J • Q G H ü L G G H W O L 2+66 W D Q x V x N R Q X O G X + D V W D Q H G H J • Q N D O G x Y H E D W L Q I H U W L O K D V W D \ G x + L o , 9) W H G D Y L V L J \ U P H P L ü W L , 9) W H G D Y L V L Q G H Q | Q F H * Q 5+ D J R Q L V W W U L J J H U L \ D S x O G x 7 R S O D Q D Q R R V L W H U D ü P H Q 2+66 P H \ G D Q D J H O P H P L ü W R O P D N O D E L U O L N W H J H O L ü H E L O L U (ý H U K L S R J R Q D G R W U R S L N K L S R J R Q D G L] P K D V W D O D \ H U L Q H * Q 5+ D J R Q L V W W U L J J H U \ D S x O D E L O L U Y H 2+66 | Q O H Q H E L O L U \$ Q D K W D U . H O L P H O H U \$ 57 I U H H D O O * Q 5+ D J R Q L V W W U L J J H U K \ S R J R Q D G R W U R S L F K \ S

\$ G G U H V V I R U & R U U H V S R Q G H Q F H < D \ x ü P D \$ G U H V L \$ O L 6 D P L * • U E •] 0'

Novafertil IVF Center, Clinict of Obstetrics and Gynecology, Konya Turkey

Phone: +90 533 553 04 42 (P D L O D O L V D P L J X U E X] # K R W P D L O F R P 25 & , , ' orcid.org/0000-0001-7747-3074

5 H F H L Y H G * H O L ü 7 D U L K L 15.07.2020 \$ F F H S W H G . D E X O 7 D U L K L 16.10.2020

©Copyright 2020 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

+ \ S R J R Q D G R W U R S L F K \ S R J R Q D G L V P + + L V D S X E H U W A G H O D G D Q G
 amenorrhea-causing disorder due to deficiency of gonadotropins D Q G V H [V W H U R L G V L Q W K H F L U F X O D W L R Q Q G L Y L G X D O V Z L W K + + K D Y H + H
 defects either in the secretion of the gonadotropin-releasing K R U P R Q H * Q 5 + I U R P K \ S R W K D O D P X V R U * Q 5 + U H F H S W R U V I Q
 the hypophysis. Ovaries are not stimulated depending on the G H I L F L H Q F \ R I J R Q D G R W U R S L Q V W K X V + F W 2 Q W K R H M Q K I W I G X Q D M L R D (3 U
 6 W L P X O D W L R Q Z L W K H [R J H Q J R Q D G R W U R S L Q V Z L W K , 8 K 0 * 0 H Q R J R Q) H U U L Q J -
 treatment because folliculogenesis and ovulation are defective L Q S D W L H Q W V Z L W K + + + X P D Q F K R U P R Q L F J R Q D G R W U R S L Q V K J
 L Q M H F W L R Q L V P D Q G D W R U \ W R P D W X U H J O O D P S 0 6 7 X U N H O 7 R D Y R L G
 V W L P X O D W L R Q E H F D X V H W K H O X W H I O L Q J K R U P R Q H / + S H D N G R H V
 not exist in these patients P H G L F D W H G Z L W K F D E H U J R O I R Q H G R D W W
 2 Y D U L D Q + \ S H U V W L P X O D W L R Q V \ Q G U R P H 2 + 6 6 L V W K H P R Y W
 serious, life-threatening, iatrogenic complication of assisted U H S U R G X F W L Y H W H F K Q R O R J \ \$ 5 7 F F O H Y + & * V W K H P D M R U
 P R O H F X O H W K D W T F e d e n e H t \ p r e v e n t s and IVF outcomes are shown in Table 2. On the embryo transfer
 P D Q D J H 2 + 6 6 * Q 5 + D J R Q L V W V K D Y H E H H O V W D U W H G W R E H X V H G
 for final oocyte maturation. As a result, a segmented approach L Q F O X G L Q J * Q 5 + D J R Q L V W W U L J J H U L Q J R D O O H P E U R V
 especially for patients with an extreme ovarian response Z D V U H F R P P H Q G H G I R U W K H F R P S O W H S U H Y H Q W L R Q R I 2 + 6 6
 hCG is the primary choice for oocyte maturation + R Z H Y H U 16.2, and beta-hCG: 61.7. Accordingly, she was accepted as
 L Q V B D M W L H Q W V Z L W K + + D K \ S H U U H M S P O V H P D I D O V R P F F X U
 and hCG triggering might be a life-threatening event in these S D W L H Q W V 7 K H H [D F W S D W K R O R J \ L Q S D W L H Q W V Z L W K + + P D V E H U H O D W H G
 to pituitary receptors or hypothalamus, and a patient with + + P D \ Q R W U H V S a g o o s a f f i c i e n t l y . Therefore, hydroxyethyl starch was administered every day. The patient
 WKH R U H W L F D O O \ * Q 5 + D J R Q L V W V D U H Q R W U H F R P P H Q G H G W R E H X V H G
 I R U W U L J J H U L Q J R R F \ W H P D W X U D W L R Q L Q S D W L H Q W V Z L W K + +
 , Q W K H I R O O R Z L Q J D U W L F O H + + D Q G D I R O L Y W W U L J J H U Z L O O E H G L V F X V Y H
 F R Q V L G H U L Q J W Z R S D W L H Q W V Z L W K + + Q W K H I L U V W F D V H V H Y H U H
 2 + 6 6 Z D V V H H Q L Q W K H V H F R Q G S R W H Q W L D O 2 + 6 6 G H Y H O R S P H Q W
 was prevented using a * Q 5 + D J R Q L V W W U L J J H U

Case Reports

The patients were treated in Novafertil In vitro

7 D E O H Clinical characteristic of two patients with hypogonadotropic

		Case 1 2 + 6 6	Case 2 * Q 5 + \$ J W U
\$ J H < H D U V	31	26	
% 0, N J P	24	30.1	
% D V D O V H U X P) 6 + 1 P , 8 P 0.9			
% D V D O V H U X P / + P 0.15 P / 0.73			
% D V D O V H U X P (V W 2 0 6 6 L R 2 0 S J P)			
% D V D O V H U X P 7 6 + 2 B 2 8 P 2.43			
K D G Q H Y H U G H Y H O R S H G 2 + 6 6 L Q D Q % D V D O V H U X P R U X P K 3 H U R M O H H M P H Q Q W P V 7 R			
U H J X O D W H K H U P H Q V W U X D O F F O H V 2 + 6 6 2 Y D U L D Q + \ S H U V W L P X O D W L R Q V \ Q G U R P H Q 5 + *			
S U R J H V W H U R Q H 3 F R P E L Q D W L R Q 7 6 + 7 K U R L G V W L P X O D W L Q J K R U P R Q H			
S D W L H Q W R W K H U W K D Q D Q R U P D O R O O L			

+0* ZDV X VHG X QWL O X QLW V I RU FURHQWSURQOQH H G HRY H DURLSDHG V W R E M Q B W L W Q H ZLWKLQ DQ ,8, SODQ +RZHYHU QR SUHHASHROQW H GZ B V SUHHFIRUYPHLQJI UDQP * Q 5 + D the patient. When she was examined, it was determined that the first day of treatment, she had a small uterus and thin endometrium. Moreover, a fresh embryo was transferred to the first patient according to PDQ\ VPDOO DQWUDO IROOLFOHV ZHRXHU R, Y HAUHYDHPG VR Q HEFR W K R QY DVRLFLD O+H H EDVDO FKDUDFWHULVWLFB DUH VXP B D W L K J R I X G K QH D D D O H + 6 6% GI HRY U H D R / SVPDHQWAL C WUHDWPHQW D WULDO RI * Q 5 + D Q DZOLRNUK HW K H J H L L Q Q L J Q Z DR/I S H K L H RSLUPHJQ D C D Q G P J WULSWRUHOLQ * R Q D S H S econd ovary duration lasting until the 13 week of the pregnancy. administered subcutaneously. After triggering, in the first and, QWHUHVWLQJO VKH KDG D YHU VHU VHFRQG KR XUV / + OHYHOV ZHUU B Q G D P L Q J D HUVHR D S O I O W L Y H G R Y D U 6 R 6 WLPXODWLRQ ZDV VW D U W H G ZLW K was aspirated via replacement paracentesis. If the OLT was cancelled, 7XUNH\ R Q WKH VDPH GD\ ZLWKR X W + G D IDWQLGQ L W R UF RPQVQH/TAXUH QDFM V R ZQR X O G Follicle growth, as well as estradiol levels, were followed and W R U H F R Q V L G H U W & W LPHDQMDV HZPLHNGK W + R IZ gonadotropin doses were arranged according to the response to controlled ovarian stimulation. : K H Q D W O H D V W W K U H H O H D G L Q J I R G D W E B Q W V H D F W K I + P D W Q G Q B O M Q H H G L Q were developed, oocyte maturation was triggered with 0.2 from the point of ovarian stimulation. Although the patients mg triptorelin. Thirty-two oocytes were retrieved 36 hours have the same clinical findings, their response to ovarian D I W H U W K H WULSWRUHOLQ L Q M H F W stimulation may be hyper, normal or poor. Both ovaries can be H G is presented in Table 2. Following the first menstruation, she Y L V X D O L] H G D V K \ S R S O D V L F L Q X O W U D received hormone replacement therapy. One good quality counting antral follicles is quite challenging. The prediction of embryo was transferred after the second menstruation using the response to gonadotropins is challenging because the exact (K H P L K \ G U D W H (V W U R I H P P J 1 R number of antral follicles cannot be identified and the levels of thawing protocol. This procedure resulted in pregnancy. At the time of writing, the patient was in her 13 week of pregnancy.

7 D E O Hn vitro I H U W L O L] D W L R Q R X W F R P H V R R I J R Q D G R W U R S L Q V W 3 D U W G 2 B 5 V H ,8 hypogonadotropic hypogonadism

	Case 1 2+66	Case 2 * Q 5 + \$ J W
'D \ V RI VWLPXODWL13Q G D1		
* R Q D G R W U R S L Q V W 3 D U W G 2 B 5 V H ,8		
7 R W D O J R Q D G R W U R 3 S 5 Q G 6 2 5 H ,8		
(V W U D G L R O R Q W U 1 5 0 9 5 H U T G 9 A S J P /		
1 R RI RRF\WHV UH 10 U L H Y 3 2 G Q		
1 R RI RRF\WHV WK D W P D 2 8 X U H G Q		
1 R RI I H U W L O L] H G 6 R R F \ W 1 0 V Q		
1 R RI WUDQVIHUUH2G HPE1U\R V Q		
1 R RI FU\R SUH V H U 3 H G H P 2 E U \ R V Q		
2+66 2 Y D U L D Q + \ S H U V W L P X O D W L R Q V \ Q G U R P H		

Discussion

, Q S DWLHQWV ZLWK ++ WKH DLP single pregnancy through monofollicular development with L Q WKH L U V W X G L H V ' H V S L W H X V L Q J stimulation and coitus or IUI. When ovulation induction and/ study, Kuroda et al. GLG Q R W H P S O R \ * Q 5 + Z K L R U ,8, IDLOV RU D G G L W L R Q D O S D W K U R Q J H U B J J H Q W X E D P R D M R / W X U F M D V F R Q Q Z R U R O L J R V S H U P L D D F F R P S D Q L H V of a decreased response with agonist triggering. L V warranted. The I L U V W S DWLHQW K D G V H Y H U K H 2 F D & V H Y R H I Q + W K F R D Q J K E N K G H W H F W H G E had a single ovary. In the second case, response to stimulation H D N O H Y H O V D I W H U D * Q 5 No D u t f Q L V W was received over a long period and finally, an excessive ovarian D O X H V I R U / + R U) 6 + S H D N K D Y H E H H

the peak equal or more than twofold is considered sufficient for maturation. This test would show a problem either with gonadotropin levels were detected to be increased like healthy controls in a previous study : R P H Q F D U U \ L Q J * Q 5 + mutations were indicated to ovulate either spontaneously or pump .

In our second case, it was planned to start the stimulation with high-dose gonadotropin because her BMI was high and no response was obtained despite long-term gonadotropin use in triggering was performed knowing that the patient would was prevented and a healthy pregnancy was acquired in the was triggered before controlled ovarian stimulation cycles in

(D U O \ R U O D W H 2+66 F D Q G H Y H O R S L Q D S D W L H Q W 9 Z L D W K I K D J D Y H Y H U H G G \ 1 2+66 F D Q E H S U H Y H Q W H G Z L W K * Q 5 + R I K & * W U L S J D H M I L I Q Q W L Q Z L W K ++ Z L W K 7 K H X V H R I D * Q 5 + V W L P X O D W L R Q W H Y H W Z L Q D Y E H Y H U R K H Q S J X O J R O H J . W K H V H O H F W L R Q R I S D W L H Q W V Z K R 50. trigger before controlled ovarian stimulation cycles in S D W L H Q W V Z L W K ++ \$ F N Q R Z O H G J H P H Q W V

We would like to thank the staff at the Novafertil IVF Center and all staff in the department of obstetrics and gynecology of Necmettin Erbakan University because of their disciplined and careful work.

(W K L F V

, Q I R U P H G & R Q V H Q W Written informed consent was obtained from the patients.

3 H H U U H Y L H Z Externally and internally peer-reviewed.

\$ X W K R U V K L S & R Q W U L E X W L R Q V

6 X U J L F D O D Q G 0 H G 1 F D O C o n d e p t F W 6 F H V R.D., Design: R.D., Data Collection or Processing: F.K., Z.U.G., Analysis or Interpretation: \$ 6 / L W H U D W X E G I , 6 H D Writing: Z.U.G., R.D.

& R Q I O L F W R I , Q W H U H V W The authors declare no conflict of interest received no financial support.

) U D L H W W D 5 = \ O E H U V W H M Q ' 6 (V W H Y K * Q 5 + S U R G X F W L R Q W L V R Q W L Q & W K H L F V 6 D F

K \ S R W K D O D P X V , I W K H F R Q G L W L R Q L 8 / F D X V H G E \ S L W X L W D U \ * Q 5 + U H F H S W R U V / + D Q G) 6 + O H Y H O V Z L O O L Q G R W L F L Q F U H F D V H R J D X W & L S W W D L L V 5 F D X V H G E \ * Q 5 + S U R G X F W L R Q J R Q D G R

) X U W K H U P R U H H Y H Q L Q Z R P H Q Z L W K Q S T U P F H S W R U V X W D W L R Q V

hypogonadotropic hypogonadism and tubal factor infertility. Clin

Exp Obstet Gynecol 2010;37:120-2.

+ X P D L G D Q 3 4 X D U W D U R O R - 3 D S D Q L N R O

K Y S H U V W L P X O D W L R Q V \ Q G U R P H J X L G D Q F I

2010;94:389-400.

D G P L Q H L V W U D R M O L F R Q Y & D % D R F S N R I W W D E O \$ Q

V H J P H Q W D W L R Q R I , 9) W U H D W P H Q W + X P S

* D R < < X % 0 D R - : D Q J ; 1 L H 0 : X ; \$ V

techniques with congenital hypogonadotropic hypogonadism

patients: a systematic review and meta-analysis. BMC Endocr

Disord 2018;18:85.

L Q J P W Q D I W H Q b J H V b Q J Z L M W K G * D Q 5 + * Q 5

D J R Q L V W Z D V F R Q V L G H U H G G X H W R W K E G U E W N R R I R I + F F I W Q H 5 P D D W X R U Q W W Q L Q

6:27 D Q D O \ V L V 5 H S U R G % L R P H G 2 Q O L Q H

U H V S R Q G E H F D X V H W K H / + R Q F W K H P H Q W V Z D V R E A H U Y H G L Q F \$ 6 < X P X V D N 2 .

G D \ R I W K H * Q 5 + V W L P X O D W L R Q W H V V W % 7 K H X V 2+66 7 K H U H S U R G X F W L Y H R X W

K \ S R J R Q D G R W U R S L F K \ S R J R Q D G L V P X Q G H

6 \ V W % L R O 5 H S U R G 0 H G

W U D Q H R E W P D Q H G 0 D I W H H Q D Q 5 + K H U R

R R U D Q W H H U S Q D W L Q H D V 2+66 I S Q U H H Y H D Q W V L R Q

Metab 2011;96:3609-14.

L Q D S D W L D Q W 9 Z L D W K I K D J D Y H Y H U H G G \ 1

of assisted reproductive technology cycle in patients with

K \ S R J R Q D G R W U R S L F K \ S R J R Q D G L V P - + X P

K \ S H U U H V S R Q V H 50.

Z L H Q Q U H H R V S D R Q G Q W K R S A Q B W L P X B Q W V M Q V

oestrogen concentrations in a hypogonadotropic, hypogonadal

S D W L H Q W + X P 5 H S U R G

8 O X J 8 % H Q 6 K O R P R , 7 R V X Q 6 (U G H Q +)

The reproductive performance of women with hypogonadotropic

K \ S R J R Q D G L V P L Q D Q L Q Y L W U R I H U W L O

program. J Assist Reprod Genet 2005;22:167-71.

- L D Q J 6 7 . X D Q J < 3 5 H V H D U F K S U R J U H V V H

W H F K Q L T X H V I R U K \ S R J R Q D G R W U R S L F K \ S

'L H U < L N H ' D [X H ; X H E D R % L D Q M L 6 K L

. X U R G D . () R H . . D W R . < D E X X F K L \$ 6

H W D O , Q I H U W L O L W \ W U H D W P H Q W V W U D

an embryos and single vitrified-warmed embryo transfer during

K R U P R Q D O U H S O D F H P H Q W F \ F O H I R U L Q

with hypogonadotropic hypogonadism. J Obstet Gynaecol Res

2018;44:922-8.

6 X Q 4 + = K H Q J < = K D Q J ; / 0 X < 0 5 R O H

U H O H D V L Q J + R U P R Q H 6 W L P X O D W L R Q 7 H V V

Deficiency in Both Males and Females with Delayed Puberty. Chin

Q H G - (Q J O

0 D L R Q H /) q Y U H \$ 1 H W W R U H , & 0 D Q L O D

H W D O 6 L P L O D U L W L H V D Q G G L I I H U H Q F H V

Women with congenital hypogonadotropic hypogonadism caused

that this study X W D W L R Q V D Q G Z R P H Q Z L W K S R

+ X P 5 H S U R G

Rectus abdominis muscle with different abdominal pathologies: A cite to myofascial trigger point

) D U N O x D E G R P L Q D O S D W R O R M L O H U O H
0 L \ R I D V \ D O W H W L N Q R N W D \ D E L U D W x

②) D W L K % D Ÿ F x H U

% L U X Q L 8 Q L Y H U V L W \) D F X O W \ R I 0 H G L F L Q H ' H S D U W P H Q W R I 3 K \ V L F D O 0 H G L F L Q H D

Keywords: Rectus abdominis muscle, primary dysmenorrhea, myofascial pain syndrome

Anahtar Kelimeler: 5 H N W X V D E G R P L Q L V N D V x S U L P H U G L V P H Q R U H P L \ R I D V \ D O W H W L N Q R N W D

' H D U (G L W R U

I read the article, "Relation between uterine morphology and primary dysmenorrhea" with interest. Although the etiologic factors in primary dysmenorrhea are covered in the article, the role of muscle structures in etiology is not mentioned. In this article, we would like to discuss the rectus abdominis muscle as an underdiagnosed cause of primary dysmenorrhea.

The rectus abdominis muscle extends from the pubic symphysis and tubercle as a beam and ends at the anterolateral aspect of the xiphoid process and superiorly in three fragments of the costal cartilages of the ribs 5-7. The rectus abdominis muscle has been associated with pathologies such as pain in the abdominal wall and primary dysmenorrhea. Primary dysmenorrhea is a frequently encountered condition that reduces the quality of life of the patient and considerably impacts the economy of the healthcare system.

Primary dysmenorrhea is a recurrent, cramping pain in the lower abdomen occurring during menstruation without any pelvic pathology. Medical treatments, yoga, pilates and stretching exercises, massage techniques for soft tissues, and invasive approaches can be used to treat this patient.

to treat primary dysmenorrhea. According to the literature,

needle treatment for MTrP of the rectus abdominis muscle in the article, the role of muscle structures in etiology is not mentioned. As observed by physicians, abdominal pain has been most frequently associated with intraabdominal pathologies.

Therefore, numerous consultations and tests are required, and abdominal surgeries are occasionally performed, although the necessity thereof is debatable. When patients cannot find a remedy for their pain, they visit various clinics for pelvic. Contributing to the increased abdominal pressure with psychiatric disorders. In fact, MTrP of the rectus abdominis muscle should be considered. MTrPs of the rectus abdominis muscle in a patient with Crohn's disease who had a complex history of medical treatments and clinical courses. A stretching exercise program for the relevant

muscle was used to treat this patient. These patients should be thoroughly evaluated and appropriate treatments, yoga, pilates and stretching exercises, massage, and related muscles can have different clinical manifestations. These patients should be thoroughly evaluated and appropriate

\$ G G U H V V I R U & R U U H V S R Q G H Q F H < D > x ü P D \$ G U H V L) D W L K % D Ÿ F x H U 0'

% L U X Q L 8 Q L Y H U V L W \) D F X O W \ R I 0 H G L F L Q H ' H S D U W P H Q W R I 3 K \ V L F D O 0 H G L F L Q H D Q G 5 H K D E L O L W D W L R Q p V W D

Phone: +90 544 242 90 42 (P D L O bagcier_42@hotmail.com 2 5 & , ' , ' orcid.org/0000-0002-6103-7873

5 H F H L Y H G * H O L Ü 7 D U L K L 30.09.2020 \$ F F H S W H G . D E X O 7 D U L K L 01.11.2020

controlled studies with a long-term follow-up are required in this field.

(W K L F V

3 H H U U H Y L H Z Externally peer-reviewed

) L Q D Q F L D O 'L V F O R V X U H The author declared that this study received no financial support.

References

- ýHQW•UN ý 5HODWL RQ EHWZHHQ XWHULQJ Abdominal Muscles for Treatment of Primary Dysmenorrhea. Turk J Obstet Gynecol 2020;17:84-9.

0DTXLUUULDLQ - *KLVL -3 .RNDOM \$0 5HFW

LQ WHQQLV SOD\HUV %U - 6SRUWV OHG

*DXEHFD *LODUUDQ] \$)HUQiQGH] GH /DV

-5 6HRDQH 5XL] -0 &R PSDQ\ 3DORQpV \$

Effectiveness of dry needling of rectus abdominis trigger points for the treatment of primary dysmenorrhoea: a randomised parallel-group trial. Acupunct Med 2018;36:302-10.

4. Muscolino JE. Abdominal wall trigger point case study. J Bodyw Mov Ther 2013;17:151-6.

+X D Q J 4 0 /LX / :HW QHHGOLQJ RI P\RID

Acupuncture of Abdominal Muscles for Treatment of Primary Dysmenorrhea. Acupunct Med 2014;32:346-9.

2020 Referee Index

\$ \$N\times Q 6LYDVO\times R\circ OX	(QLV g]ND\D	0HWH ,ü\times NR\circ OX
\$EG•ONDGLU 7XUJXW	(UDOS %DVHU	0XKDPPHW (UGDO 6DN
\$EGXOODK .DUDHU	(UD\ dDO\times\NDQ (0XUDW \$SL
\$OL \$NGHPLU	(UFIDQ %DüWX	0XUDW %DNDFDN
\$OL .ROXVDU\times	(VUD (VLP %•\•NED\UDN	0XUDW <DVVD
\$üN\times (OOLEHü .D\ D	(YULP (UGHPR\circ OX	0XVWDID &RüDQ 7HUHN
\$\OLQ 3HOLQ dLO)LOL])DWPD <DQ\times N	0XVWDID .DUD
\$\üHQ 7HOFH *•UE•]	* NoH \$Q\times N þOKDQ	1HVOLKDQ %D\UDPR\circ OX 7H
%DQX 'DQH	* UNHU 6HO	1XPDQ dLP
%DWXKDQ g]PHQ	*•OÜHQ 'R\circ DQ 'XUGD\circ	gPHU /•WIL 7DS\times V\times]
%HJXP <\times OG\times]KDQ	+DNDQ 1D]LN	2QXU (URO
%HUQD 'LOED]	+DOLO *•UVR\ 3DOD	2UNXQ dHWLQ
%HUQD +DOLOR\circ OX 3HNH	+DUDQ\times P *•OHU \circ YDKLQ	2]DQ 'R\circ DQ
%XOHQW dDNP DN	+DULND %RGXU g]W•UN	g]NDQ g]GDPDU
%XUDN 7DW DU	+DUXQ (JHPHQ 7TROXQD\	5DKLPH 1LGD (UJLQ
dD\circ ODU +HOYDF\times R\circ OX	+DVDQ <\•NVHO	5HFHS <\times OG\times]KDQ
dD\circ U\times *•O•PVHU	+•VH\ LQ &HQJL]	5HP]L \$EDO\times
&DQ 7•UNOHU	+•VQ• dHOLN	5HP]L \$W\times OJDQ
&DQVXQ 'HPLU	þEUDKLP 3RODW	6DEUL &DYND\W DU
&HP 'DQH	þEUDKLP <DOoxQ	\yIDN +DW\times UQD]
&HP <DüDU 6DQKDO	þONHU þQDQ \$U\times NDQ	6HOoXN (UN\times O\times Qo
&HQN 1 6D\times Q	þONHU 6HOoXN	6HOoXN g]GHQ
dHWLQ dHOLN	-DODO 5DRXIL	6HQHP <DPDQ 7XQo
&LK DQ .DUDGD\circ	.DGLU dHWLQND\D	6HUKDQ &DQ þüFDQ
&LK DQ .D\ D	.D]\times P (PUH .DUDÜDKLQ	6HUWDo (VLQ
'HQL] &HPJLO &HPJLO \$U.*HNP\circ DQ *•QJ UG•N	0)XQGD &HYKHU \$NGXO X\circ DODW 8PXW .XWOX 'LOHN	6XQXOODK 6R\VDO
(OLI \$üDoD\DN	0HKPHW \$Q\times O 2QDQ	7D\IXQ &RN
(PHN 'R\circ HU	0HKPHW 6\times GG\times N (YVHQ 7D\ODQ \circ HQRO	
(PLQ hVW•Q\times XUW	0HKPHW 6•KKD %RVWDQ F\circ QDO þVDR\circ OX	
(PUH (NPHN oL	0HNLQ 6H]LN	<DNXS <DOoxQ
(PUH g]J•	0HOLNH 'R\circ DQD\	<DVLQ &H\ODQ
(PUH =DIHU	0HQWH *•URO 8\circ XU	<L\circ LW dDN\times UR\circ OX
(QGHU <DOoxQND\D .DO\ 0HQWH *•URO 8\circ XU		

2020 Author Index

\$EGXONDGLU 7XUJXW.....	15.....	'LQ.H.N..ý.DKLQ.....	98.....
\$GQDQ 'HPLUHO.....	253.....	'L.P.LWULRV)LOLSSRX.....	58.....
\$IVKD \$QMXP.....	40.....	'L.P.S\ %HJXP.....	46.....
\$IÜLQ . NHU.....	259.....	'R ýXü %XGDN.....	149.....
\$KPHW \$\\GRýDQ.....	259.....	'X\\JX .DüxNFx.....	259.....
\$KPHW %DUxü *•]HO.....	209.....	(E.U.X..&HOLN .DYDN.....	28.....
\$KPHW <DVVD.....	155.....	(E.U.X g]W•UN.....	186.....
\$OL 'R ýXNDQ \$QýxQ.....	128.....	(E.U.X..6D\QXU +DWxUQD].....	247.....
\$OL 6DPL *•UE•].....	314.....	(G.L.S (PLU.....	149.....
\$OSDVODQ \$N\RO.....	28.....	(PLQ...hVW•Q\XUW.....	108, 202
\$OSHU %DüEXý.....	175, 247.....	(PUH %DüHU.....	102.....
\$OSHU .DUDORN.....	292.....	(PUH.. OH.....	149.....
\$QGUHD 7LQHOO.....	300.....	(PUH..1L\DL 7XUJXW.....	240.....
\$QWRQLR ODOYDVL.....	300.....	(PUH..<DÝX].....	149.....
\$U]X %LOJH 7HNLQ.....	155, 225.....	(PVDO 3xQDU 7RSGDýx <xOPD]....	73.....
\$VOx <DUFx *•UVR\.....	139.....	(QLV..g]ND\D.....	182.....
\$VOx <D\ODOx.....	253.....	(UD..dDOxüNDQ.....	15, 175.....
\$VOxDQ \$OKDQ.....	139.....	(UNDQ .DODIDW.....	225.....
\$VPLWD 0 5DWKRUH.....	161.....	(URQ..\$UVODQ.....	170.....
\$üNx (OOLEHü .D\D.....	21, 175.....	(URO 1DGL 9DUOx.....	98.....
\$WDNDQ 7DQDoDQ.....	65.....	(VUD..\$DQRýOX.....	225.....
\$WHü .DUDWHNH.....	52, 149.....	(VUD..%.L.Q.L.U.....	196.....
\$\NDQ <•FHO.....	98.....	(WKHP 6HUGDU <DOYD o.....	102.....
\$\NXW 8UIDOxRýOX.....	253.....	(J.JL..!DUXFx.....	182.....
\$\üH g]IHU g]oHOLN.....	90.....	(DUJ.DQ .KHLUNKD.....	1.....
\$\üHJ•O 0XW.....	63.....	(DWLK %DýFxHU.....	318.....
%DUxü \$WD.....	196.....	(DWPD .xOxo.....	314.....
%HUQD .D\D 8ýXU.....	186.....	(DWPD 1XUJ•O 7DüJ].....	202.....
%KDJ\DVKUL 3DWLO.....	278.....	(DWPD..6xODQ.....	9.....
%LMDO 3DWHO.....	46.....	(JLQHW ..•EUD %R\QXND OxoQ.....	240.....
%LUVHQ 8oDU.....	285.....	(JUDW 2UWD o.....	310.....
%XUDN (UVDN.....	133.....	(X.Q.GD * GH.....	314.....
%XUDN *LUD\.....	236.....	(X.Q.GD *•OF• %XOPXü.....	28.....
%XUDN .DUDGDý.....	146.....	(*P.J.H 6LQHP dDýODU.....	139.....
%XUFX \$\NDQ <•NVHO.....	146.....	(*DULPD 3DQGH\.....	46.....
%•OHQW 'HPLU.....	9.....	(*HRUJH 7VDNRWRV.....	58.....
&DQDQ g]FDQ.....	175.....	(*KQLP .KDWLE.....	209.....
&HPDO 7DPHU (UHO.....	63.....	(*L.R.Y.D.QQL 6LVWL.....	77.....
&HPLO *•UVHV.....	146.....	(*N.KDQ %R\UD].....	292.....
&HYUL\H &DQVx] (UV).....	310.....	(*N.KDQ *•O\DüDU.....	128.....
&H\KXQ .xOxo.....	225.....	(*N.PHQ \$NWDü.....	215.....
&KHWQD 3DUHNK.....	46.....	(*X.O.F.KLQ %DED\HYD.....	236.....
&LKDQ .DUDGDý.....	15.....	(*•Q..dDÝXüRýOX.....	155.....
&LKDQJLU..<LUPLEHü.....	155, 225.....	(*•OGHQL] 7RNOXF.....	233.....
dHWLQ &DP.....	52.....	(*•UNDQ %R]GDý.....	65.....
dHWLQ .xOxo.....	182.....	(+DM.DU 3DVKD.....	1.....
dLýGHP \$NoDED\.....	170.....	(+DNDQ .(UHQHQ.....	63.....
dLýGHP 3XODWRýOX.....	21, 115.....	(+DNDQ .xUDQ.....	253.....
'PHHW \$\\GRýDQ .xUPx]x.....	102.....	(+DNDQ <DOoxQ.....	133.....
'HQL] (VLQOHU.....	102.....	(+DPLG 6KDIHH.....	1.....
'HQL] 7DWDURýOX.....	123.....	(+DUXQ (JPHHQ.7RQXQD).....	98.....
'HU\D *•P•UG•O•.....	209.....	(+DVDQ (URýOX.....	98.....
'LGHP dDNP DN.....	139.....	(+HOLQ %DýFx.....	28.....

2020 Author Index

+HYHV 6•UPHOL.....	123.....	0.X.V.W.D.I.D . D.S.O.D.Q.R.ý.O.X.....	253.....
+LNPHW .x]WDQxU.....	285.....	0.X.V.W.D.I.D . D.U.D.....	102.....
,RDQQLV 7VRXNQLGDV.....	58.....	0.X.W.Q.X..8.PDUR.ý.O.X.....	133.....
bOKDQ ýDQYHUGL.....	182.....	0.X.J.D.I.I.HU 6H\KDQ d x NPDQ.....	128.....
bONHU 6HOoXN.....	21.,133.....	0•J.H . HVNLQ.....	139.....
bVPDLO &•QH\W (YU•NH.....	170.....	0•M.J.D.Q. (UFQ.....	102.....
.D\KDDQ <DNxQ.....	196.....	0\NKDLOR 9 0HGYHGLHY.....	300.....
.HPDO 6DQGDO.....	155,225.....	1 D GL\H 3 x QDU \$ \.....	52.....
.xOxo \$ \G x QOx.....	63.....	1.D.J.Q.x 1XU \$ VODQ d LQ.....	90.....
.RQVWDQWLQRV /LDSDLV.....	58.....	1.H.V.Q.L.K.D.Q % H]LUJDQR.ý.O.X \$ OWX\W D ü.....
.RQVWDQWLQRV 9ODVLV.....	58.....	1.L.N.R.Q.D.R.V. 7 DVLV.....	58.....
.UXSD +...6.K.D.K.....	40.....	1 L\ D]L 7 XJ.....	149.,155, 225, 233.....
.•EUD g]NDQ .DUDFDHU.....	9.....	1.X.U.H.W.W.LQ % RUDQ.....	292.....
/DWLND 6DKX.....	161.....	1.X.UHWWLQ < L\ L W.....	149.....
/•WIL\H 3LUEXGDN.....	186.....	2.Q.X.U. (URO.....	247.....
\XGPLOD \$QJHORYD.....	34.....	2.U.K.D.Q. g]DWLN.....	259.....
0DKEREHK)DUDPDU]L.....	1.....	2.]D.Q. !R.ý.D Q.....	21,175.....
0DKPXW *•P•ü.....	123.....	g P H U)DUXN % RUDQ.....	253.....
0DKPXW 6DEUL 0HGLVR.ý.O.X.....	21.....	g.P.H.U...R.Q.....	149.....
0DKPXW <DVVD.....	225.....	g.P.H.U /•WIL 7DS x Vx].....	143.....
0DQLVKD 8SDGK\D\.....	278.....	g.Q.G.H.U 6DNLQ.....	128,149.....
0DUL +DFKPHUL\DQ.....	34.....	g.]F.D.Q. % DODW.....	186.....
0DUL\D /HYNRYD.....	34.....	g.]Q.H.P (UFHOHS.....	123.....
0DVXP .D\D.S.x.Q.D.U.....	170.....	g]OHP 0RUDQ.R.ý.Q.X..7.H.N.L.Q.....	143.....
0HKPHW \$NLI 6DUJLQ.....	233.....	g.]Q.H.P..g]PHQ.....	259.....
0HKPHW \$OL 9DUGDU.....	209.....	3.D.Q.D.J.LRWLV..6.N.D.Q.G.D.Q.D.N.L.V.....	58.....
0HKPHW \$OLXVWDR.ý.O.X.....	123.....	3.D.U.L.V.H.HPD 'DYH.....	46.....
0HKPHW &HQJL] dRODNR.ý.O.X.....	236.....	3.D.U.Y.D.W.K.L 1DLU.....	40.....
0HKPHW (PUH .XUWJLO.....	215.....	3.D.U.Y.D.W.L % KDW.....	40.....
0HKPHW)HULW *•UVX.....	28.....	3.H.Q.L.Q. RüJHU.....	285.....
0HKPHW +DOxJ•U.....	259.....	3.H.P.E.H 2OWXOX.....	236.....
0HKPHW g]V•UPHOL.....	170.....	3.x.Q.D.U % LUR.O.....	149.,155,225.....
0HKPHW hQVDO.....	143,292.....	3 L Q N H \ /D N U D	278.....
0HKWDS *L]LU.....	253.....	5.D.E.L.D \$.Q.D.N.X.ü.....	236.....
0HNLQ ..6.H].LN.....	259.....	5 D K L P H 1LG D % D \ x N.....	21.....
0HOLK 9HOLSDüDR.ý.O.X.....	285.....	5.D.M.H.V.K.ZDUL * % KDW.....	40.....
0HOLNH 'HPLU dDOWHNLQ.....	102.....	5.D.M.L.Y..0D K H Q G U X.....	278.....
0HOLNH g]oHOLN.....	123.....	5.D.P.D]DQ 'HQL]OL.....	128.....
0HPLü \$OL 0XWOX.....	155,225.....	5.D XI 0HOHNR.ý.O.X.....	28.....
0HUDO *•OWRPUXN.....	240.....	5.H.E.D.L 3DEXoFX.....	139.....
0HUYH dDNxU . OH.....	149.....	5.X.F.K.L \$URUD.....	46.....
0HWH *•URO 8ýXU.....	186.....	5•\D.. 'HYHHU.....	314.....
0HWH 6XFX.....	170.,270....	6 D Q J H H W D % K D V L Q	161.....
0HYO•G H..b.Q.D.Q.o.....	123.....	6 D U D K * X V W D S D Q H	300.....
0LFKDHO 'DKDQ.....	247.....	6.H.D.Q J 7 D Q	247.....
0LQH .DQDW 3HNWDü.....	247.....	6.H.G.D..ý.DKLQ \$ NHU	310.....
0RKDPDG 5H]D \$OLSRXU.....	79.....	6.H.I.D..7.L.ýUDN	202.....
0RKDPDGWDJKL 6DUHE D Q K D V V 09Q D E6H\GOLD.K.D.W.W.L.Q..0.x.V x U O x R.ý.O.X.....	170.....		
0XUDW %D.N.D.F.D.N.....	253.....	6 H O L P %•\•NNXUW	170.....
0XUDW <DVVD....21.,115.,149, 155, 175, 225, 233	6 H O L P . D U D W D ü.....		146.....
0XVWDID \$NüDU.....	98.....	6.H.P.L.U 3DüD	9.....
0XVWDID %DKoHFL.....	240.....	6.H.U.H.Q.D.W < D O o x Q	102.....
0XVWDID 'H.ý.L.U.P.H.Q.F.L.....	123.....	6 H\HGHK 0DKGLHK 1DPD\DQGHK.79.....	

2020 Author Index

6H]FDQ 0•P•üRÿOX	65	7.X.E.D 7•OD\ .RFD	215
6KDVKLNDOD %KDW	40	7.X.ÿ.o.H.P...H.V.N.L.Q.....	285
6KLOSD 3DWHO	46	8.P.X.U...* NWXÿ hQO•.....	155
6KLYDQL 6KLYDQL	278	h.P.U.D.Q .•o•NJ] *•OHO	209
6LQHP \$\\üH 'XUX d WHOL	292	9.L.M.D.\D.WD...6.D.Q.J.Z.D.Q.....	278
6LQHP 'HPLUFDQ	15	9.R.O.NDQ 7XUDQ	65
6XDW (UHQ).....	73	<D.NXS .XPWHSH.....	73
6XQLWD 6LZDFK.....	278	<D.S.U.D N (QJLQ hVW•Q.....	133
6•OH\PDQ &DQVXQ 'HPLU.....	170,270	<D.V.LQ 'XUPXÜ.....	292
6•UH\\D 6DUxGDü 'HPLU.....	9	<H.üLP...\$NGHPLU.....	52
ÿDGxPDQ .x\ND o \$OWxQEDü	143	<X.Q.X.V.(PUH 3XUXW.....	236
ÿDIDN +DWxUQD].....	247	<X.Q.X.V (PUH 7RSGDÿx	73
ÿHQRO ÿHQW•UN.....	84	<X.V.X.I. hVW•Q	133
ÿXOH g]HO.....	133	=D KUD %DVLUDW	1
ÿXOH <xOGx].....	196	=D.QLK H <DUNxQHU.....	240
7DQHU 7XUDQ	292	=H.KUD OHOWHP 3LULPRÿOX	128
7DUDQJ 3UHHW..DXU.....	161	=H\QHE %DNDFDN.....	253
7D\ODQ 2QDW	102	=H\QHS 8PD\ *•UE•].....	314
7ULIRQ &KHUYHQNR Y	34	=R.K.U.H.K 3H]HVKNNSRXU	79

\$EVHQW YDJLQD 9DMLQDO DJH **Q82**]L.....
 \$FDGHPLF SHUIRUPDQFH \$NDGH **196**L N SHUIRUPDQV.....
 \$FXSXQFWXUH \$NXSXQNWXU.....253.....
 \$GHQRLG F\VWLW FDUFLQRPD RI WKH %DUWKROLQ.V JODQG \$GHQRLG
 NVWLN EDUWKROLQ NDUVLQR **P30**.....
 \$GYHU VH SUHJQDQF\ RXWFRPHV **40**OXPVX] JHEHOLN VRQXoODUx....
 \$QDWRLPF YDULDWL RQ..\$Q.D.W.R.P.**58**N YDU\DV\RQ
 \$QLPDO PRGHO +D\YDQ PRGHO **I259**.....
 \$QWL HSLOHSWLF GUXJV \$QWL **161**SLOHSWLN LODoODU.....
 \$QWL PXOOHULDQ KRUPRQH..\$Q.W**15** P•OOHULHQ KRUPRQ
 \$QWUDO IROOLFOH FRXQW \$QWU**50** IROLN•O VD\xVx.....
 \$Q[LHW\ \$.Q.N.V.L\H.W.H.....155, 253
 \$RUWRLOLD F RFFOXVLRQ..\$.R.U.W.**R61**OLDN RNO•]\RQ
 \$57 \$57.....314.....
 \$UWLILFLDOO\ SUHSDUHG IUR]HQ HPEU\R WUDQVIHU GRQGXUXOPXü
 o|]•OP•ü HPEUL\R WUDQVIHUL.....240.....
 %DUWKROLQ JODQG FDUVLQRP **310**D UWKROLQ EH]L NDUVLQRPX.....
 %HWDWURSKLQ %HWDWURSLQ28.....
 %HYDFL]XPDE %HYDVL]XPDE123.....
 %UDQFK 'GDO58.....
 %UHDVW FDQFHU OHPH NDQVH **U215**.....
 &DGDYHULF VWXG\ .DGDYUD oD**Q1k ü**PDVx.....
 &DQFHUSKRELD .DQVHUIREL247.....
 &EF77.....
 &' &'236.....
 &HUYLFD O FDQFHU 6HUYLNV N **D103**VHUL.....
 &HUYL[6HUYLNV133.....
 &KHPRWKHUDS\ NHPRWHUDSL46.....
 &OXEIRR W dDUSxN D\DN270.....
 &RPSOLF DWLRQV .RPSOLNDV\R **Q02**D U.....
 &RQJHQLWDO KHDUW GLVHD.V.H.**285**QMHQLWDO NDOS KDVWDOxNODUx
 &RQL]DWLRQ .RQL]DV\RQ133.....
 &RQVHUYDWLYH WHFKQL.T.X.H....R**Q08**HUYDWLI WHNQLN
 &RQWUROOHG RYDULDQ VWLPXOD**W51**RQ .RQWUROO• RYDU\DQ VWLP•ODV\RQ...
4C004900030057621 2.552 05.10028605500520046562

0DMRU YHVVHOV 0DM|U GDPDUO²¹U....3.D.W.L.H.Q.W...V.D.W.L V I D F W.L.R.Q...+D.V.W¹⁸⁶ P H P Q
 0DOH VH[XDO G\VI XQFWLRQ (UNHN F B Q MDFLS D¹HQ EHRQXN Q XDjYXU.x.....196.....
 0DWHUQDO DQG SHULQDWDO FRPS OLOFDDWHLORQW ODPASHKURQFDV H YUD. W H R. 180 DODWDH
 NRPSOLNDV\RQODU.....161.....3.RU.W...VLWH KHUQLD 3RUW DOD²⁰² K H U G
 0DWHUQDO DQG SHULQDWDO 3UFRRPHS²⁰W D W D QM QGHWR RIB W D 0196 Q V W U
 NRPSOLNDV\RQODU.....161.....3.U.L.P.D.U\ DPHQRUUKHD..3.U.L.P.H.U..182 H Q R U
 0DWHUQDO PRUWDOLW\ \$QQH | 078P...3.U.H.G.L.F.W.L.R.Q..7.D.K.P.L.Q.....278
 0D\HU 5RNLWDQVN\ .•VWHU +DXVHU 3WHDH¹⁵ O DFRSNLLWDQWHN N OWDPSWL ..102.....
 +DXVHU.....182.....3UHHNODPSVL.....77.....
 0HWDVWDWLF PHWDVWDWL.....123.....3.U.H.J.Q.D.Q.F.\..D.VVRFLDWHG SODVPD SURV
 0L\RIDV\DO WHWLN QRNWD318.....S.UR.W.H.L.Q.L. D.....40.....
 \$EVHQW YDJLQD 9DMLQDO DJHQ²²L...3.U.H.J.Q.D.Q.F.\.:@ PDQ @UW VFÂ p 0`J^av 0 ðg,
 ORGHO PRGHO.....278.....
 0RUELG REHVLW\ 0RUELG REH²⁰⁹H ..
 0RUEGLW\ 0RUEGLW H.....149,292.....
 0XOWL SOH JHVWDWL RQV 0XOW¹⁴⁶O JHVWDV\RQ.....
 0\RPD XWHUL..0\RP...X.W.H.U.L.....128.....
 0\RPHFWRP\ 0L\RPHNWRPL.....139.....
 1HRQDW¹ <HQLGRyDQ.....79.....
 1HXURSURWHFWLRQ 1|URNRUX²⁵⁹D.....
 1HXWURSKLO O\PSKRF\WH UDWL¹⁸⁸ 1|WURILO OHQIRVLW RUDQx.....
 1QHXWURSKLO O\PSKRF\WH UDWL⁹⁸R 1|WURILO OHQIRVLW RUDQx.....
 1|WURILOOHU77.....
 2EVHVVLYH FRPSXOVLRQ 2EVH¹⁵⁵ NRPS•OVL\RQ.....
 2+66 2+66.....314.....
 2R[LGDWLYH VWUH.V.V..2.N.V.L.G.D.W.¹⁸⁶ VWUHVV
 2SSRUWXQLVWLF VDOSLQJHFWR¹⁵¹ 3URILODNWLN VDOSLQJHNWRP
 2ULJLQ 2ULMLQ.....58.....
 2YDULDQ FDQFHU 2YHU NDQV^{52,202}.....
 2YDULDQ F\VV <XPXUWDOxN NL³⁰⁰W.....
 2YDULDQ +\SHUVWLPXODWLRQ V\QGURPH 2YDULDQ +LSHUVWLPXODV\RQ
 VHQGURPX.....65,247.....
 2[LGDWLYH VWUHVV 2NVLGDWL¹⁰²WUHV.....
 2R[LGDWLYH VWUH.V.V..2.N.V.L.G.D.W.¹⁸⁶ VWUHVV
 2[LGDWLYH VWUHVV 2NVLGDWL¹⁸⁶WUHV.....
 2[LGDWLYH VWUHVV 2NVLGDWL¹⁸⁶WUHV.....
 3DLQ UHOLHI \$yUx NHVLFL.....253.....
 3DLQ \$yUx.....84.....
 3DWLHQW VDWLVIDFW.L.R.Q..K.D.V.¹⁸⁶ PHPQXQL\HWL
 3HFWLQHDO OLJDPHQW 3HNWLQ²¹⁰D O LJDPDQ.....
 3HOYLF RUJDQ SURODSV.H..3.H.Q.Y.²¹N RUJDQ SURODSVXV
 3HOYLF SDLQ 3HOYLN D¹⁹⁶.....
 3HQWR[LI\OOLQH 3HQWRNVLIL²⁵⁹.....
 3HUPDQHQW FRQWUDFHSWLRQ 1¹⁵⁰x F x NRQWUDVHSVL\RQ ..
 3HUVLVWHQW SXOPRQDU\ K\SHUWHQVLRQ 3HUVLVWDQ SXOPRQHU
 KLSHUWDQVL\RQ79.....
 3ODFHQWD DFFUHW D VSHFWUX²⁰⁸ODVHQWD DNUHWD VSHNWUXPX.....
 3ODFHQWD DFFUHW D 3ODVHQW¹⁰⁸D NUHWD.....
 3ODWHOHW O\PSKRF\WH .U.D.W.L.R.⁹⁸ODWHOHW OHQIRVLW RUDQ
 3RUW VLWH KHUQLD 3RUW DOD²⁰² KHUQLVL.....
 3RVW PHQRSDXVH 0HQRSR] VR¹²⁸D V x.....
 3RVWSUWXP KHPRUUKDJH 'R yX⁷³ VRQUDVx NDQDPD.....
 3RVWSUWXP VWHULOL]DW.L.R.Q.¹³⁵ RVWSUWXP VWHULOL]DV\RQ

2020 Subject Index

8 XUHWKURSODVW\ h • UHWURSO233 W L8.X.U.L.Q.D.U\...W.U.D.F.W L Q I H F W L.R.Q...h233 Q H U
8 ULQDU\ LRGLQH FRQFHQWUDWL9R Q 3G WIDQD D\ B MU WR QDV \W Q W \DFH R QXH208Q 6 H]D
8 ULQDU\ WUDFW LQIHF W L.R.Q...h.U23Q H U9 \JLDQNRMS CHQV WN \LD\ \QQR S O D V W L182.....
8 WHULQH DUWHU\ 8WHULQ D U W 1589.D.V.F.X.Q.D.U..D.Q.D.W.R P\ 9 D V N•O H U \Q D W R P
8 WHULQH GLPHQVLRQV 8WHULQ 8\ R \X9W O \D\ \LQ...9.L.U.M.L.Q.....84.....
8 WHULQH KRUQ 8WHULQ KRUQ ...1439.L.V.X.D.O..D.Q.D.O R J VFDOH VFRUH 984]•\HO
8 WHULQH OHLRP\R PD.V...8.W.H.U.L.Q.128H L R9P\Q\PD U FDQFH U 9XOYDU NDQV 1310.....
XWHULQH QDWXUDO NLOOHU F.H2360 V \\$YDHU\W IQQR SQODW\WLAH.SOD.M.L.Q.Q.B.O.DKV\W132H OH U L
8 XUHWKURSODVW\ hUHWURSO233\ L....E.F.....77.....